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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas with sudden onset. The 
severity of acute pancreatitis may vary from mild to life threatening. There are many 
risk factors for acute pancreatitis, among which gallstones and alcohol abuse are most 
widely known. Drugs are considered as potential risk factors for acute pancreatitis, but 
have received relatively little attention in the medical literature. 
In this thesis, several epidemiological studies were performed to assess the rela-
tionship between drug use and acute pancreatitis.
Outline of the thesis
To estimate the public health impact, the incidence and mortality of acute pancreati-
tis were studied in chapter 2. Chapter 3 starts the exploration of the relation between 
drug use and acute pancreatitis with a description and evaluation of spontaneous 
reports on drug-associated acute pancreatitis. Next, we systematically reviewed the 
literature to summarise current knowledge on drug-associated acute pancreatitis. On 
the basis of the descriptive studies described in chapter 3, we conducted several ana-
lytic epidemiologic studies to quantify the association between use  anti-ulcer drugs, 
cardiovascular drugs, psychotropic drugs, vitamin D, lipid lowering drugs and acute 
pancreatitis in chapter 4. The results of our studies on drug-associated acute pancre-
atitis are discussed in chapter 5.
ACUTE PANCREATITIS: A GENERAL OVERVIEW
Introduction
Acute pancreatitis is an acute infl ammatory process of the pancreas. The clinical signs 
may vary from mild disease in most patients to multi-organ failure and sepsis in about 
20% of patients.(1,2) In mild acute pancreatitis there is minimal tissue damage which 
is followed by resolution of the infl ammatory process with relatively little tissue 
damage. In severe acute pancreatitis, the pancreas contains areas of both oedema and 
necrosis. Veins and venules are often affected with granulocytic infi ltration, thrombo-
sis, necrosis, rupture and haemorrhage.(3)
The overall case-fatality of acute pancreatitis is 5-10%,(4) but may be as high as 
40% in patients with infected necrosis of the pancreas.(5) Early deaths in acute pan-
creatitis are mainly due to multi-organ failure, which is probably caused by release of 
mediators and cytokines from the infl amed and necrotic pancreas.(6) The majority 
of deaths, however, are due to local and systemic septic complications later in the 
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disease course.(6)
Clinical presentation and diagnosis
Acute pancreatitis usually has a rapid onset of severe upper abdominal pain, nausea, 
vomiting, and low-grade fever. In its most typical form, the pain is located in the epi-
gastric area, radiates to the back, and is worse in the supine position.(2) Signs of peri-
tonitis are usually absent or mild, due to the retroperitoneal location of the pancreas. 
In its most severe form, acute pancreatitis may present with cardiac and renal failure, 
hypovolemic shock, and pulmonary insuffi ciency within two weeks of onset. Local 
complications such as pseudocysts, and pancreatic abscess usually develop later in 
the course of acute pancreatitis.(1)
The diagnosis of acute pancreatitis rests on careful clinical examination with 
supportive evidence from laboratory and radiological techniques. The association 
between acute pancreatitis and elevated serum levels of amylase has been recognised 
for decades,(7) and amylase measurement is still the most frequently used diagnostic 
test for acute pancreatitis. However, serum amylase is also elevated in patients with 
salivary gland disorders, renal failure, and intestinal perforations.(8) Serum lipase is 
a more specifi c sign of acute pancreatitis than serum amylase and remains elevated 
for a longer period of time.(9) Other potential markers such as phospholipase A2, pan-
creas-associated protein, and trypsinogen-2 have been tested, but have failed to fi nd 
their way into clinical practice.(10)
Ultrasonography and computed tomography may show edema of the pancreas, 
pancreatic necrosis, peripancreatic fat infi ltrations, fl uid collections, pseudocysts, or a 
pancreatic abscess. However, these imaging procedures may be negative in over 30% 
of patients.(11,12)
Treatment
Treatment of acute pancreatitis depends on on the severity. In most cases, treatment 
of acute pancreatitis is largely supportive and consists of eliminating oral intake, vig-
orous rehydration, and parenteral analgesia. Patients with a severe attack of acute 
pancreatitis should be admitted to an intensive care unit for optimal support. Sev-
eral prognostic models have been developed to identify patients with a high risk of 
running a severe course (table 1a and 1b). The APACHE II score is accurate, can be 
assessed in the fi rst 24 hours after admission, but is cumbersome. Many single value 
predictors have been tested, but most assays are not routinely available (table 2). C-
reactive protein (CRP) is the most practical single value predictor, but is only accurate 
after 48 hours.(13) Measurement of trypsinogen activation peptide (TAP) in urine is a 
promising development.(14)
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In severe pancreatitis, the patient requires careful monitoring for development of 
local and systemic complications. Shock should be treated immediately and respira-
tory support and dialysis are used to treat pulmonary complications and renal failure. 
Patients with a severe attack of acute pancreatitis should also receive nutritional sup-
port. Enteral feeding has shown to be superior to total parenteral nutrition.(15,16) 
Drug therapy has not proven to be successful. Amongst others, somatostatin, apro-
tinin, gabexate, and lexipafant have failed to ameliorate the clinical course of acute 
pancreatitis.(1,17) The debate on prophylactic use of antibiotics continues, but imipe-
nem-cilastatin probably reduces the incidence of pancreatic infection in patients with 
pancreatic necrosis.(18)
Endoscopic retrograde cholangiopancreaticography (ERCP) should be performed 
in patients with severe pancreatitis if biliary obstruction is suspected on the basis 
of hyperbilirubinemia or clinical signs of cholangitis.(18) Infected pancreatic necro-
sis needs urgent surgical debridement as mortality in untreated patients reaches 
100%.(18) CT-guided fi ne needle aspiration may be needed to distinguish between 
sterile and infected necrosis. Percutaneous and endoscopic drainage of infected 
pancreatic necrosis has successfully been attempted and can be used in selected 
patients.(18)
Pathogenesis
Acute pancreatitis is an autodigestive disease; i.e. the pancreas is injured by its own 
digestive enzymes. The pancreas synthesizes and stores its digestive enzymes as inac-
tive pro-enzymes or zymogens. Trypsinogen is hydrolysed to trypsin and TAP by the 
Table 1b
Glasgow criteria for severity prediction in 
acute pancreatitis
Factor Positive if
Age >55 years
Arterial PO2 <8.0 kPa
serum albumin <32 g/l
Serum calcium <2.0 mmol/l
White blood cell count >15.109/l
ASAT >100 U/l
LDH >600 IU/l
Blood glucose
>10 mmol/l (in 
absence of DM)
plasma urea >16 mmol/l
The presence of 3 or more prognostic factors is 
associated with severe acute pancreatitis
Table 2
Single value predictors
Predictors
C-reactive protein (CRP)*
Tumour necrosis factor (TNF) *
Interleukin-6* 
Interleukin-8*
Polymorphonuclear elastase*
Trypsinogen activation peptide (TAP) *
Phospholipase A
2
*
Pancreas-associated protein (PAP) *
Carboxypeptidase B activation peptide *
Obesity (BMI >30 kg/m2)
Pleural effusion
*Cut-off levels differ between studies
IE1.indd   6 04-11-2002, 14:16:39
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brush border enzyme enteropeptidase in the duodenum. Trypsin subsequently acti-
vates the remaining pro-enzymes. In acute pancreatitis there is premature, intrapan-
creatic activation of trypsinogen, which leads to autodigestion.(19) The mechanisms 
responsible for premature activation are unknown, but activation of trypsinogen as 
the central event in the induction of pancreatitis is exemplifi ed by recent discoveries 
in hereditary pancreatitis. Mutations in the cationic trypsinogen gene (PRSS1) inhibit 
autolysis or promote auto-activation of trypsinogen thereby overwhelming the pan-
creatic defence mechanisms.(20,21) Mutations in the pancreatic secretory trypsin 
inhibitor gene (PSTI, SPINK1) lower the threshold for other etiological factors.(21) 
In experimental models, co-localisation of lysosomal enzymes, notably cathepsin B, 
with trypsinogen leads to activation of the latter.(19, 22) Recent evidence showed 
that elevated intracellular calcium levels are important in the premature activation of 
trypsinogen.(23)
Once zymogens are activated within the pancreas, acinar cell damage occurs which 
leads to a local infl ammatory response. In severe acute pancreatitis, the infl ammatory 
mediators reach the general circulation leading to a systemic infl ammatory response 
syndrome (SIRS).(24) As a consequence, systemic leukocyte activation leads to dis-
tinct organ damage. Blockage of pro-infl ammatory mediators (table 3) may potentially 
ameliorate acute pancreatitis, but this has only been demonstrated in experimental 
models.(24) 
Etiology
There are many risk factors for acute pancreatitis (table 4). However, the link between 
these risk factors and the above-described pathophysiological mechanisms remains 
unexplained. Although alcohol abuse and cholelithiasis are present in a majority of 
patients, only 3% of patients with gallstones and 10% of patients with alcohol abuse 
develop pancreatitis.(25) Refl ux of bile into the pancreatic duct and stasis of pancre-
Table 3
Infl ammatory mediators in acute pancreatitis
Pro-infl ammatory Anti-infl ammatory
Tumour necrosis factor-α Interleukin-10
Interleukin-1β C5a
Interleukin-6
Interleukin-8
Platelet activating factor
C5a
Substance P
Intercellular adhesion molecule-I
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atic secretions due to obstruction have been proposed as a possible explanation for 
biliary pancreatitis. (26,27) Smaller stones seem to carry a higher risk of acute pancre-
atitis than larger stones. (28) 
About 5% of patients undergoing ERCP develop clinical pancreatitis. Risk factors 
include female gender, prior pancreatitis, lack of experience with ERCP of the per-
forming gastroenterologist, and diffi culties in the cannulation. Hypercalcemia and 
hypertriglyceridemia are the most likely causes for acute pancreatitis in a few percent 
of all patients with acute pancreatitis. In 10-20% of patients no apparent cause for 
acute pancreatitis can be found.
Drugs have since long been acknowledged as a potential risk factor for acute 
pancreatitis. (29) Since drugs are considered a rare cause of acute pancreatitis, they 
are frequently overlooked as a possible cause. The Drug Safety Unit of the Dutch 
Inspectorate for Health Care received numerous spontaneous reports on drug-associ-
ated acute pancreatitis concerning a wide variety of drug classes. This thesis aims to 
describe the relationship between use of therapeutic drugs and development of acute 
pancreatitis.
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Incidence and mortality of acute pancreatitis between 1985 and 1995
Introduction: The incidence of acute pancreatitis seems to have risen in Western countries. 
It has been suggested that this rise can be explained by improved diagnostic procedures. We 
performed a nationwide study to assess the annual gender and age specifi c incidence and 
mortality rates of acute pancreatitis in the Netherlands between 1985 and 1995, a period in 
which diagnostic procedures did not change considerably.
Methods: We conducted a population-based retrospective follow-up study, in which we used 
automated hospital discharge data accumulated by Prismant Health Care Information. All 
patients admitted with acute pancreatitis (ICD-9CM; 577.0) in the Netherlands were identi-
fi ed. We accounted for referrals to other hospitals to avoid double counting and for miscod-
ing of chronic pancreatitis as acute pancreatitis. The annual population size was retrieved 
from the Netherlands Central Statistics Offi ce.
Results: The observed incidence rate of acute pancreatitis increased from 12.4/100,000 
person-years (95% CI; 11.8-12.9)  in 1985 to 15.9/100,000 person-years (95% CI; 15.3-16.5) 
in 1995. The annual mortality rate of acute pancreatitis remained fairly stable at 1.5/
100,000 person-years. The incidence and mortality rate of acute pancreatitis rose consider-
ably with age. The case-fatality proportion of fi rst admissions for acute pancreatitis declined 
from 14.3% to 10.7%. The case-fatality for relapses remained stable at 3.2%.
Conclusions: In this retrospective study, the observed  incidence rate of acute pancreatitis 
increased by 28% between 1985 and 1995. Due to a decline in the case-fatality proportion, 
the mortality remained stable during this period.
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INTRODUCTION
Acute pancreatitis is a severe disease with a considerable mortality. Despite advanced 
critical care, the case-fatality remains about 5-10%.(1-4) Gall-stones and alcohol are 
the most important risk factors for acute pancreatitis.(5-7) Other risk factors include 
hyperlipidemia, hypercalcemia, ERCP and trauma. In 10 to 25% of the patients with 
acute pancreatitis no obvious risk factors are present.
In the past 30 years, the incidence of acute pancreatitis seems to have risen in 
Western countries.(1,3,8-11) However, it has been suggested that this rise in incidence 
of acute pancreatitis may be explained by improved diagnostic tests and imaging pro-
cedures. In order to assess the recent trends in incidence and mortality rates of acute 
pancreatitis, we performed a nationwide retrospective follow-up study in the Nether-
lands between 1985 and 1995. 
METHODS
Setting
Prismant Health Care Information maintains the National Information System on 
Hospital Care (NISHC). The NISHC is a nationwide, automated database, which col-
lects anonymized data on all hospitalizations in academic and general hospitals in the 
Netherlands. Recorded data include gender, date of birth, place of residence, type of 
health care insurance, admission date, number of days in hospital, mortality, plus a 
primary discharge diagnosis and  up to nine secondary discharge diagnoses, which are 
coded according to the International Classifi cation of Diseases, 9th revision, Clinical 
Modifi cation (ICD-9CM). All data are verifi ed by Prismant on a monthly and yearly 
basis.
Design and source population
We conducted a population based retrospective follow-up study, using automated 
discharge hospital data, which are accumulated by Prismant. The source population 
comprised all inhabitants of the Netherlands between 1985 and 1995. The annual 
population size was retrieved from the Netherlands Central Statistics Offi ce.
Case ascertainment
Cases were defi ned as all persons who were admitted for acute pancreatitis between 
1985 and 1995. To this purpose we identifi ed all persons who had a primary or second-
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ary diagnosis of acute or chronic pancreatitis (ICD-9CM; 577.0, 577.1) between 1980 
and 1995. An identifi cation code consisting of gender, date of birth and place of resi-
dence was assigned to each patient.
In order to avoid double counting of cases we accounted for referrals to other hos-
pitals by checking for consecutive discharge and admission dates, and for identical dis-
charge diagnoses within one admission. Thirty-seven admissions were notifi ed twice 
to Prismant, these second notifi cations were removed from the analysis.
To avoid overestimation of the incidence of acute pancreatitis due to miscoding 
of  chronic pancreatitis, we recoded all discharge diagnoses of acute pancreatitis into 
chronic pancreatitis if an accompanying discharge diagnosis of chronic pancreatitis 
was recorded for the same admission. In addition, we recoded a discharge diagnosis of 
acute pancreatitis into chronic pancreatitis if the patient had a discharge diagnosis of 
chronic pancreatitis in the fi ve years prior to admission.
An admission for acute pancreatitis was considered as a fi rst admission if the patient 
had no history of acute pancreatitis in the fi ve years preceding the admission.
Etiology
The total yearly consumption expressed in litres of pure alcohol per capita was 
obtained from the Commodity Board for the Distilled Spirits Industry. (12) The 
number of patients admitted for gallstone diseases from 1985-1995 and the total 
number of endoscopic procedures to the pancreatic and bile ducts from 1991-1995 
were collected from the NISHC.
Validation of NISHC
In order to quantify underreporting of acute pancreatitis discharge diagnoses to Pris-
mant, we evaluated coded discharge information of 17 consecutive patients who were 
recruited for a population-based case-control study on acute pancreatitis in 1997. Inclu-
sion criteria for this study were a clinical picture compatible with acute pancreatitis 
combined with  a serum amylase or lipase of more than two times the upper normal 
limit, or a typical picture at CT, ultrasound examination, laparotomy, or autopsy.
Secondly, to check the concordance of Prismant discharge information with the 
information recorded in the original medical records, we scrutinized the medical 
records of all patients of the University Hospital Rotterdam who were notifi ed to Pris-
mant as having acute pancreatitis in 1985, 1990 and 1995. A diagnosis of acute pancre-
atitis was accepted when the above described case-defi nition was met.
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Analysis
Annual gender and age specifi c incidence rates were calculated using the number 
of cases of acute pancreatitis in the numerator and the mid-year average number of 
inhabitants as denominator. Incidence rates were expressed as number of cases per 
100,000 person years. According to Rothman et al, 95 percent confi dence intervals 
(95% CI) should be calculated even if an entire population is included in a study.(13) 
We calculated the intervals  on the basis of a Poisson distribution.(14) In addition, we 
recalculated the annual incidence of acute pancreatitis by reference to the age and 
gender structure of 1985.
Mortality rates were calculated as the annual number of patients who died during 
admission for acute pancreatitis divided by the mid-year average number of inhabit-
ants in each age and gender category. Ninety-fi ve percent confi dence limits were 
calculated on the basis of a Poisson distribution.
The case-fatality proportion was calculated as the percentage of patients with an 
acute pancreatitis who died during admission. Ninety-fi ve percent confi dence limits 
were calculated on the basis of a normal approximation to the binomial distribution.
The correlation between the incidence of gallstone diseases, the incidence of endo-
scopic procedures to the pancreatic and bile ducts, the amount of alcohol consumed 
and the incidence of acute pancreatitis was calculated using Spearman’s correlation 
coeffi cient (rs). 
RESULTS
Admissions
In the period 1985-1995 we identifi ed a total of 22,266 admissions for acute pancreati-
tis, in 19,327 (86.8%) of these it concerned a fi rst attack. Of the 9,579 patients admitted 
with a fi rst attack of acute pancreatitis in the period 1985-1990, 1047 (10.9%) patients 
experienced a relapse within 5 years and 608 (6.4%) patients developed chronic pan-
creatitis within 5 years.
Males (54.8%) and people with a sickfund health insurance (70.7% vs. 61.5% in 
the population) -representing the lower income groups- were overrepresented. The 
mean age at fi rst admission for acute pancreatitis was 53.8 years (95% CI; 53.5- 54.1) 
for males and 59.3 years (95% CI; 58.9-59.7) for females. 
The average duration of a hospital stay for acute pancreatitis decreased from 25.2 
(95% CI; 24.1-26.4) days in 1985 to 20.8 (95% CI; 19.9-21.7) in 1995.
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Incidence
The observed incidence rate of acute pancreatitis increased from 12.4/100,000 person-
years (95% CI; 11.8-12.9)  in 1985 to 15.9/100,000 person-years (95% CI; 15.3-16.5) in 
1995. This rise in the observed incidence rate was explained by a rise in the incidence 
rate of acute pancreatitis as primary discharge diagnosis. The incidence rate of acute 
pancreatitis as secondary discharge diagnosis remained stable between 1985 and 
1995.
Figure 1 shows the gender specifi c incidence curves, which indicate that the inci-
dence of acute pancreatitis was consistently higher among men than among women 
and increased in both sexes during the study period. In men, the incidence of acute 
pancreatitis increased from 14.8/100,000 person-years (95% CI; 13.9-15.7) in 1985 to 
17.0/100,000 person-years (95% CI; 16.1-18.0) in 1995. In women the increase was 
from 9.9/100,000 person-years (95% CI; 9.2-10.7) in 1985 to 14.8/100,000 person-years 
(95% CI; 13.9-15.6) in 1995. Figure 1 shows that the increase did not occur steadily 
over the years but appeared predominantly after 1990.
 The incidence rate of acute pancreatitis rose markedly with age (fi gure 2).  An 
increase of the incidence during the period 1985-1995 was seen primarily among 
the elderly. Recalculation of the annual incidence rates by reference to the age and 
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Figure 1
Annual gender specifi c incidence rate of acute pancreatitis per 100,000 person-years in the Nether-
lands between 1985 and 1995 (Bars represent 95% CI). Male (◆), female (■).
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gender structure of 1985 showed an increase of 12.4 per 100,000 person-years in 1985 
to 14.8 per 100,000 in 1995.
Mortality rate and case-fatality proportion
The overall annual mortality rates for acute pancreatitis remained fairly stable at  1.5/
100,000 person-years between 1985 and 1995. The mortality was very low in children 
and young adults, but increased rapidly after 30 years of age to 14.4/100,000 person-
years (95% CI; 12.7-16.1) in the age category above 85 years (fi gure 3).
Figure 4 shows that the case-fatality proportion declined from 13.2% (95% CI; 
11.1-15.2) to 9.5% (95% CI; 7.9-11.1)  in men (p=0.005) and from 13.0% (95% CI; 
10.6-15.5) to 10.0% (95% CI; 8.3-11.8) in women (p=0.043) between 1985 and 1995. 
The case-fatality of fi rst admissions declined from 14.3% (95% CI; 12.6-16.1) in 1985 
to 10.7% (95% CI; 9.4%-12.0%) in 1995. The case-fatality of relapses remained stable 
at approximately 3.2%. Figure 5 illustrates that the case-fatality proportion increases 
rapidly with age up to 38.2%(95% CI; 32.1-44.3) in men aged 85 years and over and up 
to 30.7% (95% CI; 27.1-34.4) in women aged 85 years and over.
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Figure 2
Age and gender specifi c incidence rates of acute pancreatitis in the Netherlands in the period 1985-
1995 (Bars represent 95% CI). Male (◆), female (■).
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Figure 3
Age and gender specifi c mortality rates of acute pancreatitis in the Netherlands in the period 1985-
1995 (Bars represent 95% CI). Male (◆), female (■).
Etiology
During the study period the total amount of pure alcohol consumed per inhabitant 
steadily declined from 8,5 liters in 1985 to 8,0 liters in 1995. The incidence of gallstone 
diseases increased slightly from 143.5/100,000 person-years in 1985 to 159.5/100,000 
person-years in 1995 (rs with incidence of acute pancreatitis=0.76, p<0.01). The 
incidence of endoscopic procedures to the pancreatic and bile ducts increased from 
38.2/100,000 person years in 1991 to 61.2 per 100,000 person-years in 1995 (rs with 
incidence of acute pancreatitis=0.90, p<0.05)
Validation of NISHC
Of the 17 consecutively enrolled patients in a prospective study on acute pancreatitis, 
13 (76%)  were correctly notifi ed to Prismant.
We retrieved the medical records of 101 patients from the University Hospital 
Rotterdam, who were notifi ed to Prismant with a discharge diagnosis code for acute 
pancreatitis in 1985, 1990 and 1995 by the University Hospital Rotterdam. Eighty-
three (82.2%) were correctly coded with a discharge code for acute pancreatitis. This 
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Figure 4
Annual gender specifi c case-fatality proportion of acute pancreatitis in the Netherlands in the period 
1985-1995. Male (◆), female (■).
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Figure 5
Age and gender specifi c case-fatality proportion of acute pancreatitis in the Netherlands in the period 
1985-1995. Male (◆), female (■).
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percentage was consistent over the years 1980, 1985, and 1995. Of the 18 remaining 
patients, nine patients had an amylase value less than double the upper normal limit 
and could therefore not be classifi ed as acute pancreatitis. Furthermore, we found no 
mention of abdominal pain in the medical records of an unconscious patient admitted 
to a coronary care unit, four patients had chronic pancreatitis, and four patients were 
admitted for other diseases.
DISCUSSION
We performed a nationwide study to assess annual age and gender specifi c incidence 
rates of acute pancreatitis in the Netherlands between 1985 and 1995. We observed a 
rise in the  incidence of acute pancreatitis from 12.4/100,00 person-years in 1985 to 
15.9/100,000 person-years in 1995 (28.2%). This trend is consistent with the results of 
several other studies.(1,3,8-11) It has been advocated that the increase in incidence 
rate found in previous studies may be explained by improved diagnostic procedures. 
During 1985-1995 however, diagnostic procedures for acute pancreatitis underwent 
no considerable changes and it is therefore unlikely that changed procedures can 
explain the observed rise in incidence. Although there is no evidence that hospitaliza-
tion patterns for acute pancreatitis have changed during the study period, one cannot 
exclude that certain factors may have infl uenced the observed incidence rates in this 
retrospective study.
A study on the incidence of acute pancreatitis conducted in Scotland over the 
period 1985-1995 showed an increase in the incidence from 25.8/100,000 inhabitants 
in 1985 to 41.9/100,000 inhabitants in 1995. (15) A previous study in the Netherlands 
observed a rise in the rate of acute pancreatitis from 5.7/100,000 in 1969  to 8.1/100,00 
in 1976  for men and a stable incidence of 7.3/100,000 person years for females.(8)  On 
the assumption that the estimation of the incidence rates were comparable, this would 
translate in a rise in incidence of acute pancreatitis of 198.2% for men and 102.7% for 
women from 1969 to 1995.
We found strong associations between age and gender and the incidence of acute 
pancreatitis. This is consistent with the results of other studies.(3,11) However, the 
increase in incidence cannot be solely explained by an aging population as the 
incidence of acute pancreatitis standardized for age and gender also showed a rise. 
Although the incidence of acute pancreatitis increased between 1985 and 1995, the 
annual mortality rate remained fairly stable. This is due to a drop in the case-fatality, 
which may be explained by more effi cacious intensive care treatment or by a higher 
proportion of patients with mild acute pancreatitis. However the case-fatality was still 
10% in 1995, which is  high compared with the 4.5% which was found in a similar 
study in Scotland.(15) One of the reasons for this discrepancy may be an underes-
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timation of mild acute pancreatitis in our study. The mortality rate and case-fatality 
proportion rose profoundly with age; in people aged 75 years and over case-fatality 
was more than 30%. Fan et al. showed that this higher mortality was accounted for by 
a higher occurrence of deaths related to concomitant diseases.(16) The case-fatality 
in fi rst attacks was markedly higher than in relapses, which was consistent with other 
studies.(9, 17-20)
Previous studies have shown that in 12 to 42 % of patients who die of  acute pan-
creatitis, the diagnosis is fi rst discovered  at autopsy. (4,21) As not all patients dying in 
hospital are autopsied, the incidence of acute pancreatitis may have been underesti-
mated. Autopsy data that are available are used for coding of discharge diagnoses. This 
is exemplifi ed by the fact that of 84 patients who had a fatal attack of acute pancreatitis 
and were identifi ed in the database to originate from the University Hospital Rotter-
dam, 45 were fi rst discovered at autopsy. 
About 6% of patients who presented with a fi rst attack of acute pancreatitis devel-
oped a chronic pancreatitis within a period of 5 years.  This fi gure is considerably 
lower than the 24% found in a study by Reid.(17) These differences are probably 
explained by differences in duration of follow-up.
During the study period the total amount of pure alcohol consumed per inhabitant 
steadily declined from 8,5 liters in 1985 to 8,0 liters in 1995. Although causal inferences 
cannot be drawn from ecological data it seems unlikely that the overall increase in 
incidence of acute pancreatitis during the study period can be explained by an overall 
decrease in  alcohol consumption. On the other hand  the incidence rates of gallstone 
diseases and the incidence of endoscopic procedures to the pancreatic and bile ducts 
were positively correlated with the incidence of acute pancreatitis. The incidence rate 
of gallstone diseases increased primarily after 1991, as did the incidence rate of acute 
pancreatitis. Unfortunately we had no data on the number of endoscopic procedures 
performed in the period 1985-1990, but the numbers are likely to have increased more 
in the period 1991-1995 than in the preceding period. Estrogen use is likely to have 
increased in the studied period and may partly explain the rise in incidence of acute 
pancreatitis in women.
The NISHC contains information on at least 99 % of all admissions to general- and 
academic hospitals in the Netherlands. Hospitals supply data to Prismant on a monthly 
basis. Thorough validation of the data with feedback to the hospitals increases accu-
racy of the data.
It has been suggested that hospital disease registry systems are an unreliable 
source for incidence calculations. (5) Our limited validation procedures showed that 
83% of acute pancreatitis admissions notifi ed to Prismant by the University Hospital 
Rotterdam in the years 1985, 1990 and 1995 were correctly coded, which could mean 
that the incidence rates in this study are overestimated by 10-20%.  
On the other hand, we found that 76% of patients identifi ed as having acute pan-
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creatitis in a prospective study were notifi ed to Prismant. Due to the underreporting 
on the one hand, and the overreporting due to miscoding , the observed incidence 
rates may refl ect the true rates. Since these errors are not likely to have changed 
considerably during the study period, we do not think they can explain the observed 
trend.
In conclusion, we observed an increase in the incidence of acute pancreatitis by 
28% in the Netherlands between 1985 and 1995. With a trend downward in case-fatal-
ity, the mortality remained stable in this period.
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Incidence of acute pancreatitis in the general population
Introduction: Incidence studies on acute pancreatitis have largely been based on hospital 
discharge data. We estimated the incidence and referral rate of a fi rst attack of acute pan-
creatitis in the general population.
Methods: We conducted a population-based cohort study in the Integrated Primary Care 
Information (IPCI) general practitioners database in the Netherlands. We identifi ed all 
patients with a diagnosis of acute pancreatitis (ICPC: D99.4, free text) and all patients with 
an elevated amylase or lipase between 1 January 1995 and 1 may 1999. For all potential 
cases additional clinical information was obtained to validate the diagnosis.
Results: The total study population comprised 242,451 patients, who contributed a total of 
599,368 person-years. 110 patients had a computerised primary care history compatible 
with a fi rst episode of acute pancreatitis. Acute pancreatitis could be substantiated in 84 
(76%). Biliary pancreatitis was more frequent in women (46% vs. 35%), alcohol-related pan-
creatitis was more frequent in men (29% vs. 3%). The overall incidence rate of a fi rst attack 
of acute pancreatitis standardised for the age and gender structure of the Dutch population 
in 1995 was 14.2/100,000 person-years. The incidence of acute pancreatitis was higher in 
men than in women and rose markedly with age. 82 out of 84 patients with acute pancre-
atitis were referred to hospital.
Conclusion: Hospital-based incidence studies on acute pancreatitis are comparable to inci-
dence studies based on general population data.
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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas with considerable 
morbidity and mortality. Clinically, acute pancreatitis is characterised by severe 
acute abdominal pain, nausea, and vomiting. Laboratory examinations usually reveal 
elevated levels of serum amylase and lipase. Gallstones and alcohol are the most 
important risk factors for acute pancreatitis. Other risk factors include hyperlipidemia, 
hypercalcemia, ERCP and trauma. In 10 to 25% of the patients with acute pancreatitis, 
no obvious risk factors are present.(1)
The incidence of acute pancreatitis varies around 10 to 40 per 100,000 inhabit-
ants.(2-7) Recent studies have shown an increase in the incidence of acute pancreati-
tis.(3,8) Incidence studies on acute pancreatitis have been based on hospitalisation 
data. These studies may underestimate the true incidence rate of acute pancreatitis if 
not all patients with acute pancreatitis are referred to hospital. We conducted a study 
within a general practitioners database to estimate the incidence and referral rate of a 
fi rst episode of acute pancreatitis in the general population.
METHODS
Setting
In the Dutch health care system, nearly every citizen is enrolled in the practice of a 
general practitioner (GP). The GP acts as a gatekeeper in the health care system and 
co-ordinates the secondary medical care for patients registered in the GP practice.(9) 
In the Netherlands, over 400,000 patients are registered with one of the 150 GPs 
who participate in the Integrated Primary Care Information (IPCI) database project. 
Medical data are continuously recorded and sent anonymously to the department of 
Medical Informatics of the Erasmus Medical Center Rotterdam in order to be used 
for research projects. The computerised information contains demographic data, GP 
notes, diagnoses and fi ndings, laboratory values and prescriptions. Summaries of the 
hospital discharge letters or information from specialists are included as free text. 
Patient complaints and diagnoses are coded according to the International Classifi -
cation for Primary Care (ICPC). Prescription drugs are coded according to the Ana-
tomical Therapeutic Chemical classifi cation (ATC). To maximise completeness of the 
information, GPs participating in the IPCI project are not allowed to have a system of 
paper records besides the electronic medical records. The IPCI database has shown to 
be a valid database for the conduct of epidemiological research.(10)
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Study population
Our study population comprised all patients who were permanently registered with 
one of the participating GP practices. Patients were followed from January 1st 1995, 
the date of fi rst participation of the GP in IPCI, or the date of patient registration in 
the GP practice, whichever was latest. Follow-up ended upon death, transferring out 
of the GP practice, the occurrence of a fi rst episode of acute pancreatitis or chronic 
pancreatitis or May 1st 1999, whichever came fi rst. We excluded all patients with a 
history of pancreatitis before the inclusion date.
Case ascertainment and defi nition
By means of a computerised algorithm we identifi ed all patients with an ICPC-code for 
pancreatitis (D99.4), and all patients with an elevated serum amylase, serum lipase 
or urinary amylase. To avoid potential underascertainment of acute pancreatitis due 
to non-coded information (for example from discharge letters) we included a free text 
search on pancreas and pancreatitis. 
The computerised medical records were reviewed manually for all potential 
cases and additional information (discharge letters and laboratory examinations) was 
requested from the GP if acute pancreatitis was suspected. All cases were classifi ed as 
either defi nite, probable, chronic, or excluded. Acute pancreatitis was labelled defi nite 
when there was a clinical picture compatible with acute pancreatitis combined either 
with an increase in serum amylase or lipase of more than two times the upper limit 
of normal, or with confi rmatory evidence of acute pancreatitis at imaging procedures, 
laparotomy or autopsy. Acute pancreatitis was labelled probable if the medical record 
explicitly mentioned that the patient experienced an episode of acute pancreatitis, 
but no further information was available. Chronic pancreatitis was defi ned by the 
presence of exocrine pancreatic insuffi ciency, pancreatic calcifi cations, or irregular 
pancreatic ducts. 
Analyses
Age and gender specifi c incidence rates of acute pancreatitis were calculated by divid-
ing the number of patients with a fi rst episode of acute pancreatitis by the amount of 
person time in the study population. Ninety-fi ve percent confi dence intervals (95% 
CI) were calculated on the basis of a Poisson distribution. Overall incidence rates were 
standardised to the age and gender structure of the Dutch population in 1995.
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RESULTS
The total study population comprised 242,451 patients, who contributed a total of 
599,368 person-years of experience to the study. Ninety-one patients were excluded 
as they had a history of acute pancreatitis before entry into the study. We identifi ed 
110 patients who had a computerised history compatible with a fi rst episode of acute 
pancreatitis and for whom additional information was requested from the GP. After 
review of this information, the diagnosis could not be substantiated in 26 patients 
(24%), in 26 (24%) patients the diagnosis was probable, and 58 (53%) patients had a 
defi nite diagnosis of acute pancreatitis. Of the 84 patients with defi nite or probable 
acute pancreatitis, 49 (58%) were male and the average age of the cases was 55.5 (SD 
17.1) years. Twenty-one (25%) patients had no obvious cause for their acute pancreati-
tis episode. In the others, acute pancreatitis was probably related to gallstones (n=33), 
alcohol abuse (n=17), ERCP (n=7), pancreas malignancy (n=4), HIV disease (n=1), 
and hypertriglyceridemia (n=1) Biliary pancreatitis was more frequent in women 
(46% vs. 35%), alcohol-related pancreatitis was more frequent in men (29% vs. 3%). 
Five patients (6%) died during their fi rst attack of acute pancreatitis Two (2%) patients 
with defi nite pancreatitis were not referred to hospital. Both had acute abdominal pain 
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Age specifi c incidence rates of a fi rst attack of acute pancreatitis.
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and a serum amylase or lipase of more than fi ve times the upper limit of normal. The 
course was uneventful in both patients. The overall incidence rate of a fi rst episode of 
acute pancreatitis was 14.0/100,000 person-years (95% CI: 11.0-17.0). The incidence 
rate standardised for the age and gender structure of the Dutch population in 1995 
was 14.2/100,000 person-years. The incidence of acute pancreatitis was higher in men 
than in women and rose markedly with age (Figure 1).
DISCUSSION
We conducted a study into the incidence of a fi rst episode of acute pancreatitis in the 
general population. The overall incidence rate standardised for the age and gender 
structure of the Dutch population in 1995 was 14.2/100,000 person-years. The inci-
dence of acute pancreatitis was markedly higher in men and in the elderly. Ninety-
eight percent of all  patients with a fi rst episode of acute pancreatitis was referred or 
admitted to hospital. 
Previous studies reporting the incidence of acute pancreatitis were based on hos-
pitalisation data. (2-7,11,12) As we studied the incidence of acute pancreatitis in the 
general population, we had the opportunity to assess the true incidence rate and the 
potential underestimation due to non-referral in previous studies. Out of 84 patients 
with acute pancreatitis, only 2 had not been referred to hospital. As almost all patients 
were referred, underestimation of the incidence of acute pancreatitis due to non-refer-
ral of patients will be limited in hospital-based studies.
A study on the incidence of acute pancreatitis in the Netherlands based on hos-
pital discharge diagnoses showed an overall incidence of 15.9/100,000 person-years 
in 1995.(8) This study concerned both fi rst admissions and relapses of acute pan-
creatitis. The incidence of fi rst admissions in this study (13.7/100,000 person-years; 
unpublished data) is similar to the incidence of a fi rst attack of acute pancreatitis in 
our present study. If one only considers the number of patients that were referred to 
hospital, the incidence rate in our present study would be 13.9/100,000 person-years. 
The number of studies that reported the incidence of fi rst attacks of acute pancreati-
tis is limited. (2,6,11,12) Two studies in Malmö (S) and North-East Scotland showed 
incidence rates of 23-24/100,000 person-years, two other studies in Nottingham and 
Bristol (UK) showed incidences of 9-11/100,000 person-years.
Inherent to an incidence study based on computerised medical records is the fact 
that we may have underestimated the incidence of acute pancreatitis due to undiag-
nosed acute pancreatitis. In a substantial number of patients with fatal acute pancre-
atitis, the diagnosis is fi rst discovered at autopsy.(13) As the number of performed 
autopsies is low, diagnoses of acute pancreatitis may be missed. In addition, not all 
patients with acute pancreatitis may seek medical attention. To limit underascertain-
IE22.indd   32 04-11-2002, 14:19:38
General population
33
ment we used broad search criteria and a free text search on pancreas and pancreatitis. 
We limited misdiagnosis of acute pancreatitis by checking the computerised medical 
fi les and by requesting additional information from the GP if acute pancreatitis was 
suspected.
CONCLUSION
The overall incidence of a fi rst attack of acute pancreatitis in the general population is 
14.2/100,000 person-years. Ninety-eight percent of all patients with acute pancreatitis 
were referred to hospital. Underestimation due to non-referral is therefore limited in 
hospital-based incidence studies on acute pancreatitis.
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Drug-associated acute pancreatitis: 21 years of spontaneous reporting in the 
Netherlands
Introduction: Drugs are considered a rare cause of acute pancreatitis. We conducted a 
descriptive study to assess which drugs have been associated with acute pancreatitis in 
spontaneous adverse drug reaction reports in the Netherlands.
Methods: Our study is based on reports of drug-associated acute pancreatitis which were 
notifi ed to the Netherlands Center for Monitoring of Adverse Reactions to Drugs and the 
Netherlands Pharmacovigilance Foundation LAREB between January 1st 1977 and Janu-
ary 1st 1998. We used an algorithm to validate the diagnosis and to assess the causal rela-
tionship between acute pancreatitis and use of the suspected drug.  
Results: A total of 55 cases were available for review. We excluded 11 (20.0%) reports, as we 
could not confi rm the diagnosis of acute pancreatitis.  Another 10 (18%) cases were excluded 
since the causal relationship with the suspected drug was unlikely. 
In the remaining 34 reports, acute pancreatitis was labeled as defi nite in 11 (32%) and as 
probable in 23 (68%). 24 (71%) patients were female. The age of the patients ranged from 
17 to 84 years with a median of 41. Of these 34 cases, 27 (79%) recovered, 5 (15%) died and 
in 2 (6%) the outcome was unknown. Azathioprine, cimetidine, interferon-α, methyldopa, 
metronidazole, olsalazine, and oxyphenbutazon all had a defi nite causal relationship with 
acute pancreatitis. Doxycycline, enalapril, famotidine, ibuprofen, maprotiline, mesalazine 
and sulindac had a probable causal relationship with acute pancreatitis.
Discussion: A variety of drugs was associated with acute pancreatitis in Dutch adverse 
drug reaction reports. Quantitative information about drug-induced pancreatitis is scanty. 
Epidemiological studies to assess the risk of drug-induced acute pancreatitis are therefore 
needed. 
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INTRODUCTION
Acute pancreatitis is a severe disease with considerable morbidity and mortality. The 
incidence of acute pancreatitis seems to be rising in Western countries.(1-5) Despite 
advanced critical care, the case-fatality proportion remains around 5-10%.(1,3,6,7) 
Gallstones and alcohol are the most important risk factors for acute pancreatitis.(8-10) 
Other risk factors include hyperlipidemia, hypercalcemia, ERCP and trauma. In 10 to 
25% of the patients with acute pancreatitis, no obvious risk factors are present.
Drugs are rarely associated with the occurrence of acute pancreatitis.(11-14) The 
pathogenesis of drug-induced acute pancreatitis has not been clarifi ed yet. 
The spontaneous adverse reaction-reporting scheme has operated since the early 
sixties in the Netherlands. From 1977 until 1998, the Netherlands Center for Monitor-
ing of Adverse Reactions to Drugs of the Inspectorate for Health Care and the Neth-
erlands Pharmacovigilance Foundation LAREB received 55 spontaneous reports of 
potential drug-induced acute pancreatitis. We conducted a descriptive study to assess 
which drugs were associated with acute pancreatitis in Dutch adverse drug reaction 
(ADR) reports.
METHODS
All reports of drug-associated acute pancreatitis which had been reported to the Neth-
erlands Center for Monitoring of Adverse Reactions to Drugs and the Netherlands 
Pharmacovigilance Foundation LAREB between January 1st 1977 and January 1st 
1998 were independently reviewed by two of the authors (IA, EP), as to the probability 
of the diagnosis of acute pancreatitis, and as to the likelihood of a causal relationship 
with the suspected drug. Discrepancies were discussed in a consensus meeting (IA, EP, 
BHCh). Agreement was reached on all reports. 
The diagnosis acute pancreatitis was labeled as defi nite when acute pancreatitis 
was confi rmed by computer tomography (CT), laparotomy or autopsy. The diagnosis 
was also considered defi nite when positive fi ndings on ultrasound were combined 
with abdominal pain and an elevated level of serum amylase or lipase. Acute pan-
creatitis was labeled as probable when two out of the following three criteria were 
present: positive fi ndings on ultrasound examination, abdominal pain, elevated 
serum amylase or lipase. We defi ned a swollen or enlarged pancreas, an unsharp or 
vague bordered pancreas, peripancreatic fat infi ltration, and necrosis of the pancreas 
on CT or ultrasound examination as positive signs of acute pancreatitis. Cases were 
excluded if above-mentioned criteria were not met, or if  signs of chronic pancreatitis 
were found at endoscopic retrograde cholangiopancreaticography (ERCP), surgery or 
autopsy. We defi ned pancreatic calcifi cations, or an irregular pancreatic duct as signs 
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of chronic pancreatitis.
The causal relationship between acute pancreatitis and the suspected drug was 
assessed according to fi gure 1 if no data on rechallenge were provided. The causal 
relationship was classifi ed possible when other risk factors for acute pancreatitis were 
present, or when the presence of gallstones or alcohol abuse (>5E/24h) was not 
known. In patients with a relapse of acute pancreatitis after rechallenge the causal 
relationship was considered defi nite.
RESULTS
From 1977 until 1998 the Netherlands Center for Monitoring of Adverse Reactions 
to Drugs received 45 reports and the Lareb Netherlands Pharmacovigilance Founda-
tion received 13 reports of drug-associated acute pancreatitis. Three of the 58 reports 
were notifi ed to both reporting centers, leaving 55 episodes of suspected drug-induced 
acute pancreatitis.
Eleven (20%) reports were excluded, as we could not confi rm the diagnosis of 
acute pancreatitis. In 6 cases the criteria for defi nite or probable acute pancreatitis 
were not met, and 5 cases concerned chronic pancreatitis. In ten (18%) cases the 
causal relationship between the suspected drug and the occurrence of acute pancre-
atitis was labeled unlikely because of an incompatible time relationship between start 
of drug treatment and development of acute pancreatitis or because of a relapse after 
discontinuation of the drug. These cases were excluded from the analysis.
In the remaining 34 case-histories, the diagnosis of acute pancreatitis was consid-
ered defi nite in 11(32%) and probable in 23(68%) cases. A discharge summary could be 
obtained for 33 of these 34 (97%) adverse drug reaction reports. The remaining report 
had enough clinical data for a reliable assessment. It concerned 24 (71%) females and 
10 (29%) males. The age ranged from 17 to 84 years with a median of 41. Twenty-seven 
cases (79%) were admitted with abdominal pain, three (9%) were admitted with back 
pain and in four (12%) the symptoms on admission were unknown. Thirty-two cases 
(94%) had an elevated level of serum amylase or lipase, 1 case (3%) had a normal 
level of serum amylase and in 1 case (3%) no enzyme levels were mentioned. CT 
scanning and US examination revealed signs of acute pancreatitis in 7 and 9 cases 
respectively.
The causal relationship with the suspected drug was considered defi nite in 9 (26%), 
probable in ten (29%), and possible in 15 cases (44%). Table 1 lists patient characteris-
tics, other risk factors for acute pancreatitis, the time- and causal relationship between 
drug intake and development of symptoms and the outcome in our 34 patients.
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DISCUSSION
In this case series, we evaluated 55 Dutch reports of drug-associated acute pancreatitis 
which resulted in 14 drugs with a probable or defi nite association with the outcome: 
azathioprine, cimetidine, doxycycline, enalapril, famotidine, ibuprofen, interferon-α, 
maprotiline, mesalazine, methyldopa, metronidazole, olsalazine, oxyphenbutazon and 
sulindac. To our knowledge maprotiline and famotidine have not been reported to be 
associated with acute pancreatitis before.
Most of the ‘evidence’ of associations between drugs and acute pancreatitis is based 
on anecdotal case-reports. Reviews mention aminosalicylates, L-asparginase, estro-
gens, thiazide diuretics, valproate, azathioprine, corticosteroids, furosemide, mercap-
topurine, tetracycline, sulindac, and pentamidine most frequently.(11-14) The WHO 
has received a total of 2749 reports of drug-associated acute pancreatitis in the period 
between 1968 and 1993. ACE-inhibitors (n=209), valproate (n=219), H2-receptor-
blockers (n=127), sulindac (n=121), azathioprine (n=73), gemfi brozil (n=72), lovas-
tatin (n=72), pentamidine (n=62), and didanosine (n=61) were the most frequently 
reported drugs.(15)  
Despite this relatively large volume of case-based evidence, surprisingly little is 
known about the epidemiology (incidence and relative risks) and mechanisms of drug-
associated pancreatitis. Epidemiological evidence is limited to 2 small case-control 
studies which have shown an increased risk of acute pancreatitis associated with use 
of diuretics.(16, 17) 
It is well known that the incidence of an adverse effect cannot be validly estimated 
from spontaneous reports. This is due to large underreporting to voluntary reporting 
schemes, and the scantiness of information on spontaneous reports which compli-
cates validation of the outcome, and assessment of causality to the suspected drugs. In 
order to facilitate validation and causality assessment in our case series, we collected 
additional clinical information. Causality assessment was based on the temporal 
relationship, effect of dechallenge, rechallenge and the presence of other established 
causes (e.g. gallstones, excessive alcohol intake, ERCP). Although our assessments 
were based on retrospective review of discharge summaries that may lack information 
on the presence of  risk factors we excluded 11 out of  55 cases on the basis of an non-
ascertained diagnosis, and another 10 were excluded because a causal relationship was 
unlikely. This shows that thorough evaluation of spontaneous reports is indeed neces-
sary prior to making inferences on any kind of frequency or association. 
The mechanism of drug-induced pancreatitis is largely unknown. In general, 
characteristics of the adverse event such as the temporal relationship, dose response, 
dechallenge and rechallenge may help in suggesting potential mechanisms. For 
instance, mesalazine may possibly provoke immunological damage to the pancreas, 
as rechallenge with small doses can induce relapses of acute pancreatitis within 
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hours.(18-32) However, one should be careful associating these drugs to acute pancre-
atitis since infl ammatory bowel disease itself may also cause pancreatitis.(33-37) The 
same argument holds for azathioprine. This drug has often been associated with pan-
creatitis, even with positive rechallenge, (38-43) but other studies could not confi rm 
this association (44-46).
Localized angioedema with obstruction of the pancreatic duct may be the mecha-
nism by which ACE-inhibitors cause acute pancreatitis.(47) Time intervals between 
the start of ACE-inhibitor treatment and the onset of acute pancreatitis vary between 
one day and two years.(47-55) These intervals are consistent with induction times 
described for ACE-inhibitor induced angioedema.(56-58)
Protopathic bias (prescription of a drug for pro-dromal symptoms of the outcome) 
may explain the reports regarding use of H2-blockers and acute pancreatitis.(59-61) 
An argument in favor of a real association is the positive rechallenge that we and 
others have observed following the re-administration of cimetidine.(60) If true, the 
mechanism remains unknown but the rapid relapse within 24 hours after re-exposure 
suggests an idiosyncratic reaction. As compared to cimetidine, famotidine is a rela-
tively new H2 blocker, which may explain why we are the fi rst to report an associa-
tion between this drug and  acute pancreatitis. However, the previous considerations 
regarding a potential protopathic bias  are equally valid for this H2 blocking agent.
Reports of NSAID-induced acute pancreatitis are sparse, and so are hypotheses 
on a possible biologic mechanism.(62-68) Sulindac seems to stand out, followed by 
oxyphenbutazon.(69-82) One report has been published on a patient who developed 
a possible acute pancreatitis as part of a generalized hypersensitivity syndrome to 
ibuprofen.(83) However, this patient also had parotitis which may explain the hyper-
amylasemia and systemic lupus erythematosus which in itself may be a risk factor for 
acute pancreatitis.(8) As for the H2 blockers, the association between NSAID use and 
acute pancreatitis may be explained by  protopathic bias, since analgesics may be used 
for abdominal pain.
One case has been described previously of a 9-year old girl who developed acute 
pancreatitis after 14 months of treatment with interferon-α for chronic myelogenous 
leukemia.(84) In our case series, we described one patient with a recurrence of acute 
pancreatitis  after re-administration of interferon-α, which makes a causal association 
likely.
Our two reports of methyldopa-associated pancreatitis are consistent with one case 
which has been published previously.(85) All three cases experienced a positive reac-
tion to rechallenge within hours after intake, which suggests an  idiosyncratic reaction 
(85-87).
The association between metronidazole and acute pancreatitis remains unclear. No 
mechanism is known but 5 reports have suggested a possible association, (88-92) but 
a cohort study among 6485 users of  metronidazole did not yield one hospitalization 
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for acute pancreatitis.(93)
In conclusion, a wide variety of different drugs were associated with acute pancre-
atitis in our Dutch case series. Most of the drugs have been associated before, however, 
acute pancreatitis due to famotidine and maprotiline has not been reported before. 
Despite the presence of numerous case-reports on drug-induced acute pancreatitis, 
quantitative information on this subject is scanty. Large scale epidemiological studies 
are necessary to assess the  risk of drug-induced acute pancreatitis.
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Acute pancreatitis attributed to the use of interferon-α-2B
Two patients experienced an episode of acute pancreatitis shortly after starting treatment 
with interferon-α-2B (IFN-α) for chronic hepatitis C infection. The fi rst patient was a 40-
year-old man who developed acute pancreatitis after 15 weeks of IFN-α three MU s.c. thrice 
a week and ribavirin 1200 mg. After disappearance of symptoms and normalization of 
laboratory values, oral intake of solid foods and IFN-α therapy were restarted. Within hours 
a relapse of acute pancreatitis occurred. A rechallenge with IFN-α four days later was 
followed by a prompt increase in serum lipase and IFN-α therapy was discontinued. The 
second patient was a 38-year-old man who developed acute pancreatitis two hours after 
administration of fi ve MU IFN-α s.c. Ultrasound endoscopy showed sludge in the gallblad-
der. The patient was rechallenged fi ve weeks later with IFN-α three MU s.c. Although serum 
amylase and lipase increased after re-administration of IFN-α, treatment was continued. 
The patient was readmitted two weeks later with severe abdominal pain after which IFN-α 
was discontinued.
Considering the temporal relationship between start of IFN-α treatment and development of 
acute pancreatitis, the absence of other clear etiological factors for acute pancreatitis, disap-
pearance of symptoms after discontinuation of IFN-α and a positive reaction to rechallenge, 
IFN-α is the most probable cause for development of acute pancreatitis in these patients. 
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INTRODUCTION
Interferon-α is used primarily for the treatment of viral hepatitis and  hematological 
malignancies.(1,2) Interferon-α is formed in reaction to viral infections in vivo and is 
produced by recombinant DNA technology for therapeutic purposes. The therapeutic 
activity of interferon-α is incompletely understood. Apart from its antiviral properties, 
the immunoregulatory and anti-infl ammatory activities of interferon-α are of impor-
tance.(3)
Flu-like adverse reactions are common during interferon-α therapy. These symp-
toms are generally acute and consist mainly of fever, chills, myalgias and malaise, but 
anorexia and fatigue may persist.(4) Several  serious adverse events have been associ-
ated with interferon-α: agranulocytosis, thrombocytopenia, arthritis, thyroid dysfunc-
tion, rhabdomyolysis, pneumonitis, retinopathy, and renal insuffi ciency.(5-12). We 
describe the case-histories of two patients who developed acute pancreatitis after 
initiating interferon-α-2B (IFN-α) therapy for chronic hepatitis C.
CASE-HISTORIES
Patient A
A 40-year-old man was admitted with diffuse, progressive abdominal pain that started 
two days before, as well as nausea, vomiting and diarrhea that had been present for 
12 weeks. Non-A-non-B hepatitis had been diagnosed 18 years before admission and 
the patient had a history of intravenous drug abuse up to nine years before admission. 
Fifteen weeks before admission, the patient was started on ribavirin 1200 mg daily 
and  IFN-α three MU (s.c.) thrice a week for chronic hepatitis C. The patient used 
40 mg omeprazole and 400mg mebeverine daily. The patient used up to fi ve units of 
alcohol per day. Physical examination revealed diffuse tenderness in the abdomen 
and rebound tenderness in the right lower abdomen. Laboratory examination showed 
a gamma-glutamyl transferase of 124 u/l (normal 15-70), a serum amylase of 136 u/l 
( normal 30-120), a serum lipase of 740 u/l (normal <300) and a C-reactive protein 
of 30.9 (normal <8.0 mg/l). Calcium, triglycerides, and cholesterol were all within 
normal limits. Ultrasound examination (US) revealed no gallstones or pancreatic 
abnormalities.
Five days after admission the complaints had disappeared and amylase and 
lipase values had returned to normal. As the development of acute pancreatitis was 
originally attributed to ribavirin, antiviral treatment was restarted with IFN-α  alone. 
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Within hours after re-administration of IFN-α abdominal pain returned and serum 
lipase had increased to 348 u/l (fi gure 1). The restart of solid food in the same period 
was considered as a possible explanation for the relapse of acute pancreatitis. After 
attenuation of complaints and normalization of lipase values four days later the 
patient was therefore rechallenged with IFN-α. Although the patient did not experi-
ence clinical symptoms of acute pancreatitis, the serum lipase had increased to 1903 
u/l one day later (fi gure 1). IFN-α was discontinued and the patient remained relapse 
free during one year of follow-up.
Patient B
A 38-year-old man was admitted with nausea and severe pain in the left upper abdo-
men and epigastric area. He had a history of meningitis, multiple episodes of throm-
bosis of the right subclavian vein necessitating vascular interventions and multiple 
blood transfusions, post transfusion hepatitis C, and erectile dysfunction. The patient 
was a teetotaler. Six hours before admission the patient injected papaverine intra-cav-
ernally and two hours before admission he administered his fi rst dose of IFN-α s.c. The 
patient had used papaverine eight times before without any problems. No other medi-
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Figure 1
Serum amylase and lipase of patient A during hospitalization. ■= serum amylase (normal 30-120), 
◆=serum lipase (normal <300), = interferon-α-2B, 3 MU.
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cation was taken. Physical examination revealed diffuse tenderness most profoundly 
in the left upper abdomen. Laboratory examinations showed a serum amylase of 137 
u/l (normal 0-100), a serum lipase of 1014 u/l (0-190 ), aspartate-aminotransferase 31 
u/l (normal 0-30), alanine-aminotransferase 69 u/l (normal 0-30). Serum cholesterol, 
triglycerides, and calcium levels were all within normal limits. Computerized tomog-
raphy (CT) and ultrasonography showed no signs of acute pancreatitis, cholelithiasis, 
or dilated bile ducts. US-endoscopy showed sludge in the gallbladder.
Complaints disappeared and amylase and lipase normalized within 2 days. Five 
weeks after admission the patient was rechallenged with 3 MU IFN-α s.c. Two-and-
a-half hours later serum amylase and lipase had risen to 123 u/l and 456 u/l respec-
tively. However, treatment was continued. The patient presented 2 weeks later with 
severe abdominal pain in the left upper abdomen and epigastric area. Serum amy-
lase, lipase, cholesterol and triglycerides were within normal limits. CT-scanning, US 
and endoscopic retrograde cholangiopancreaticography (ERCP) showed no signs of 
gallstones, dilated bile ducts, and no abnormalities of the pancreas. Bile examination 
showed one single cholesterol crystal. Treatment was not reinitiated and the patient 
remained without symptoms for the next two years. The patient continued intermit-
tent use of papaverine intra-cavernally without problems.
DISCUSSION
Considering the temporal relationship between start of IFN-α treatment and devel-
opment of acute pancreatitis, the absence of other clear etiological factors for acute 
pancreatitis, disappearance of symptoms after discontinuation of IFN-α and a positive 
reaction to rechallenge in the 2 case-histories, we conclude that IFN-α is the most 
probable cause of acute pancreatitis in these patients.
Alcohol abuse, cholelithiasis, ERCP, hypercalcemia and hyperlipidemia are the 
most common risk factors for acute pancreatitis.(13) Neither of the patients abused 
alcohol. Although patient A used up to 5 units of alcohol until admission, he was free 
of alcohol intake during rechallenge. Neither had gallstones, hypercalcemia, or hyper-
lipidemia and neither patient underwent an ERCP in the weeks preceding the onset of 
acute pancreatitis. Patient A received IFN-α and ribavirin as anti-viral treatment. An 
association between ribavirin and acute pancreatitis is unlikely as the patient had a 
positive reaction to rechallenge to IFN-α after discontinuation of ribavirin. Mebever-
ine and omeprazole have not been associated with acute pancreatitis. Patient B used 
papaverine for erectile dysfunction six hours before admission, but had used papaver-
ine injections without problems 8 times before. Moreover, the patient continued use of 
papaverine for two years after acute pancreatitis without any problems. US-endoscopy 
showed sludge in the gallbladder of patient B. Although microlithiasis has been associ-
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ated with acute pancreatitis,(14) lipase elevation and return of clinical symptoms after 
reexposure to IFN strongly suggests a causal relation to IFN-α.
Drugs have been recognized as risk factors for acute pancreatitis. (15) Acute pan-
creatitis attributed to interferon has been described in two patients.(16,17) A 9-year-
old girl developed acute pancreatitis after 14 months of treatment with IFN-α for 
chronic myelogenous leukemia.(16) The other patient concerned a 54-year-old man 
who received interferon for chronic hepatitis C.(17) Neither of these two patients were 
rechallenged with interferon. Five patients with HIV treated with didanosine and 
interferon combination therapy experienced acute pancreatitis. However, didanosine 
was the most likely causative agent in these patients.(18,19) In a trial of 25 patients 
treated with fl uorodeoxyuridine, leucovorin and IFN for metastatic renal-cell cancer, 
two patients experienced pancreatitis, mental confusion and volume overload, but 
the authors concluded that these events were probably cardiogenic in nature.(20) One 
patient developed two episodes of acute pancreatitis shortly after start with IFN-α 
for leukemia, but both episodes were preceded by hypercalcemia.(21) Up to january 
2000, 105 reports of interferon-α-2b-associated acute pancreatitis have been notifi ed to 
Schering-Plough (personal communication).
IFN-α has been shown to increase triglyceride levels,(22,23) but this phenomenon 
cannot explain the occurrence of acute pancreatitis in the above described patients 
as both patients had normal levels of triglycerides on admission. The mechanism of 
IFN-α-induced acute pancreatitis remains unknown, but IFN-α should be regarded as 
a potential cause of acute pancreatitis.
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Drug-induced acute pancreatitis: a systematic review
Introduction: Drugs are considered a rare cause of acute pancreatitis. We reviewed the 
medical literature to summarise the current knowledge on drug-induced acute pancreatitis.
Methods: We conducted a search on drug-induced acute pancreatitis and its associated 
terms in PubMed (including MEDLINE) during the period 1966-2001. All English, German, 
French, and Dutch papers on drug-induced acute pancreatitis were retrieved. Reference lists 
of papers were checked to maximise completeness. The causal relationship between drugs 
and development of acute pancreatitis was assessed according to a standard algorithm.
Results: ACE-inhibitors, 5-ASA, asparaginase, azathioprine, codeine, didanosine, isonia-
zid, metronidazole, estrogens, pentavalent antimonials, beta-blockers, sulindac, tetracycline, 
and valproic acid had a defi nite causal relationship with acute pancreatitis; 34 other drugs 
had a probable causal relationship with acute pancreatitis.
Conclusions: Drug-induced acute pancreatitis does not have unique features which dis-
tinguish it from acute pancreatitis due to other causes. A wide variety of drugs have been 
suspected of causing pancreatitis. Despite numerous case-reports on drug-induced acute 
pancreatitis, quantitative information on this subject is scanty. Formal epidemiological 
studies are needed to quantify the risk of drug-induced acute pancreatitis.
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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas characterized by abdom-
inal pain, nausea, and vomiting. Laboratory examinations usually reveal elevated 
levels of serum amylase and lipase. Acute pancreatitis has an overall case-fatality of 
5-10%,(1,2) but case-fatality can be as high as 40% in patients with infected necrosis 
of the pancreas.(3)
Gallstones and alcohol abuse are the most important risk factors for acute pancre-
atitis.(4) It has, however, since long been acknowledged that drugs may trigger acute 
pancreatitis.(5) Drug-induced pancreatitis has no unique features that distinguish it 
from acute pancreatitis due to other causes. Evidence linking drugs to acute pancreati-
tis is mostly derived from spontaneous reporting systems and individual case-reports 
in the medical literature. We conducted an extensive literature search to summarize 
the current knowledge about drug-induced acute pancreatitis.
METHODS
We conducted a search using the terms drug-induced pancreatitis, drug-associated 
pancreatitis, chemically-induced pancreatitis, toxic pancreatitis, drug reaction pan-
creatitis, drug allergy pancreatitis and drug hypersensitivity pancreatitis in PubMed 
(including MEDLINE) during the period January 1966 – December 2001. We retrieved 
all English, German, French, and Dutch papers on acute pancreatitis associated with 
therapeutic or diagnostic drugs. Acute pancreatitis possibly related to calcium intake, 
parenteral feeding, or endoscopic retrograde cholangiopancreaticography (ERCP) was 
not considered in this review. Reference lists of papers were checked to maximise 
completeness. Evidence from case reports and case series was assessed according to 
the algorithm in table 1. The temporal relationship was considered compatible with 
drug-induced acute pancreatitis if symptoms and signs had a reasonable temporal 
relationship to drug intake given the pharmacokinetics of the drug. Information from 
Table 1
Assessment of the causal relationship between a drug and development of acute pancreatitis
Criterion Defi nite Probable Probable Possible Unlikely
Temporal relationship compatible Yes Yes Yes Yes No
Other risk factors No No NA
Patients >1 Yes Yes No
Relapse after deliberate rechallenge Yes Yes
NA = not assessed
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animal, clinical, and observational studies was further used to classify the causal rela-
tionship between drugs and acute pancreatitis. This review focuses on reports with a 
certain or probable causal relationship.
LITERATURE REVIEW
Antibiotics
Ampicillin
One patient experienced two episodes of acute pancreatitis 6 and 4 days after start of 
ampicillin. She had no other risk factors for acute pancreatitis.(6)
Ceftriaxone
Ceftriaxone may induce sludge or small stones in the gallbladder.(7,8) Acute pancre-
atitis attributed to ceftriaxone-induced sludge or cholelithiasis has been described in 4 
patients.(9-12) Analysis of gallstones derived after cholecystectomy showed the stones 
to be composed of ceftriaxone in two patients.(9,10) Imaging procedures failed to show 
sludge or stones in a fi fth report of ceftriaxone-associated acute pancreatitis.(13) An 
association between ceftriaxone and acute pancreatitis is probable given ceftriaxone’s 
capability to induce gallstones.
Macrolide antibiotics
Five patients developed acute pancreatitis within 30 minutes to 3 hours after an oral 
overdose or after intravenous administration of a high dose of erythromycin.(14-18) 
Another patient developed multi-organ toxicity with rhabdomyolysis and pancreatitis 
after addition of erythromycin to long term lovastatin therapy.(19) Rhabdomyolysis 
was probably caused by increased serum-levels of lovastatin when erythromycin 
inhibited its metabolism. Acute pancreatitis attributed to the newer macrolides rox-
ithromycin and clarithromycin has also been reported.(20,21) Erythromycin has a 
prokinetic effect on the smooth muscle of the gastrointestinal tract and the gallblad-
der(22) and may increase the pressure of the sphincter of Oddi.(17) 
Nitrofurantoin
Two cases of nitrofurantoin-induced acute pancreatitis have been described. (23,24) 
Both cases were confi rmed by rechallenge: one by deliberate and one by inadvertent 
re-exposure. One patient had cholestatic liver disturbances.(23) The other patient 
used an oral contraceptive.(24) Nitrofurantoin-associated acute pancreatitis was fur-
ther mentioned in a survey from a spontaneous reporting centre.(25)
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Sulfonamides
Sulfonamide-associated acute pancreatitis has been described in case-reports (26-33) 
and is briefl y mentioned in 3 studies.(34-36) An early paper reported meningitis and 
pancreatitis attributed to sulfamethizole on 2 occasions.(37) Antonow, et al. described 
a case of sulfamethoxazole-trimethoprim-associated acute pancreatitis. Although this 
patient used other medications associated with acute pancreatitis, prompt recurrence 
of symptoms after rechallenge suggested that sulfamethoxazole-trimethoprim was the 
causative agent.(38) Sulfonamide-associated acute pancreatitis is probably immune-
mediated as relapse after rechallenge occurs rapidly and some patients had a positive 
lymphocyte transformation test (39) and accompanying rash or fever.
Tetracyclines
The earliest reports linking tetracycline and acute pancreatitis concerned patients 
who developed acute fatty liver of pregnancy after use of tetracycline.(40-42) Tetracy-
cline-induced acute fatty liver and pancreatitis has been reported in 5 non-pregnant 
patients. In three, however, pancreatitis was present before tetracycline intake,(43) 
one had cholelithiasis,(44) and in the fi fth patient, pancreatitis was detected at 
autopsy.(45) Acute pancreatitis after tetracycline intake without acute fatty liver has 
been described in 4 patients in whom other major risk factors for acute pancreatitis 
were absent.(46-48) Two of them experienced a relapse of pancreatitis after restart 
of tetracycline.(47,48) Acute pancreatitis associated with the use of minocycline has 
been reported in 5 patients,(49-51) although in one patient the development of pan-
creatitis was probably related to liver transplantation(50) and 2 other patients had 
cystic fi brosis.(51) Doxycycline-associated acute pancreatitis has been reported to the 
Dutch and Swiss reporting centres.(29,52) and in 2 clinical studies (2/54 and 9/72 
patients respectively). (53, 54)
Anti-HIV agents
Didanosine and other nucleoside analogues
Didanosine (2’,3’-dideoxyinosine) is a purine analogue with antiretroviral activity 
which has been associated with acute pancreatitis in case-reports (25,29,33,52,55-61) 
and clinical studies.(62-90) The cumulative incidence of pancreatitis in didanosine 
treated HIV-patients varied from 1 to 24% in different studies.(77,86) Risk factors for 
didanosine-induced acute pancreatitis are a history of acute pancreatitis,(73) advanced 
stage of HIV-disease,(80) use of pentamidine,(91) high plasma levels of didanosine,(91) 
and a high cumulative (79) or daily dose of didanosine.(87-89, 91) Hydroxyurea and 
ribavirin increase the active metabolite of didanosine (ddATP) and acute pancreatitis 
after addition of ribavirin and hydroxyurea to didanosine therapy has been reported in 
several patients.(92-94) One study reported a relative risk of 8.6 (95% CI 1.9-39.4) for 
IE33.indd   63 04-11-2002, 14:21:52
DRUG-INDUCED ACUTE PANCREATITIS: DESCRIPTIVE STUDIES
64
adding hydroxyurea to didanosine, (95) although another study could not substantiate 
this.(96) Acute pancreatitis in sickle cell patients receiving hydroxyurea monotherapy 
has been reported.(97)
Relapse after rechallenge to didanosine has been described,(75) but such patients 
may respond favourably to dose reduction.(79) Acute pancreatitis has not been 
reproduced in animal studies.(98,99) Didanosine-induced hyperlipidemia has been 
proposed as a possible mechanism,(100) but mitochondrial toxicity is a more likely 
explanation.(101) The assessment of a causal relationship with didanosine is com-
plicated by the association between HIV itself and acute pancreatitis,(26,102) and by 
the use of other drugs associated with acute pancreatitis, notably pentamidine and 
trimethoprim/sulfamethoxazole. However, a consistent time relationship between 
intake of didanosine and symptoms (12-18 weeks), dose dependency, and positive 
rechallenges point to a defi nite causal relationship. The capacity of didanosine to 
induce mitochondrial toxicity is shared by other nucleoside analogues, (101) and acute 
pancreatitis attributed to these agents has been described.(103-106) Indeed, similar 
incidences of acute pancreatitis have been observed in didanosine and zalcitabine 
users.(107)
HIV-protease inhibitors
Ritonavir is capable of inducing gross hypertriglyceridemia.(108,109) Acute pancreati-
tis due to HIV-protease-inhibitor-associated hypertriglyceridemia has been described 
in 8 patients 1-8 months after start of ritonavir or saquinavir.(109-114) Nelfi navir-asso-
ciated pancreatitis with a positive rechallenge has been described in a non-alcoholic 
HIV-infected patient without cholelithiasis. However, the patient was on didanosine 
during the fi rst attack and had normal levels of triglycerides on the fi rst and second 
attack of pancreatitis.(115) 
Other anti-infective agents
Antitubercular agents
Five patients experienced acute pancreatitis after starting antitubercular therapy 
including isoniazid, in whom a relapse occurred in three after readministration.(116-
120) 
Chan, et al. reported no cases of pancreatitis in 6024 isoniazid/rifampicin treated 
patients, suggesting that the absolute risk of acute pancreatitis in patients receiving 
these medications is low.(121) 
Fialuridine
In a study on the treatment of chronic hepatitis B with fi aluridine (FIAU), 7 out of 
15 patients developed severe hepatotoxicity after 9-13 weeks of therapy.(122) All 
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7 had elevated lipase levels, all 5 patients who died had evidence of pancreatitis 
at autopsy. Three patients had mild fi aluridine-induced toxicity, of whom one had 
elevated pancreatic enzyme levels and epigastric discomfort. Toxicity was probably 
mediated by FIAU-induced mitochondrial injury.(123) The similarities in the clinical 
picture and temporal relationship between start of treatment and start of symptoms in 
these 7 patients, suggests a causal relationship between FIAU and acute pancreatitis/
hepatitis.
Interferon
Acute pancreatitis attributed to interferon has been described in two children 
(124,125) and in 8 adult patients. (25,126-129) In three of them acute pancreatitis 
returned upon rechallenge with interferon. However, one patient used up to 5 units 
of alcohol per day, one had sludge in the gallbladder,(129) and in one the information 
was scanty.(128) A patient with adult T-cell leukaemia (ATL) experienced acute pan-
creatitis shortly after start of interferon therapy,(130) but this episode was probably 
provoked by ATL associated hypercalcemia.(131). In a study on fl uorodeoxyuridine, 
leucovorin and interferon treatment in patients with metastatic renal-cell cancer two 
developed pancreatitis.(83,132) 
Metronidazole
An association between metronidazole and acute pancreatitis has been suggested in 6 
case reports.(133-138) Four patients experienced a relapse of pancreatitis after inad-
vertent re-exposure to metronidazole.(133-136) The fi fth patient had used numerous 
other medications, but apart from metronidazole all drugs had been used for at least 
36 months.(137) Crohn’s disease may have played a role in the development of acute 
pancreatitis in this last patient.(139-141) Among 6485 users of metronidazole, none 
were hospitalised for acute pancreatitis within one month of treatment.(142) This is, 
however, not surprising: if one assumes an incidence rate of 25/100,000 person-years 
in the general population, and a relative risk of 5 for metronidazole, the number of 
cases that one would expect to fi nd would be 0.7. 
Pentamidine
Pentamidine is frequently used in patients with HIV-disease. Twenty-seven patients 
with pentamidine-associated acute pancreatitis have been reported, 14 of whom 
died.(29,143-164) Acute pancreatitis developed mostly within 2-3 weeks after start-
ing treatment. Relapse of pancreatitis after re-exposure has been reported (159,160) 
but both patients had also used trimethoprim-sulphamethoxazole. Acute pancreatitis 
after aerosolised pentamidine has also been reported.(161-163) Pentamidine-asso-
ciated acute pancreatitis has been reported in clinical studies.(34-36,62,165,166) 
Mycobacterium avium intracellulare, age, gallstones, and use of pentamidine are risk 
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factors for development of pancreatitis/hyperamylasemia in patients with HIV infec-
tion.(167-169) Renal impairment has been proposed as an additional risk factor since 
pentamidine is excreted by the kidneys.(157) One animal experimental study found 
pancreatitis in pentamidine infused rats only if they had undergone bilateral nephrec-
tomy.(170) Pentamidine accumulates in the pancreas where it can be found up to 1 
year after stopping treatment,(171) and pentamidine was detectable in serum samples 
up to 2-4 weeks after end of therapy.(150,164) Pentamidine has a cytotoxic effect on 
pancreatic isle β-cells (35) and may possibly have the same effect on acinar pancreatic 
cells. 
Pentavalent antimonials
There are numerous reports on pentavalent antimonials and acute pancreatitis.(172-
187) Of the 12 patients described in case-reports, 6 were treated with stibogluconate 
and 6 were treated with meglumine antimoniate.(172-179) Five patients were HIV-
positive, four patients had received a renal transplant, conditions which are associ-
ated with an increased risk of pancreatitis.(102,188-190) Out of 7 patients treated 
with meglumine antimoniate, 4 developed hyperamylasemia.(182) Three patients 
experienced symptomatic pancreatitis during 46 treatment episodes with pentavalent 
antimonials.(183) In another study, 5 out of 25 patients treated with meglumine anti-
moniate experienced acute pancreatitis. None of them abused alcohol or had choleli-
thiasis.(184) In the period 1989-1996, 96 patients with leishmaniasis were treated with 
stibogluconate in the Walter Reed Army Medical Center (WRAMC). Over 95% of the 
patients had elevated amylase or lipase values, 30% had abdominal pain, and in 15 
patients treatment was temporarily interrupted because of chemical or symptomatic 
pancreatitis. Most patients tolerated reintroduction of stibogluconate well. Pancreatic 
abnormalities tended to occur early in therapy and declined despite continuation of 
treatment.(185) An earlier report of the WRAMC showed elevated pancreatic enzyme 
levels in 32 Peruvian patients, of whom 11 had symptoms of pancreatitis. Treatment 
with pentavalent antimonials was continued in all 32 patients.(186) The latter studies 
suggest that acute pancreatitis is a frequent adverse-effect of pentavalent antimonials 
therapy that does not necessarily require treatment withdrawal.
Cardiovascular agents
Angiotensin converting enzyme inhibitors (ACE-inhibitors)
Captopril, enalapril, lisinopril, perindopril, benazepril, and quinapril have all been 
associated with acute pancreatitis.(25,52,191-210) Three patients experienced a 
relapse after restart of captopril, enalapril, and perindopril respectively.(191-193) 
One other patient possibly experienced pancreatitis after previous exposure to lisino-
pril.(206) The incidence of lisinopril-associated acute pancreatitis in clinical trials is 
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0.3-1.0%.(201) Pancreatic duct obstruction by local angioedema may be the mecha-
nism by which ACE-inhibitors cause pancreatitis.(198) Others have proposed a direct 
toxic effect on pancreatic cells.(199) Because captopril is structurally dissimilar to 
enalapril and lisinopril, an allergic reaction seems less likely.(198).
Losartan
Two patients experienced pancreatitis after intake of losartan, and in both patients 
the association was confi rmed by a positive reaction to rechallenge. (211,212) One had 
renal insuffi ciency, the other had used enalapril up to 4 days before the fi rst attack 
and atenolol up to 3 days before the second attack. Noteworthy is that one patient 
had a recent history of enalapril-related cough,(212) and that the other patient had a 
recent history of enalapril-associated acute pancreatitis.(211) 
Antiarrhythmic drugs
Two cases of amiodarone-associated acute pancreatitis have been described. One 
patient had fatal hepatotoxicity with epigastric pain and mildly elevated amylase and 
lipase serum levels after 3.5 years of therapy, but this patient had an unremarkable 
CT-scan.(213) In the other patient, the relationship between amiodarone and pancre-
atitis was confi rmed by recurrence of pancreatitis after rechallenge, which makes an 
association probable.(214)
Acute pancreatitis related to procainamide has been described in 2 patients. Both 
patients had procainamide-induced lupus syndrome.(215,216) One had recurrence of 
symptoms after inadvertent re-exposure.(215) 
Diuretics
One of the few epidemiological studies on drug-associated acute pancreatitis 
showed a signifi cant excess of diuretic users – mostly cyclopenthiazide - among 
patients with pancreatitis. (217) A subsequent study was suggestive of a threefoldly 
increased risk.(218) Many reports of acute pancreatitis to thiazides,(29,219-229) and 
the related compounds chlorthalidone, metolazone, and indapamide have been 
reported.(29,228,230-234) One patient developed a relapse of pancreatitis after 
restart of methychlothiazide/triamterene combination therapy.(229) Hypercalcemia 
induced by thiazides could theoretically explain the association. However, elevations 
of serum calcium are usually mild, transient, and asymptomatic.(235) A study in 300 
mice treated with chlorothiazide, showed acute pancreatitis in 7.1%.(236)
Acute pancreatitis has been associated with furosemide in several patients.(25,34,237-
242) Three had a relapse of pancreatitis after rechallenge with furosemide. The fi rst 
patient had type II hyperlipidemia and had received morphine.(239) The second 
patient had gross hyperlipidemia and used estrogens upon admission. She was chal-
lenged in normolipemic state with estrogen, which she tolerated well and with furo-
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semide, after which she relapsed.(238) The third patient was known with renal failure 
and malignant hypertension. He developed acute pancreatitis twice after furosemide 
intake and hyperamylasemia after subsequent bumetanide intake.(240) 
Methyldopa
Five cases of methyldopa-associated acute pancreatitis have been described,(243-246) 
of which 4 were confi rmed by rechallenge.(243-245) Although most patients used 
other medications that have been associated with acute pancreatitis and 1 patient had 
cholelithiasis,(244) a causal relationship between methyldopa and acute pancreatitis 
is highly probable. 
β-Blockers
A 64-year-old man developed marked hyperlipidemia with pancreatitis by reduced 
clearance of lipids after starting atenolol.(247) One patient developed hyperlipidemia 
with secondary acute pancreatitis after exposure and re-exposure to nadolol.(248) 
Other cases of hyperlipidemia by β-blockers have been reported.(249,250) 
Gastrointestinal agents
5-ASA
The literature on aminosalicylate-associated acute pancreatitis is abundant.(25,245,251-
279) Both sulfasalazine (25,245,251-260) and mesalazine (25,253,258-280) have been 
implicated. The fi rst reports on sulfasalazine suggested that the sulfapyridine moiety 
was responsible for this adverse effect. Cross-reactivity between sulfasalazine and 
mesalazine(258-260) and the numerous reports on mesalazine-associated pancreatitis 
has shifted the attention to the aminosalicylates. One should take into account that 
infl ammatory bowel disease itself is associated with acute pancreatitis,(139-141) and 
that several patients used other medications that have been associated with acute 
pancreatitis (prednison, azathioprine) or had other risk factors for acute pancreatitis. 
Even so, the large number of recurrences of pancreatitis after rechallenge demon-
strate a defi nite relationship between aminosalicylates and acute pancreatitis.(25, 
255-268), one of which after rectal rechallenge (258) Aminosalicylate-associated acute 
pancreatitis is probably immune-mediated as rechallenge with small doses can pro-
duce relapses of acute pancreatitis within hours and because lymphocyte transforma-
tion tests were positive in one patient.(275) 
Diphenoxylate/atropine
A 62-year-old woman developed acute pancreatitis within 3 hours of taking 
diphenoxylate/atropine on 2 separate occasions. There were no other risk factors for 
acute pancreatitis.(281)
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H2-Blockers
Cimetidine has been associated with pancreatitis in six cases.(52,282-285) The associa-
tion was confi rmed by a deliberate rechallenge in 2 patients,(284) and inadvertent re-
exposure in two others.(52,283) Relapse of pancreatitis after inadvertent re-exposure 
with cimetidine and a case of famotidine-associated pancreatitis are mentioned in a 
study of spontaneous reports to a national monitoring centre of adverse drug reac-
tions.(52) An 81-year-old woman experienced three bouts of acute pancreatitis after 
(re)start of ranitidine.(286) One study suggested that cimetidine may cause acute 
pancreatitis in rats,(287) but others have questioned this.(288,289) Two observational 
studies found an elevated risk of acute pancreatitis for H2-blockers, albeit non-signifi -
cant. (290,291) In assessing a relationship between H2-Blockers and acute pancreatitis 
one has to bear in mind that acid-suppressing drugs may be prescribed for prodromal 
symptoms of acute pancreatitis. 
Somatostatine analogues
Nine patients experienced acute pancreatitis while on the somatostatine analogues 
octreotide and lantreotide. (292-298) One patient already had an enlarged pancreas 
before start of therapy, (294) 2 were HIV-positive (292,293), 2 had relapsing acute pan-
creatitis before start of therapy, (295), one had pancreatitis only on octreotide-codeine 
therapy and not on these drugs apart, (295) and in 1 patient with rechallenge the infor-
mation was very scanty. (297) Deliberate rechallenge in 3 patients resulted in a relapse 
of acute pancreatitis. (293,296) However, symptoms settled and amylase normalised 
while treatment was continued in 2 other patients. (296,298) Numerous hypotheses 
regarding the mechanism of somatostatine have been proposed, but increased con-
tractility of the sphincter of Oddi seems to be the most plausible. (293,296) Sphincter 
of Oddi manometry showed a higher frequency of Oddi contractions after octreo-
tide administration in 6 patients with idiopathic recurrent pancreatitis. Pancreatitis 
developed in 5 of them after the procedure.(299) Most of above described patients 
developed acute pancreatitis within hours, which is compatible with this hypothesis. 
Long-term octreotide therapy is associated with cholelithiasis. (300,301) 
Immunosuppressives and antineoplastic agents
Asparaginase
Asparaginase is an anti-neoplastic drug that has been associated with acute pancreati-
tis since more than 30 years.(302) Evidence from case-reports, however, is anecdotal 
and other risk factors for acute pancreatitis were not always excluded.(29,34,303-
328) Most patients received other drugs, notably prednison and vincristine. Recur-
rence of pancreatitis after rechallenge has not been described. Most cases pertain to 
asparaginase derived from Escherichia coli (319,329) but pancreatitis associated with 
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asparaginase derived from Erwinia chrysanthemi has also been reported (327) and 
seems to have a lower incidence. (330) Another patient experienced several adverse 
reactions, among which pancreatitis after a single injection of 1000 IU/kg. Rechal-
lenge at half the dose several months later was well tolerated.(326) The cumula-
tive incidence of acute pancreatitis in studies of patients treated with asparaginase 
averages around 5-10%.(302,329,331-346) Another study found a higher incidence in 
polyethylene glycol-L-asparaginase than in native E. Coli asparaginase (9/50 vs. 1/50) 
Weetman, et al suggested a role for estrogens as most of their patients were pubertal 
females.(337) Interestingly, a study on rat liver asparaginase activity reported higher 
activity in female than in male rats. Asparaginase activity decreased after gonadec-
tomy in female rats.(347) Asparaginase-induced hypertriglyceridemia has also been 
proposed as a possible mechanism.(328) Indeed a study on lipid abnormalities during 
asparaginase therapy found triglyceride levels of more than 11 mmol/l in 7 out of 38 
patients. However, pancreatitis developed in 4 patients and all had normal triglyceride 
levels.(346) Serial ultrasound examinations have been proposed for early detection 
of asparaginase-induced acute pancreatitis, but results of this strategy are equivo-
cal.(341,348) 
Azathioprine/6-mercaptopurine
Numerous case-reports linking azathioprine,(25,29,52,349-364) and its metabolite 
6-mercaptopurine (364-367) to acute pancreatitis have been published, the majority 
with recurrence of pancreatitis after rechallenge.(25, 357-365) In addition, acute pan-
creatitis has been described in patients with systemic lupus erythematosus,(368,369) 
and in patients with renal transplants on immunosuppressive therapy that included 
azathioprine.(188,190,370-373) The occurrence of symptoms within weeks after start-
ing azathioprine therapy, recurrence of symptoms within hours after rechallenge, 
and dose independency suggest an immune-mediated reaction. One report men-
tioned among others acute pancreatitis after addition of allopurinol to azathioprine 
therapy, possibly due to impairment of azathioprine/mercaptopurine breakdown 
by xanthine-oxidase.(374) Both synergistic and protective effects of concomitant 
prednison therapy have been suggested.(357,375) In a randomised trial comparing 
azathioprine, prednison, sulfasalazine, and placebo, 6 (5.3%) patients in the azathio-
prine group developed acute pancreatitis versus none in the other 3 groups. Four of 
them reported prompt recurrence of symptoms after self-initiated stop and restart of 
azathioprine intake.(376) Another study reported acute pancreatitis in 12 out of 400 
patients treated with immunosuppressive therapy that contained 6-mercaptopurine 
for infl ammatory bowel disease. All 7 patients that were rechallenged developed a 
relapse of pancreatitis, some on very small dosages.(377) Azathioprine-induced pan-
creatitis is mentioned in several other azathioprine/6-mercaptopurine safety reports 
(375,378-380) and clinical reports (53, 381) but has not been reproduced in two animal 
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studies (382,383). One study advocates weekly laboratory examination during the fi rst 
2 months of therapy to detect elevated levels of amylase before pancreatitis becomes 
clinically manifest.(384) 
Combination chemotherapy
One patient developed acute pancreatitis after the 5th and 6th course of vincristine, 
methotrexate, mitomycin, 5-FU and cyclophosphamide.(385) A second patient devel-
oped acute pancreatitis after the 2nd, the 3rd, and the 4th treatment cycle with cyclo-
phosphamide, doxorubicin, vincristine and prednison.(386) Similar cases have been 
reported ,(387) one which was able to continue chemotherapy after substituting vin-
blastine with etoposide. Noteworthy is that vinblastine or vincristine were included 
in all these regimens as an animal study found marked autophagy after high dose 
vinblastine/vincristine.(388) 
Corticosteroids
Oral cortisone is the fi rst drug for which a potential causal relationship to acute 
pancreatitis was considered.(389) Since then, over 50 case-histories have been pub-
lished.(29,368,370,373,390-417) and corticosteroid-associated acute pancreatitis is 
briefl y mentioned in several case-series.(53,54,381,418-421) Interestingly, acute 
pancreatitis in patients with Cushing’s disease has also been reported.(422,423) As 2 
critical reviews have pointed out, however, most reports on corticosteroid-induced pan-
creatitis do not fi rmly support a causal relationship.(424, 425) Autoimmune disorders, 
hypercalcemia, history of alcohol abuse, or cholelithiasis was noted in some reports 
and may have been causative. There is no apparent time relationship and rechallenge 
data are scanty. An HIV-positive patient with a history of didanosine-associated pan-
creatitis developed pancreatitis after 2 days of prednison therapy. He again experi-
enced an episode of pancreatitis 2 weeks later after 1 day of dexamethasone therapy. 
(395) Another patient had a rise of serum amylase after restart of 30 mg prednisolone, 
but amylase values normalised after lowering the dose of prednison.(410) One patient 
experienced 3 episodes of acute pancreatitis 2-6 days after start of dexamethasone, but 
had a history of alcohol abuse.(409) Two autopsy studies found higher prevalences of 
pancreatic lesions in patients treated with steroids.(416,426) One compared deceased 
patients before and after 1955,(416) the other compared deceased patients who had 
used steroids to a matched control group that had not used steroids.(426) Studies on 
the infl uence of corticosteroids on secretory function of the pancreas are confl ict-
ing.(427,428) Studies in steroid treated rabbits have shown peripancreatic fat necrosis 
and mild pancreatic changes.(429, 430) Studies in dogs have been less successful in 
inducing pancreatic lesions.(431-433) In one study, 5/31 methylprednisolone treated 
patients versus 10/103 non-treated patients developed acute pancreatitis, (434) but 
another study was negative.(435) Given the inconclusive evidence described above, 
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we conclude that the association between corticosteroids and acute pancreatitis is 
questionable.
Cytarabine
Acute pancreatitis attributed to cytarabine has been described several times.(29,436-
441) One patient developed acute pancreatitis after continuous infusion of cytarabine. 
Rechallenge with intermittent high-dose cytarabine was well tolerated. Subsequent 
rechallenge with continuous infusion led to relapse of acute pancreatitis. An ultra-
sound 17 days later showed sludge in the gallbladder.(436) Altman, et al. described the 
case of a 14-year-old boy who developed acute pancreatitis on the 3rd cycle of cyta-
rabine maintenance regimen. He developed abdominal pain on the 4th cycle, which 
was not further investigated, and he experienced a relapse of pancreatitis on the 5th 
cycle.(438) Two cases-series mention acute pancreatitis in 2/25 and 3/93 patients 
treated with cytarabine.(439, 440) A third study showed pancreatitis in 7 out of 137 
patients.(441) One out of the 5 patients in whom treatment was continued experi-
enced a relapse of pancreatitis.
Ifosfamide
One patient experienced two episodes of acute pancreatitis within 24 hours after the 
2nd and 4th dose of ifosfamide.(442) She had abdominal pain after the 1st cycle. An 
ultrasound showed sludge during the fi rst attack of acute pancreatitis. Another patient 
developed a petechial rash after 2 days ifosfamide treatment. Two days later she devel-
oped acute pancreatitis without presence of conventional risk factors.
Neuropsychiatric agents
Clozapine
There are several reports on clozapine-associated acute pancreatitis.(443-450) 
However, 3 patients had no abdominal pain.(443-445) One patient had a return of 
abdominal pain after restart of clozapine. Amylase values were not reported during 
this relapse and she had used valproate before her fi rst attack.(446) Another patient 
relapsed twice after consecutive restarts of clozapine, but this patient had concomitant 
cholelithiasis.(447)
Pyritinol
A 23-year-old male experienced 3 episodes of acute pancreatitis.(451) The time 
between start of pyritinol decreased from 3 months to 6 and 4 days respectively. He 
was rechallenged with a single dose of pyritinol and developed a relapse of acute pan-
creatitis within 3 hours. A lymphocyte stimulation test was positive for pyritinol.
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Valproic acid
The antiepileptic drug valproic acid has been associated with acute pancreatitis in 
over 40 patients.(29,452-486). Most cases concerned children, which is consistent with 
the prescription pattern of valproic acid. Acute pancreatitis usually develops in the 
fi rst year of therapy, but delayed onset of acute pancreatitis has been described.(462) 
After restart of valproic acid, 8 patients had recurrence of pancreatitis. Four patients 
tolerated restart of valproic acid: one on the original dose, one on a lower dose, and 
2 after renal transplantation.(452-462) One patient developed chronic pancreatitis 
while on valproic acid.(487) Although acute pancreatitis after intoxication with val-
proic acid has been described,(480,486) most patients had serum levels within the 
therapeutic range. It has been postulated that valproic acid causes acute pancreatitis 
by inhibiting detoxifi cation of free radicals. Valproic acid enhances the clearance of 
selenium, copper, and zinc. These trace elements are essential for the functioning of 
radical scavengers.(485) One toxicity study in rats showed atrophic pancreatitis after 
52 weeks of valproic acid intake.(488) The incidence of valproic acid-associated acute 
pancreatitis is unknown. In a survey among physicians with an interest in epilepsy, 
14.5% of respondents indicated they had encountered pancreatitis attributed to val-
proic acid.(462) Out of 100 children that were treated with valproic acid, one devel-
oped acute pancreatitis.(489) Out of 78 patients with renal failure, 4 developed acute 
pancreatitis. All 4 were valproic acid users, while none of the other 74 patients used 
valproic acid.(461) 
Miscellaneous drugs
Bezafi brate
A 75-year-old woman was hospitalised with fever and confusion 3 weeks after start-
ing bezafi brate for mild hypercholesterolemia.(490) She was readmitted two times for 
acute pancreatitis within hours of taking bezafi brate. She had no other risk factors for 
acute pancreatitis.
Codeine
The fi rst report of acute pancreatitis by codeine dates back to 1951 in a patient who 
had recurrent episodes of pancreatitis for many years.(5) Deliberate rechallenge with 
codeine sulphate on 2 separate occasions was followed by recurrence of pancreatitis on 
both occasions. Elevated levels of pancreatic enzymes were found in 5 other patients 
after deliberate exposure to codeine sulphate, of whom 3 had concurrent abdominal 
pain.(5) Since this fi rst report, pancreatitis attributed to codeine has been described in 
several other patients. (491-494) In one the diagnosis was by no means sure (491,492) 
In 3 others inadvertent rechallenge with codeine was followed by a relapse of acute 
pancreatitis within hours.(493) This short induction time is compatible with a hypoth-
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esis of biliary obstruction by spasm of the sphincter of Oddi.(5,495) In 2 of the patients 
acute pancreatitis developed after intake of paracetamol-codeine.(493,494) 
Estrogens
Estrogen-associated pancreatitis has been described in women taking oral contra-
ceptives,(233,496-508) in post-menopausal women taking hormonal replacement 
therapy,(509-511) and in men taking estrogens for prostate-related problems.(511,512) 
Most patients had severe estrogen-induced hypertriglyceridemia.(502-512) How-
ever, estrogen-associated acute pancreatitis without hyperlipidemia has also been 
described.(497,498) Thrombosis in pancreatic vessels has therefore been proposed as 
a potential mechanism.(497,513) Two patients had relapse of pancreatitis after restart 
of oral contraceptive therapy.(501,505) Three other patients had multiple attacks of 
acute pancreatitis while on contraceptive therapy.(505-507) In a case-series, estrogen-
induced acute pancreatitis was suspected in 15 out of 73 patients.(54) An experimen-
tal study in rats found hemorrhagic pancreatitis in female and male oestradiol treated 
rats given a choline defi cient, ethionine enriched diet, but not in control rats.(514) 
In a study of 31 women with hypertriglyceridemia, 12 used hormonal replacement 
therapy. After cessation of therapy, start of a low fat diet, and start of gemfi brozil 
therapy, lipid levels decreased sharply.(515) Estrogens are defi nitely associated with 
acute pancreatitis given the fact that estrogens are capable of inducing gross hyper-
triglyceridemia in susceptible patients,(516) and given the return of symptoms after 
restart of estrogens in 2 patients. Transdermal oestradiol therapy may be an option in 
patients with pre-existing hypertriglyceridemia.(517)
Tamoxifen and clomiphene are synthetic estrogen analogues with mixed agonist-
antagonist actions. Two patients with pre-existent familial hyperlipidemia developed 
gross hyperlipidemia with subsequent acute pancreatitis after 4 and 8 months of 
tamoxifen therapy for breast cancer. Other major risk factors for acute pancreatitis 
were not described.(518,519) Tamoxifen-induced hypertriglyceridemia without pan-
creatitis has been described before.(520) Acute pancreatitis secondary to clomiphene-
associated hypertriglyceridemia has been described in a 37-year-old woman. Restart 
of clomiphene led to severe hypertriglyceridemia with a subsequent relapse of pan-
creatitis.(521) Cholelithiasis could possibly explain development of acute pancreatitis 
in another patient on clomiphene.(233) 
Fenfl uramine
Dexfenfl uramine and fenfl uramine have been associated with acute pancreatitis in 
2 reports.(522,523) One of these patients had a history of acute pancreatitis 11 years 
earlier, which was preceded by intake of fenfl uramine.(523) The other patient had 
numerous other medications but these had been used for over 5 years and were re-
introduced after attenuation of symptoms without any problems. 
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Growth hormone
A 12-year-old boy developed acute pancreatitis after his 6th dose of growth hormone. 
After rechallenge acute pancreatitis returned promptly.(524) Other risk factors were 
not described, but alcohol abuse and gallstones are rare in children. More cases were 
reported to the manufacturer (525) and the FDA (524).
HMG CoA reductase inhibitors
One patient developed pancreatitis one week after start of lovastatin.(526) Six months 
later lovastatin was restarted with prompt recurrence of abdominal symptoms. Unfor-
tunately, serum amylase values were not assessed at that time. 
Five patients developed acute pancreatitis between 12 hours and 7 months after 
start of simvastatine therapy.(527-530) One of them stopped simvastatine intake after 
7 months on his own initiative because of abdominal pain. After restart, symptoms 
recurred in 7 days. One study from a spontaneous reporting centre mentioned a 
rechallenge proven simvastatine-associated acute pancreatitis and fl uvastatine-associ-
ated pancreatitis in another patient. However details were not provided.(25) In one 
patient acute pancreatitis developed 8 hours after start of atorvastatine.(531) Two 
patients developed rhabdomyolysis with concurrent pancreatitis after simvastatine 
and lovastatin-gemfi brozil therapy.(532,533)
Methimazole
A 66-year-old woman with Graves’ disease experienced acute pancreatitis and paroti-
tis 3 weeks after starting methimazole.(534) She had elevated levels of salivary and 
pancreatic amylase, and lipase. She developed a relapse of pancreatitis within 3 hours 
after rechallenge.
Non steroidal anti-infl ammatory drugs (NSAIDs)
In NSAID-associated acute pancreatitis, sulindac seems to stand out.(535-542) 
Seven out of the 10 patients had a relapse of pancreatitis after rechallenge.(536-542) 
Seven patients had cholestatic liver function test disturbances in absence of chole-
lithiasis.(535-539,543) This can possibly be explained by sulindac-induced bile duct 
injury.(538) Indomethacin,(544) ibuprofen,(52,545), tolfenamic acid,(29) mefenamic 
acid,(245,546) oxyphenbutazon,(547,548) phenylbutazon,(25) piroxicam,(29,549,550) 
tiaprofenic acid,(551) ketoprofen, (552-554) diclofenac,(233,550,555) naproxen, 
(550,556,557) and ketorolac (558) have sporadically been associated with acute pan-
creatitis. Recently, two cases of pancreatitis attributed to the cyclooxygenase-2 selec-
tive NSAID celecoxib have been described.(559,560) Both patients used other drugs 
previously associated with acute pancreatitis. In assessing the relationship between 
NSAIDs and acute pancreatitis, one has to consider the possibility of protopathic bias: 
the prescribing of drugs for prodromal symptoms of acute pancreatitis. Sulindac, how-
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ever, is a defi nite cause of pancreatitis. For naproxen, ketoprofen, mefenamic acid, 
and oxyphenbutazon the causal relationship with acute pancreatitis is probable.
 Propofol
Five cases of propofol-associated acute pancreatitis have been reported in the litera-
ture.(561-565) One patient had a relapse of pancreatitis after inadvertent re-exposure 
to propofol during surgery, but this patient had concomitant cholelithiasis.(561) One 
further patient has been reported who developed elevated pancreatic enzyme levels 
after propofol therapy in a patient with severe head injury.(566) However, head 
trauma in itself is associated with elevated amylase levels.(567,568) Several other 
cases have been reported to the FDA.(562,569) A recent study on propofol infusion in 
rats showed an increase of lipid levels in rats on continuous infusion. Three rats in the 
continuous infusion group (n=30) developed histological pancreatitis versus 1 in the 
control group and none in the bolus infusion group.(570) Two randomised controlled 
trials showed no differences in serum lipase and amylase,(571,572) slightly elevated 
triglyceride levels were found in one study.(572)
Retinoids
Six patients have been described with hyperlipidemia and secondary pancreatitis after 
use of retinoids for leukaemia and dermatological disorders.(573-578) One patient had 
type IV hyperlipidemia and used estrogens, which are known to produce hyperlip-
idemia.(576) Two other patients also had pre-existent hyperlipidemia.(573,577) One 
Table 2
Drugs with a defi nite or probable causal relationship to acute pancreatitis
Defi nite Probable Probable
5-ASA Amiodarone Losartan
ACE-inhibitors Ampicillin Macrolide antibiotics
Asparaginase Bezafi brate Mefenamic acid
Azathioprine/mercaptopurine Ceftriaxone Methimazole
Codeine Clozapine Methyldopa
Didanosine (ddI) Cytarabine Naproxen
Isoniazid Diphenoxylate Nitrofurantoin
Metronidazole Fenfl uramine Oxyphenbutazone
Estrogen compounds Fialuridine Pentamidine
Pentavalent antimonials Furosemide Procainamide
β-Blockers Growth hormone Propofol
Sulindac H2-Blockers Pyritinol
Tetracycline HIV-protease inhibitors Retinoids
Valproic acid HMG CoA reductase inhibitors Somatostatin analogues
Ifosfamide Sulfonamides
Interferon Thiazides
Ketoprofen Vitamin D
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Table 3
Drugs with a possible causal relationship to acute pancreatitis
Possible
Alendronate (52,586) Famotidine (see text) Mycophenolate mofetil(587)
Allopurinol(25) Felodipin(29) Nicotine(588)
Amineptine(589) Finasteride(590) OKT3(591)
Aminophylline(415) Floxuridine/mitomycin C(592) Olanzapine(593-596)
Amoxapine(25,597) Fluconazol(29) Ondansetron(598) 
Anticholinesterase agent(599) G-CSF(600) Oxcarbazepine(25)
Aspirin(601) Glicazide(602) Paclitaxel(603,604)
BHI regeneration tablets(605) Gold(606,607) Paracetamol(25,29,52,245,608-613)
Bromide(614) Granisetron(615) Paromomycin(616)
Carbamazepine(617-619) Griseofulvin(25) Penicillin(620)
Celecoxib (see text) Histamine(621) Pentagastrine(622)
Chlormezanone(623) Hydroxyurea (97) Phenacetin(624)
Cholestyramine(25,625) Ibuprofen (see text) Phenformin(626-632)
Ciprofi brate(52) Imipenem(633) Phenolphthalein(634)
Ciprofl oxacin(635) Imipramine(25) Phenprocoumon(29)
Cisplatin(636-638) Indalpine(639) Phenylbutazon (see text)
Clofi brate(640-642) Indomethacin (see text) Piroxicam (see text)
Clomipramine(25,643) Interleukin 2(644) Propylthiouracile(645)
Clonidine(646) Itraconazol(647) Ribavirin(648)
Colchicine(649,650) Ketorolac (see text) Rifampicin(583,651-653)
Corticosteroids (see text) Lamivudine(654) Riluzole(655,656)
Cyclophosphamide(368,396) Lamotrigine/vigabatrin(657) Risperidone(658,659)
Cyclosporine(29,660-663) Linomide(664) Tacrolimus(665-667)
Dapsone(668) Lithium(25) Thalidomide(669)
Diazoxide(670,671) Loperamide(672,673) Tiaprofenic acid (see text)
Diclofenac (see text) L-tryptophan (674) Ticarcillin/clavulanic acid(675)
Diethylpentenamide(676) Maprotiline(52) Ticlopine(25)
Donepezil(677) Metaraminol(678) Tolfenamic acid (see text)
Ergotamine(679) Metformin(680) Triciribine(681)
Ethacrynic acid(682,683) Methandienone(684) Ursodeoxycholic acid(685)
Ethchlorvynol(686) Methotrexate(368) Vinorelbine(687,688)
Exatecan mesylate(689) Methylphenidate(690) Warfarin(691)
Famciclovir(692) Morphine(693-699)
patient experienced 2 episodes of acute pancreatitis 2 years apart, after intake of 
isotretinoine, but this patient had concomitant sludge and cholelithiasis.(578) Acute 
pancreatitis due to bexarotene (a retinoid-X-receptor selective retinoid) induced 
hypertriglyceridemia is mentioned 2 clinical trials.(579,580)
Vitamin D
Acute pancreatitis developed in a patient with hypercalcemia due to cholecalciferol 
and calcium supplements. Unfortunately, information on other major risk factors for 
acute pancreatitis was not provided.(581) Another patient had a vitamin D concentra-
tion that was 4.5 times the normal level and hypercalcemia during his fourth admis-
sion for acute pancreatitis. On questioning, the patient admitted intake of massive 
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amounts of vitamin D. He did not have any other risk factors for acute pancreatitis, 
and neither patient had hyperparathyroidism.(582) Interestingly, the patient had 
elevated levels of vitamin D for up to 3 months after stopping vitamin D intake. This 
is probably due to mobilisation of stored vitamin D from tissues. Vitamin D is probably 
related to acute pancreatitis, most likely by inducing hypercalcemia. 
Drugs with a defi nite or probable causal relationship to acute pancreatitis are sum-
marised in table 2. Drugs with a possible causal relationship are listed in table 3.
DISCUSSION
Over 150 drugs have been proposed as a potential cause of acute pancreatitis. Evidence 
associating drugs with acute pancreatitis is largely based on individual case histories 
in which a close temporal relationship between drug intake and acute pancreatitis 
may be a chance fi nding. Relapse of pancreatitis after controlled rechallenge confi rms 
a causal relationship. Such proof is uncommon, however, as rechallenge is only ethi-
cal when it concerns a drug which is essential for the treatment of the patient.
In some conditions, drug effects may be diffi cult to separate from the underly-
ing condition. Mesalazine, azathioprine, and corticosteroids, for instance, are used 
in the treatment of infl ammatory bowel diseases which itself increases the risk of 
acute pancreatitis. Protopathic bias may further complicate assessment of the causal 
relationship between drugs and acute pancreatitis. Two case-control studies found a 
non-signifi cantly increased risk of pancreatitis among acid suppressing drug users, 
which could possibly be due to prescription of acid-suppressing drugs for prodromal 
symptoms of acute pancreatitis.(290,291) Despite these problems, clinical evidence 
strongly suggests a causal relationship for a number of drugs. Didanosine-induced 
acute pancreatitis, for instance, was reported as soon the fi rst dose escalating stud-
ies were performed and it has consistently been reported since then. For some drugs 
a causal relationship with acute pancreatitis is certain despite a low incidence. The 
causal relationship between ACE-inhibitors, azathioprine, and metronidazole for 
instance has been confi rmed by several well-documented rechallenges.
The pathogenesis of drug-induced acute pancreatitis is incompletely understood. 
Drugs or drug metabolites may theoretically have a direct toxic effect on the pancreas. 
Among the NSAIDs, sulindac seems to stand out in its ability to induce pancreatitis. 
The delay between start of sulindac and development of symptoms is several weeks 
to months, and after rechallenge symptoms reappear within days to weeks. This is 
compatible with a toxic effect on the pancreas. Didanosine-associated acute pancreati-
tis usually develops 10-18 weeks after start of therapy, which is well compatible with 
didanosine-induced mitochondrial toxicity.(101) For other drugs, an immunoallergic 
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idiosyncratic reaction is more likely. Time between start of treatment and devel-
opment of pancreatitis is usually within a few weeks for mesalazine, azathioprine, 
methyldopa and sulfonamides. Rechallenge with these drugs usually leads to prompt 
recurrence of symptoms in a dose-independent manner. Other drugs may lead to pan-
creatitis by inducing known risk factors for acute pancreatitis. For instance, estrogens, 
ritonavir, β-blockers, and other drugs are known to induce hyperlipidemia in suscep-
tible patients. Hypercalcemia may develop secondary to excessive vitamin D intake. 
Erythromycin, somatostatine, and codeine increase the pressure of the sphincter of 
Oddi and may thereby induce pancreatitis. ACE-inhibitors may possibly obstruct pan-
creatic ducts by localised angioedema. However, for most drugs the mechanism of 
acute pancreatitis remains speculative.
The incidence of drug-induced pancreatitis is unknown. Reports to adverse reac-
tion monitoring centers seem to indicate a low incidence of drug-induced pancreatitis, 
but due to underreporting incidence rates cannot be validly estimated from spontane-
ous reports.(25,29,52) In clinical studies on acute pancreatitis, 1-2% is attributed to 
drugs,(2,583,584) with a peak of 6.5% in one study.(585) This would correspond to an 
incidence of drug-induced acute pancreatitis of approximately 2-4 per million inhabit-
ants. However this might well be an underestimation as drugs are probably frequently 
overlooked as a possible cause of acute pancreatitis. The proportion of acute pan-
creatitis attributed to drugs is relatively high in children (15%),(4) probably because 
gallstones and alcohol abuse are rare in this age group. A study that compared patients 
with and without HIV infection found a drug-related aetiology in 41% and 5% of the 
patients with acute pancreatitis respectively.(34)
Drug-induced acute pancreatitis does not have unique features that distinguish it 
from acute pancreatitis due to other causes. Diagnosis and treatment of drug-induced 
pancreatitis relies on the same principles as diagnosis and treatment of acute pancre-
atitis to other causes. One study on the severity of drug-induced acute pancreatitis 
concluded that it usually runs a benign course.(583) Probably this is true as 75 to 80% 
of all episodes of acute pancreatitis runs a benign course. However, we are not aware 
of other studies demonstrating that the course in drug-induced acute pancreatitis is 
milder than in acute pancreatitis to other causes. Although the authors claimed that 
pancreatitis did not contribute to their death, 2 out of 22 (9%) patients with drug-
induced pancreatitis died, a fi gure comparable to case-fatality rates in other studies. 
Indeed many reports on fatal acute pancreatitis attributed to drug treatment show that 
drug-induced pancreatitis may be a very severe clinical condition.
A wide variety of drugs have been suspected of causing pancreatitis. Relatively 
new drugs such as HIV protease inhibitors, losartan and interferon have recently 
been published as a potential cause of acute pancreatitis. 48 drugs have a defi nite 
or probable causal relationship to acute pancreatitis. Despite numerous case-reports 
on drug-induced acute pancreatitis, quantitative information on this subject is scanty. 
IE33.indd   79 04-11-2002, 14:22:01
DRUG-INDUCED ACUTE PANCREATITIS: DESCRIPTIVE STUDIES
80
Formal epidemiological studies are needed to quantify the risk of drug-induced acute 
pancreatitis.
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The risk of acute pancreatitis associated with acid- suppressing drugs
Introduction: Several anti-ulcer drugs have been associated with acute pancreatitis in case 
reports. We quantifi ed the risk of acute pancreatitis associated with use of acid-suppressing 
drugs.
Methods: We conducted a retrospective cohort study with a nested case-control design 
within the General Practice Research Database (GPRD) in the United Kingdom. The cohort 
included 180,178 persons aged 20 to 74 years, who had received at least one prescription 
of cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, or omeprazole from January 
1992 to September 1997 and who did not have major risk factors for pancreatic diseases. 
Patients with a computerized medical history compatible with idiopathic acute pancreatitis 
were validated through review of medical records. For the nested case-control  analysis 1000 
controls were randomly selected from the study population.
Results: We identifi ed 88 potential cases of idiopathic acute pancreatitis. Medical records 
were available for 86. After review of these records 36 cases of acute pancreatitis were con-
fi rmed. Seven cases occurred during non-use, corresponding to a background incidence rate 
(IR) of 4.4/100,000 person-years (PY). Six cases occurred during current use of ranitidine (IR 
10.5/100,000 PY), fi ve patients were current users of cimetidine (IR 13.9/100,000 PY), and 
three were current users of omeprazole (IR 7.8/100,000 PY). There were no cases among 
current users of famotidine, lansoprazole, or nizatidine. Relative risk (RR) compared to non-
use and corrected for age, gender, calendar year and use of medication formerly associated 
with acute pancreatitis was 1.3 (95% CI: 0.5-3.3) for ranitidine, 2.1 (95% CI: 0.6-7.2) for 
cimetidine, and 1.1 (95% CI: 0.4-4.6) for omeprazole.
Conclusion: The results of this study do not suggest a major increased risk of acute pancre-
atitis associated with use of acid-suppressing drugs. 
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INTRODUCTION
Several drugs have been implicated as possible causes of acute pancreatitis.(1-3) Most 
information on drug-induced acute pancreatitis is derived from anecdotal case-reports, 
and very little is known about the incidence and mechanisms of drug-induced acute 
pancreatitis.
Cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, and omeprazole are 
extensively used in the treatment of peptic ulcer disease, and refl ux esophagitis. 
Adverse drug reactions concerning the central nervous system, the kidneys, the hae-
matological system, the gastrointestinal tract, and the cardiovascular system have 
been attributed to these acid-suppressing drugs.(4) Cimetidine and ranitidine have 
been associated with acute pancreatitis in several case-reports.(5-9) Although a rela-
tionship was found between cimetidine and acute pancreatitis in rats,(10) others have 
questioned this.(11) A record-linkage case-control study showed a crude signifi cant 
association between cimetidine, ranitidine and acute pancreatitis, but this association 
disappeared after adjustment for potential confounders.(12)
In view of the controversies regarding the association between acid-suppressing 
drugs and acute pancreatitis, we conducted a retrospective cohort study in the General 
Practice Research Database (GPRD) in the United Kingdom (UK) to assess the risk of 
acute pancreatitis associated with the use of cimetidine, famotidine, nizatidine, raniti-
dine, lansoprazole, and omeprazole. A nested case-control analysis was conducted to 
examine in more detail the relationship between dose and duration of treatment, and 
the risk of acute pancreatitis.
METHODS
Setting
Over 4 million residents in the UK are registered with general practitioners (GPs) who 
participate in the GPRD database. Medical data on these 4 million patients are con-
tinuously recorded and sent anonymously to the Offi ce of National Statistics (ONS) 
in order to be used for research projects. The computerized information contains 
demographic data, general practitioner consultations, referrals to consultants and 
hospitals, and all prescriptions issued. Indications for new courses of treatment are 
routinely stored in the database. In addition, the GP may record laboratory test results 
and other medical data in a free text comment fi eld. A modifi cation of the Oxford 
Medical Information System (OXMIS) classifi cation is used to code specifi c diagnoses. 
Previous validation studies have found that over 90% of all referrals are recorded with 
a code that refl ects the specialist’s diagnosis. (13,14) Drugs are coded according to a 
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drug dictionary based on data from the Prescription Pricing Authority.
Source population
The source population consisted of all patients aged 20 to 74 years registered with 337 
general practitioner practices with a permanent registration status during the study 
period January 1st 1992 and September 30th 1997.
Study Cohort
The study cohort comprised all patients who received at least one prescription for 
cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, or omeprazole during the 
study period. We excluded all subjects with a history of acute pancreatitis or assess-
ment of amylase before the date of the fi rst prescription of a study drug. Patients with 
a diagnosis of cancer, alcoholism, biliary- or pancreatic diseases, and biliary or pancre-
atic surgical procedures within fi ve years before study entry were also removed from 
the cohort. The remaining patients were followed from the date of the fi rst prescrip-
tion of one of the study drugs to the earliest of the following events: development of 
acute pancreatitis, assessment of amylase, one of the above mentioned clinical exclu-
sion criteria, death, or end of the study period.
Case ascertainment
With a computerized search we identifi ed all study members who had a code for acute 
pancreatitis or a code for assessment of amylase. Subsequently, the complete comput-
erized patient profi les blinded to drug exposure were manually reviewed to exclude all 
patients who were not referred to a specialist or hospital, all patients with a diagnosis 
of cancer, alcoholism, cholelithiasis, postoperative pancreatitis, other pancreatic disor-
ders, and all patients in whom the diagnosis of acute pancreatitis was clearly excluded. 
Potential cases were those for whom the information in the patient profi les was com-
patible with idiopathic acute pancreatitis.
Case validation
We requested the medical records of all potential cases (n=88) from the GPs. Received 
records were, independently and blinded to exposure, validated by all four authors. 
Based on this information, we excluded all individuals who had any evidence of 
alcohol abuse, cholelithiasis, chronic pancreatitis, malignant neoplasms, any other 
well-defi ned condition associated with the development of acute pancreatitis, or if 
symptoms of acute pancreatitis started before start of follow-up. Consensus was 
IE41.indd   118 04-11-2002, 14:23:13
Acid-suppressing drugs
119
reached on all cases. The diagnosis was accepted when acute pancreatitis was explic-
itly mentioned in the discharge letter or when there was a clinical picture compat-
ible with acute pancreatitis together with one of the following criteria: an increase 
in serum amylase or lipase of >2 times the upper limit of normal, confi rmatory evi-
dence of acute pancreatitis at imaging procedures or at laparotomy or autopsy.
Cohort analysis
Person-time contributed by the study participants was divided into three mutually 
exclusive categories: current use, past use and non-use. Current use was defi ned as 
the person time experienced during the length of an acid-suppressing drug prescrip-
tion and  six days thereafter. Past use included the period up to 365 days after the end 
of current use. Consequently, the time window of non-use started at the end of past 
use. Incidence rates were calculated by dividing the total number of cases of acute 
pancreatitis by the corresponding total amount of person-time experienced. Ninety-
fi ve percent confi dence intervals (95% CIs) were calculated based on a Poisson distri-
bution.
Adjusted estimates of relative risks and 95% CIs associated with current and past 
use as compared to non-use were computed using a Poisson regression model with 
age, sex, and calendar year included in the model.
Nested case-control analysis
In order to explore dose and duration effects we performed a nested case-control anal-
ysis within the study cohort. All confi rmed cases were used in the nested case-control 
analysis. The index date for the cases was the date of start of symptoms compatible 
with acute pancreatitis (same index date as used in the cohort analysis). In order to 
ascertain controls, a random date during the study period was generated for all study 
participants. A subject was an eligible control when the random date was included in 
his or her follow-up time. All exclusion criteria applied to the selection of the cases 
were also applied to the controls. From the list of eligible controls, we randomly 
selected 1000 controls and their random date was defi ned as the  index date.
A participant was defi ned as a current user of one of the study drugs if the index 
date fell within the prescription period or when the end date of the last prescription 
fell within six days preceding the index date. A person was defi ned as a past user when 
the end date of the last consecutive prescription period fell within seven to 371 days 
before the index date. A person was defi ned as a non-user when none of the study 
drugs were used in the 371 days preceding the index date. Estimates of the odds ratios 
and their 95% CIs were calculated with logistic regression analyses comparing current 
and past use with non-use of the individual acid-suppressing drugs. Age, sex, calendar 
IE41.indd   119 04-11-2002, 14:23:14
DRUG-INDUCED ACUTE PANREATITIS: ANALYTICAL STUDIES
120
year, and presence of other drugs associated with acute pancreatitis(3) (ACE-inhibi-
tors, aminosalicylates, NSAIDs, estrogens, furosemide, thiazide diuretics, valproic acid, 
and azathioprine) were included in the model to control for potential confounding.
RESULTS
The study cohort consisted of 180,178 subjects who received at least one prescription 
of cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, or omeprazole. Overall 
1,545,921 prescriptions of these acid-suppressing drugs were written during the study 
period. The age and gender distribution of users of individual acid-suppressing drugs 
is presented in table 1. There were 88 patients who had a computerized history com-
patible with an idiopathic episode of acute pancreatitis and for whom medical records 
were requested from the GPs. Of two patients, no information was received. Of the 
remaining 86 patients, 36 (42%) were classifi ed as cases. The remainder was excluded 
because of alcohol abuse (n=11), cholelithiasis (n=10), and cancer, other pancreatic 
disorders and postoperative pancreatitis in 11 patients. The diagnosis of  acute pancre-
atitis was not confi rmed in 11 patients.  In the remaining 7 patients onset of symptoms 
was before start of follow-up.
The overall incidence rate of idiopathic acute pancreatitis during current use of 
acid-suppressing drugs was 9.9 (95% CI: 4.7-15.1) per 100,000 person years (PY), 7.6 
(95% CI: 3.8-11.5) per 100,000 PY for past users, and 4.4 (95% CI: 1.1-7.6) per 100,000 
PY for non-users. After adjustment for age, gender and calendar year the RR was 1.6 
(95% CI: 0.6-4.2) for current use and 1.6 (95% CI: 0.6-4.0) for past use of an acid-sup-
pressing drug. Incidence rates and RRs for individual acid-suppressing drugs are given 
in table 2.
Table 3 shows the results of the nested case-control analysis. Out of the 36 cases, 
20 (56%) were male and the mean age was 61 years. Use of acid-suppressing drugs, 
Table 1
Age and gender distribution
Total* Male Female 20-59y 60-74y
Overall 1,545,921 52% 48% 51% 49%
Cimetidine 382,767 52% 48% 51% 49%
Famotidine 16,797 52% 48% 50% 50%
Lansoprazole 54,554 51% 49% 57% 43%
Nizatidine 49,079 51% 49% 51% 49%
Omeprazole 439,104 50% 50% 51% 49%
Ranitidine 603,62 53% 47% 49% 51%
* Number of prescriptions
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Table 2
Incidence rates of and relative risks of acute pancreatitis for individual acid-suppressing drugs
Person-years cases IR/105 Crude RR (95% CI) RR (95% CI)*
Non-users† 160430 7 4.4
Current-use‡ 141738 14 9.9 2.3 (0.9-5.6) 1.6 (0.6-4.2)
 cimetidine 35966 5 13.9 3.2 (1.0-10.0) 2.3 (0.7-7.7)
 famotidine 1551 0 -
 lansoprazole 4567 0 -
 nizatidine 4262 0 -
 omeprazole 38430 3 7.8 1.8 (0.5-6.9) 1.3 (0.3-5.3)
 ranitidine 56961 6 10.5 2.4 (0.8-7.2) 1.7 (0.6-5.4)
Past use§ 196356 15 7.6 1.8 (0.7-4.3) 1.6 (0.6-4.0)
* Age, gender and calendar year were included in the Poisson regression model
† No use of an acid-suppressing drug in the 371 days preceding the index date.
‡ Use of an acid-suppressing drug on the index date or the 6 days preceding the index date.
§ Use of an acid-suppressing drug in days 7-371 before the index date.
Table 3
Relative risk of acute pancreatitis associated with use of acid-suppressing drugs and other factors
Cases (n=36) Controls (n=1000) OR (95% CI)
Acid-suppressing drug
Non-use†  7  306 
Current use‡  14  281 1.4 (0.5-3.6)
 Cimetidine  5  65 2.1 (0.6-7.2)*
 Omeprazole  3  69 1.1 (0.3-4.6)*
 Ranitidine  6  129 1.3 (0.4-4.1)*
Past users§  15  431 1.3 (0.5-3.3)*
Age
 20-59 years  12  639
 60-74 years  24  361 3.1 (1.5-6.4)
Gender
 Male  20  486
 Female  16  514 0.6 (0.3-1.2)
Year category||
 1992-1994  16  400
 1995-1997  20  600 0.9 (0.5-1.8)
Pancreatoxic medication
 Non-use  21  760
 Current use  15  240 2.0 (1.0-4.2)
*Adjusted for age, gender, calendar year, and current use of other pancreatoxic medication.
† No use of an acid-suppressing drug in the 371 days preceding the index date.
‡ Use of an acid-suppressing drug on the index date or within the 6 days preceding the index date.
§ Use of an acid-suppressing drug in days 7-371 before the index date.
|| End of study in September 1997
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gender and calendar year were not signifi cantly associated with acute pancreatitis. 
The RR among current users of medications suspected to be associated with acute 
pancreatitis was 2.0 (95% CI: 1.0-4.2). Age was the only factor that was signifi cantly 
associated with the occurrence of acute pancreatitis. Although not signifi cant, the risk 
of acute pancreatitis was higher in the fi rst month of acid-suppressing therapy: 2.3 
(95% CI: 0.5-9.5) versus 1.1 (95% CI: 0.4-3.3) for long-term users. Exclusion of all cur-
rent users of  medications formerly associated with acute pancreatitis did not change 
the risk estimates considerably (data not shown). A dose-response relationship was 
not observed in users of cimetidine or ranitidine (table 4).
DISCUSSION
In this large cohort study, we observed no major increased risk of acute pancreatitis 
in users of acid-suppressing drugs. Cimetidine was the only acid-suppressing drug 
with a small increased risk of acute pancreatitis, but this association was no longer 
present after adjustment for potential confounders. There was a tendency towards an 
increased risk in the fi rst month of treatment. The daily dosage of acid-suppressing 
drugs had no effect on the risk of acute pancreatitis. 
The validity of epidemiological studies may suffer from selection bias, informa-
tion bias or confounding. The presence of selection bias in this study is unlikely as 
identifi cation of the study population was based on prerecorded prescriptions of acid-
suppressing drugs, and therefore unrelated to the outcome of interest. Since drug 
exposure was recorded before the onset of disease, recall bias is not present. Case 
Table 4
Infl uence of duration of acid-suppressing drug therapy on the risk of acute pancreatitis
Cases (n=36) Controls (n=1000) OR (95% CI)*
Duration of  anti-ulcer therapy†
 ≤ 30 days  3  47 2.3 (0.5-9.5)
 > 30 days  11  234 1.1 (0.4-3.3)
Daily dose of cimetidine†, ‡
 <800 mg  2  22 2.2 (0.4-12.6) 
 ≥ 800 mg  3  41 1.7 (0.4-7.7) 
Daily dose of ranitidine†, §
 <300 mg  2  26 1.9 (0.3-10.3) 
 ≥ 300 mg  4  100 1.1 (0.3-4.2) 
*Adjusted for age, gender, calendar year, and current use of other pancreatoxic medication.
† Current use compared to non-use 
‡ Data on daily dose of cimetidine was not available for 2 controls
§ Data on daily dose of ranitidine was not available for 3 controls
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histories concerning the relationship between H2-blockers and acute pancreatitis 
have been published since the late seventies, some of them proven by recurrence of 
symptoms after restart of treatment.(6,9) Physicians may therefore diagnose acute 
pancreatitis more easily in patients using these H2-receptor blockers. This diagnos-
tic bias might therefore explain the non-signifi cant increase in RR of cimetidine and 
ranitidine seen in this study. Patients with gastric acid related diseases will pay more 
visits to gastroenterological consultants and may therefore have acute pancreatitis 
more easily detected. However, as none of the acute pancreatitis diagnoses was made 
during routine check-ups of anti-ulcer treatment we expect diagnostic bias to play a 
minor role if any in explaining the results. Misclassifi cation of outcome was limited 
due to review of the medical records of potential cases. Misclassifi cation of exposure, 
for instance by non-compliance or dispensing of acid-suppressing drugs in hospital 
was probably non-differential and would therefore have biased the risk estimates 
towards null.
By restricting the study to people without major risk factors for acute pancreatitis 
we tried to control for confounding by these factors. 
A recent study on the association between H2-receptor antagonists and acute pan-
creatitis reported a non-signifi cant RR of 3.7 for cimetidine and a non-signifi cant RR of 
3.1 for ranitidine.(12) In patients without risk factors for acute pancreatitis these fi g-
ures were 2.0 and 2.5 respectively. The authors concluded that the higher RRs might 
be due to residual confounding. Prescribing of acid-suppressing drugs for prodromal 
symptoms of acute pancreatitis, sometimes referred to as protopathic bias could be 
an alternative explanation for the small increased risk seen in the former study and 
in our study. We tried to reduce the play of protopathic bias by taking the day of onset 
symptoms as index date for patients with acute pancreatitis. The risk in the fi rst 30 
days of therapy was somewhat higher than the risk thereafter, albeit non-signifi cantly. 
This could indicate either an acute effect or imperfect control of protopathic bias. 
However, protopathic bias cannot explain the different risk estimates for the different 
acid-suppressing drugs as this form of selection bias would affect all acid-suppressing 
drugs alike.
In conclusion, the results of this study do not suggest a major increased risk for 
acute pancreatitis associated with the use of acid-suppressing drugs.
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Angiotensin-converting enzyme inhibitors increase the risk of acute pancre-
atitis: The European case-control study on drug-induced acute pancreatitis 
(EDIP)
Introduction: Angiotensin-converting enzyme (ACE) inhibitors have been associated with 
acute pancreatitis in several case-reports. We quantifi ed the risk of acute pancreatitis associ-
ated with the use of ACE-inhibitors in the European study on drug-induced acute pancre-
atitis (EDIP).
Methods: The EDIP study is a multi-centre population-based European case-control study 
on the association between drug use and acute pancreatitis. Patients between 40 and 85 
years of age with acute pancreatitis were included between October 1st 1994 and Decem-
ber 31st 1998. For each case, age- and gender-matched community controls were recruited. 
Detailed information on drug use and potential confounders (e.g. co-morbidity, alcohol use) 
was obtained through a structured interview. 
Results: During the study period, we identifi ed and interviewed 724 patients with acute 
pancreatitis and 1791 community controls. A high number of previous hospitalisations, 
smoking, high intake of alcohol, a history of biliary disease, hyperlipidemia, peptic ulcer dis-
ease, pancreatic disease, ischemic heart disease, hypertension, and congestive heart failure 
were positively associated with development of acute pancreatitis. Relative to non-use, use 
of ACE-inhibitors in the week prior to the index date increased the risk of acute pancreatitis 
by 60% (95% CI: 1.1-2.3). The risk of acute pancreatitis associated with ACE-inhibitor use 
increased with higher daily doses and was most pronounced in patients who did not have 
biliary diseases; relative risk 2.7 (95% CI: 1.3-5.8)
Interpretation: Use of ACE-inhibitors is associated with a modest increase in risk of acute 
pancreatitis, but this risk seems substantially higher in patients without biliary diseases.
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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas which may lead to 
considerable morbidity and mortality. The incidence of acute pancreatitis shows an 
increasing trend in European countries.(1,2) The most important risk factors for acute 
pancreatitis are gallstones and alcohol abuse. Other risk factors include hyperlipid-
emia, hypercalcemia, and endoscopic retrograde cholangiopancreaticography (ERCP). 
The etiology remains unknown in 10 to 25% of patients with acute pancreatitis.(3)
Drugs have since long been implicated as a potential cause of acute pancreati-
tis.(4) Most information on drug-induced acute pancreatitis is derived from anecdotal 
case-reports and little is known about the incidence and mechanisms of drug-induced 
acute pancreatitis.(5)
Angiotensin-converting enzyme (ACE) inhibitors are extensively used in the treat-
ment of hypertension, congestive heart failure, and diabetic nephropathy.(6) Acute 
pancreatitis attributed to ACE-inhibitors has been described in case-reports,(7-26) 
some with recurrence of pancreatitis after rechallenge. (7-9) However, quantitative 
information on the association between ACE-inhibitors and acute pancreatitis is not 
available. Therefore, we studied the risk of acute pancreatitis associated with use of 
ACE-inhibitors in the European study on drug-induced acute pancreatitis (EDIP).
METHODS
Setting 
This study is part of the European case-control study on drug-induced acute pancre-
atitis (EDIP) which was initiated by the European Pharmacovigilance Research Group. 
Participating countries include Denmark, Italy, the Netherlands, Portugal, Sweden, 
and the United Kingdom. The source population comprised all persons between 40 to 
85 years of age in the county of Funen in Denmark, the Rijnmond area in the Neth-
erlands, the Coimbra area in Portugal, the cities Malmö, Stockholm, Uppsala, and 
Umeå in Sweden, the cities Bologna, Bolzano, Milano, and Verona in Italy, and Bir-
mingham city in the United Kingdom. For the present study only data from Denmark, 
the Netherlands, Italy, and Sweden was used because of absence of data on commu-
nity controls in the other countries. The study period ran from October 1st 1994 to 
December 31st 1998, but differed in the participating countries. Local medical ethical 
committees approved the study, and written informed consent was obtained from all 
participants.
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Case identifi cation and validation
In the Netherlands, Sweden, and Denmark potential cases were identifi ed by regular 
screening of serum amylase and lipase values of admitted patients in the participat-
ing hospitals. In Italy, the departments of internal medicine, gastroenterology, and 
surgery were regularly screened for patients admitted with acute abdominal pain. 
Patients were considered potential cases of acute pancreatitis if they had acute abdom-
inal pain combined with elevated serum amylase and lipase values of more than 2 
times the upper limit of normal within the fi rst week of admission, or if they had 
acute abdominal pain with confi rmatory evidence of acute pancreatitis on ultrasonog-
raphy, computerized tomography, laparotomy, or autopsy. Patients with post-ERCP 
pancreatitis, abdominal trauma, a perforated gastrointestinal ulcer, malignancy of the 
gastrointestinal tract, a positive HIV test, or chronic pancreatitis were excluded. Addi-
tionally, patients were excluded if they were resident in a nursing home, did not speak 
the native language, died before study assessments were completed, or if no reliable 
interview data could be obtained (e.g. due to dementia). Since Sweden combined the 
EDIP study with a national study, their exclusion criteria were slightly different in the 
cities Stockholm and Umeå. In these cities, patients with a history of biliary diseases 
and patients with a relapse of acute pancreatitis were excluded. Acute pancreatitis 
was considered of biliary origin if gallstones were present at imaging procedures or at 
laparotomy.
The clinical notes of all eligible cases were reviewed by consultant gastroenterolo-
gists who were blinded to drug exposure.  The index date for the cases was defi ned as 
the date of fi rst recorded symptoms. 
Control selection
In Sweden, Denmark, and Italy community controls were randomly selected from 
population registries. Community controls were randomly selected from the general 
practitioner’s practice of the case in the Netherlands. Controls were matched to cases 
on gender and age (± 5 years). The index date of the controls was defi ned as the date 
of interview. Exclusion criteria for controls were equal to exclusion criteria for cases.
Data collection
Each country used similar structured questionnaires and coding manuals (Interna-
tional Classifi cation of Diseases, 9th edition and the Drug Dictionary of the World 
Health Organization). Interviewers were centrally trained and supervised. The ques-
tionnaire included questions on demographics, life-long medical history, smoking 
and drinking habits, plus drug intake in the preceding six months. In order to reduce 
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recall bias, participants were asked to retrieve all packages of drugs that they had 
used before start of the interview. For each drug, the indication, strength, formulation, 
dosing regimen, start and stop dates were recorded. 
Exposure
Use of ACE-inhibitors was defi ned as use of benazepril, captopril, cilazepril, enalapril, 
fosinopril, lisinopril, perindopril, quinapril, or ramipril within one week before the 
index date. The dose of ACE inhibitor use was expressed in defi ned daily dosages 
(DDD), in which one DDD was the recommended dose for the main indication in 
adults.(27) For ACE-inhibitors the values corresponding to one DDD are: benazepril 
7.5 mg, captopril 50 mg, cilazepril 2.5 mg, enalapril 10 mg, fosinopril 15 mg, lisinopril 
10 mg, perindopril 4 mg, quinapril 15 mg, and ramipril 2.5 mg. The daily dosage of 
ACE-inhibitors was classifi ed as low (< 1DDD), moderate (1-2 DDD), and high (>2 
DDD). To study potential recall bias, we verifi ed ACE-inhibitor use at the community 
pharmacy of the participants in the Netherlands.
Covariates
As potential confounders we considered smoking, alcohol use, and co-morbidity. 
Smoking was expressed as the number of cigarettes smoked per day: 0, 1-10, 11-20, 
and more than 21. Alcohol use was expressed as the average intake of  per day: 1 unit, 
2-4 units, 5-7 units, and 8 or more units. Weight categories were created on the basis 
of body mass index (BMI): underweight (<18.5), normal (≥18.5 – <25), overweight
(≥25 – <30), and obese (≥ 30).(28) Working status was divided into employed, ill, 
unemployed, student or military service, and other. 
Analyses
Maximum likelihood estimates of odds ratios (ORs) and their 95% confi dence intervals 
(CIs) were computed using a conditional logistic regression model. In the multivariate 
analysis risk estimates for use of ACE-inhibitors were adjusted for alcohol use, smok-
ing, BMI, history of pancreatic disease, history of biliary disease, history of diabetes 
mellitus, history of hypertension, heart failure, and and use of other antihypertensive 
medication (angiotensin II receptor blockers, calcium channel blockers, β-blockers, 
diuretics). We performed additional analyses restricted to patients with a fi rst attack of 
acute pancreatitis and patients with non-biliary acute pancreatitis. All analyses were 
performed in SPSS 8.0 for Windows. 
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Table 1
Patient characteristics
Cases (n=724) Community controls (n=1791) OR
unadjusted
Country Denmark 69 155
 Italy 120 151
 Netherlands 112 112
 Sweden 423 1373
Male 422 930
Age (years) 62.7 (SD 11.7) 60.6 (SD 11.9)
BMI 25.7 (SD 4.1) 25.2 (SD 3.7)
 <18.5 10 25 1.2 (0.6-2.7)
 ≥18.5 - <25 328 895 ref.
 ≥25 - <30 288 663 1.1 (0.9-1.4)
 ≥30 90 185 1.3 (0.9-1.7)
 Unknown 8 23
No. Hosp.* 0 78 250 ref.
 1 148 387 1.3 (0.9-1.8)
 2 139 337 1.3 (0.9-1.8)
 3 97 270 1.2 (0.8-1.7)
 4 80 195 1.4 (0.9-2.0)
 ≥5 181 349 1.7 (1.3-2.4)
 Unknown 1 3
Smoking† 0 509 1343 ref.
 1-10 67 197 0.9 (0.7-1.3)
 11-20 116 196 1.7 (1.3-2.2)
 ≥21 29 37 2.0 (1.1-3.4)
 Unknown 3 18
Alcohol use‡ 0 152 276 1.3 (0.97-1.6)
 1-7 321 927 ref.
 8-28 181 526 0.8 (0.7-1.1)
 29-49 24 43 1.2 (0.7-2.1)
 ≥50 40 6 15.3 (5.9-39.9)
 Unknown 6 13
ADR§ 199 539 1.1 (0.9-1.3)
Knowledge on ADR¶ 33 196 0.4 (0.3-0.6)
Gall tract diseases ≤ 1 yr. 34 8 11.7 (5.3-25.8)
 2-5 yr. 18 12 3.5 (1.6-7.8)
 >5 yr. 75 179 1.2 (0.9-1.6)
Hyperlipidemia§ 49 70 1.7 (1.2-2.5)
Ulcus pepticum§ 92 114 2.0 (1.5-2.8)
Renal failure§ 8 9 1.9 (0.7-5.2)
Infl ammatory bowel disease§ 9 14 2.2 (0.9-5.1)
Pancreas diseases§ 52 9 13.8 (6.4-29.2)
Hypertension§ 229 432 1.3 (1.1-1.6)
Ischemic heart disease§ 98 136 1.8 (1.4-2.4)
Congestive heart failure§ 21 21 2.3 (1.2-4.3)
Diabetes mellitus§ 70 77 2.1 (1.5-3.0)
Vitamin C** 44 130 0.9 (0.6-1.3)
OR=odds ratio, SD=standard deviation, BMI=body mass index, ADR=adverse drug reaction,  * Number of hospi-
talisations in entire life, † number of cigarettes smoker per day, ‡ Units of  alcohol per week, § Ever history of,
¶ Knowledge that drugs may cause acute pancreatitis, ** use in the week before the index date.
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Table 2
Association between use of ACE-inhibitors and acute pancreatitis
Cases
(n=724)
Community controls
(n=1791)
OR
adjusted
†
ACE-inhibitors*  83  117 1.6 (1.1-2.3)
Daily dose < 1DDD  20  34 1.2 (0.6-2.3)
 1-2 DDD  55  77 1.8 (1.1-2.8)
 > 2 DDD  7  4 3.5 (0.8-14.9)
 Unknown  1  2
Duration of use ≤ 6 months  17  15 3.3 (1.4-7.6)
 > 6 months  66  102 1.4 (0.9-2.1)
ACE-inhibitor=angiotensin-converting enzyme inhibitor, DDD=defi ned daily dosage, *use in the week before the 
index date, † adjusted for other antihypertensive medication, alcohol use, smoking, bmi, history of pancreatic dis-
ease, history of biliary disease, history of diabetes mellitus, history of hypertension, history of heart failure.
RESULTS
During the study period 823 cases met our inclusion criteria. After the expert review, 
80 cases were excluded as the diagnosis acute pancreatitis could not be substantiated. 
Furthermore, 19 cases did not have a matched community control and were therefore 
excluded from the analyses. Among the fi nal 724 cases, 658 (91%) were admitted for a 
fi rst attack of acute pancreatitis. Three hundred  (41%) patients had evidence of gall-
stones and 88 (12%) patients had a history of alcohol abuse or used 5 units of alcohol 
or more per day. A total of 1791 community controls were matched to the fi nal 724 
cases. Data on dispensed prescriptions of ACE-inhibitors at community pharmacies 
showed that data on ACE-inhibitor use was complete in the Netherlands.
A high number of hospitalisations, smoking, high intake of alcohol, and a history 
of biliary disease, hyperlipidemia, peptic ulcer disease, pancreatic disease, diabetes 
mellitus, ischemic heart disease, and congestive heart failure were all positively asso-
ciated with development of acute pancreatitis (table 1). 
A higher proportion of patients with acute pancreatitis reported use of ACE-inhibi-
tors than controls (table 2). Use of an ACE-inhibitor increased the risk of acute pan-
creatitis by 60% (95% CI; 1.1-2.3). Although the relative risk estimates varied slightly 
between individual ACE inhibitors, the confi dence intervals overlapped. Additional 
adjustment for year of ascertainment had no considerable effect on the risk esti-
mate. The risk of acute pancreatitis was higher during the fi rst 6 months of therapy 
than during prolonged use (table 2). We observed a positive dose-effect relationship 
between daily dose of ACE inhibitors and acute pancreatitis (table 2). The risk of acute 
pancreatitis associated with the use of ACE-inhibitors was higher in patients without 
biliary diseases: 2.7 (95% CI: 1.3-5.8). Restriction of the analyses to patients with a 
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fi rst attack of acute pancreatitis did not change the results considerably. Among the 
antihypertensive drugs, use of calcium channel blockers and use of potassium sparing 
diuretics was also signifi cantly associated with acute pancreatitis. Concomitant use 
of other antihypertensive medication did not increase the risk of acute pancreatitis 
signifi cantly (table 3).  
DISCUSSION
In this multinational study we demonstrated that use of ACE-inhibitors increased the 
risk of acute pancreatitis by approximately 60%. The risk of acute pancreatitis was 
highest among new users of ACE-inhibitors and at higher daily dosages. The risk of 
acute pancreatitis rose considerably when the analyses were restricted to patients 
without biliary disease, probably because the background rate of acute pancreatitis in 
this subpopulation is much lower. 
ACE-inhibitors have been associated with acute pancreatitis since 1988. Over the 
years, enalapril, lisinopril, captopril, perindopril, quinapril, and benazepril have all 
been incriminated as a potential cause of acute pancreatitis.(7-26) Time between 
start of therapy with ACE-inhibitors and development of symptoms varied greatly in 
these case-reports from almost immediately to two years. Three patients experienced 
a relapse after restart of captopril, enalapril, and perindopril respectively.(7-9) Inter-
estingly, one patient with losartan-associated acute pancreatitis had experienced an 
earlier episode of acute pancreatitis 5 days after starting enalapril treatment.(29) To 
our knowledge the association between ACE-inhibitors and pancreatitis has not been 
studied before in epidemiological studies.
As with all other causes of acute pancreatitis, the mechanism by which ACE-inhibi-
Table 3
Association between use of other antihypertensive medication and acute pancreatitis
Antihypertensive medication*
Cases
(n=724)
Community controls
(n=1791)
OR
adjusted
†
AT-II-blockers  8  22 0.9 (0.4-2.1)
CCB  95  141 1.5 (1.1-2.2)
K+-sparing diuretics  41  70 1.7 (1.0-2.9)
Loop diuretics  47  94 0.6 (0.4-0.95)
Thiazide diuretics  44  91 0.7 (0.4-1.2)
β-blockers  96  183 1.3 (0.96-1.8)
AT-II=angiotensine II receptor blockers, CCB=calcium channel blockers, K+ = potassium, *use in the week before 
the index date, † adjusted for other antihypertensive medication, alcohol use, smoking, bmi, history of pancreatic, 
history of biliary disease, history of diabetes mellitus, history of hypertension, history of heart failure.
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tors cause acute pancreatitis remains speculative. Pancreatic duct obstruction by 
local angioedema has been proposed as a possible mechanism.(12) Others argue that 
ACE-inhibitors may have a direct toxic effect on pancreatic cells as ACE-inhibitors can 
induce hypoglycemia.(22) Because captopril is structurally dissimilar to enalapril and 
lisinopril, an allergic reaction seems less likely. Apart from converting angiotensin I 
to angiotensin II, ACE also degrades both bradykinin and substance P.(30) Although 
probably not involved in the initiation of acute pancreatitis, kinins are involved in 
the formation of pancreatic edema. (31) In experimental models, kinin B2 receptor 
antagonists reduce edema formation in the pancreas.(31) Substance P is released from 
nerve endings and acts via NK1 receptors. Pancreatic substance P levels and NK1 
receptors are upregulated during acute pancreatitis.(32) Knockout mice defi cient in 
NK1 receptors are protected against pancreatitis. In contrast, knockout mice defi cient 
in an enzyme that hydrolyses substance P are more susceptible to experimental acute 
pancreatitis.(32) Increased pancreatic kinin and substance P levels may therefore con-
tribute to the development of acute pancreatitis.
Apart from ACE-inhibitors, calcium channel blockers were associated with an 
elevated risk of acute pancreatitis. To our knowledge acute pancreatitis attributed to 
calcium channel blockers is only mentioned in a survey from a spontaneous report-
ing center.(33) Recent evidence showed that elevated intracellular calcium levels are 
important in the premature activation of trypsinogen.(34) This would plea against 
an association between calcium channel blockers and acute pancreatitis. Indeed one 
experimental study in animals found a protective effect of verapamil on the develop-
ment of caerulein-induced acute pancreatitis.(35) We could not substantiate earlier 
fi ndings on loop and thiazide diuretic-associated acute pancreatitis.(36,37) However, 
these early studies on drug-induced acute pancreatitis did not control for important 
confounding factors such as alcohol abuse.
A potential limitation of observational studies is their vulnerability to selection bias, 
information bias, and confounding. Selective case inclusion is unlikely because of the 
standardized and objective screening criteria and the population-based character of 
the study. Although mild cases may have been missed, symptomatic cases of acute 
pancreatitis are mostly recognized and admitted irrespective of the suspected etiology, 
hence selection bias is unlikely. Diagnostic bias due to diagnosing acute pancreatitis 
more easily in patients who use ACE-inhibitors is not likely due to the acute nature of 
the disease, the screening procedures that we used, and due to the widespread belief 
that drugs have a low attributable risk for acute pancreatitis. In addition, all cases were 
validated by experts who were blinded to exposure. 
Information bias regarding exposure is a particular problem in case-control studies 
as cases might recall drug use more accurately than controls due to their recent ill-
ness. However, verifi cation at community pharmacies in the Netherland showed that 
data on ACE-inhibitor use was complete for cases and controls. In addition, we studied 
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the infl uence of recall bias by including a question on use of vitamin C (not known to 
be associated with acute pancreatitis) and by asking whether participants knew that 
drugs may cause acute pancreatitis. Vitamin C was not associated with development 
of acute pancreatitis and slightly more controls than cases knew that drugs may be a 
possible cause of acute pancreatitis. These fi ndings suggest that recall bias did not a 
play a major role in our study. 
In pharmaco-epidemiological studies, confounding by indication may be a poten-
tial problem. We adjusted for the major indications of ACE-inhibitors, namely diabetes 
mellitus, hypertension, and heart failure. In addition, angiotensine II receptor block-
ers are prescribed for similar indications, but they appeared not to be associated with 
an elevated risk of acute pancreatitis.
All our analyses were adjusted for smoking, alcohol abuse, body mass index, a 
history of biliary diseases, a history of diabetes, a history of pancreatic diseases, and 
use of other antihypertensive medication. We had no information on the presence of 
gallstones in controls at the time of interview. Therefore we adjusted for a history of 
biliary diseases which was strongly  associated with an increased risk of acute pan-
creatitis.
In conclusion, ACE-inhibitors are associated with a small but signifi cantly increased 
risk of acute pancreatitis. ACE-inhibitors should be considered as a possible cause in 
patients with  acute pancreatitis.
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The risk of acute pancreatitis associated with psychotropic drugs:
The European case-control study on drug-induced acute pancreatitis (EDIP)
Introduction: Antidepressant drugs and antipsychotic agents have been associated with 
acute pancreatitis in several case-reports. We quantifi ed the risk of acute pancreatitis associ-
ated with the use of psychotropic medication in the European study on drug-induced acute 
pancreatitis (EDIP)
Methods: The EDIP study is a multi-centre population-based European case-control study 
on the association between drug use and acute pancreatitis. Patients between 40 and 85 
years of age with acute pancreatitis were included between October 1st 1994 and Decem-
ber 31st 1998. For each case, age- and gender-matched community controls were recruited. 
Detailed information on drug use and potential confounders (e.g. co-morbidity, alcohol use) 
was obtained through a structured interview. 
Results: During the study period, we identifi ed and interviewed 724 patients with acute 
pancreatitis and 1791 community controls. A high number of previous hospitalisations, 
smoking, high intake of alcohol, a history of biliary disease, hyperlipidemia, peptic ulcer 
disease, and pancreatic disease were positively associated with development of acute pan-
creatitis. Use of TCAs, SSRIs, and benzodiazepines was not associated with an increased 
risk of acute pancreatitis. However, use of antipsychotic drugs in the week before the index 
date increased the risk of acute pancreatitis three fold (95% CI: 1.5-6.0). The risk of acute 
pancreatitis associated with antipsychotics was largely confi ned to  patients aged 60 years 
and over: OR 4.1 (1.7-9.9).
Conclusion: Use of antipsychotic agents is associated with an increased risk of acute pan-
creatitis.
IE43.indd   138 04-11-2002, 14:24:34
Psychotropic drugs
139
INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas which may lead to 
considerable morbidity and mortality. The incidence of acute pancreatitis shows an 
increasing trend in European countries.(1,2) The most important risk factors for acute 
pancreatitis are gallstones and alcohol abuse. Other risk factors include hyperlipid-
emia, hypercalcemia, and endoscopic retrograde cholangiopancreaticography (ERCP). 
The aetiology remains unknown in 10 to 25% of patients with acute pancreatitis.(3)
Drugs have since long been implicated as a potential cause of acute pancreati-
tis.(4) Most information on drug-induced acute pancreatitis is derived from anecdotal 
case-reports and little is known about the incidence and mechanisms of drug-induced 
acute pancreatitis.(5) Acute pancreatitis attributed to benzodiazepines has not been 
described, but acute pancreatitis has been associated with tricyclic antidepressants 
(TCA), (6-10) selective serotonin reuptake inhibitors (SSRI),(11) and antipsychotic 
agents (12-21) in several case-reports. Associations between psychotropic drug use 
and acute pancreatitis have not been studied in large populations. We studied the risk 
of acute pancreatitis associated with use of TCAs, SSRIs, benzodiazepines, and antipsy-
chotics in the European study on drug-induced acute pancreatitis (EDIP).
METHODS
Setting 
This study is part of the European case-control study on drug-induced acute pancre-
atitis (EDIP) which was initiated by the European Pharmacovigilance Research Group. 
Participating countries include Denmark, Italy, the Netherlands, Portugal, Sweden, 
and the United Kingdom. The source population comprised all persons 40 to 85 years 
of age in the county of Funen in Denmark, the Rijnmond area in the Netherlands, 
the Coimbra area in Portugal, the cities Malmö, Stockholm, Uppsala, and Umeå in 
Sweden, the cities Bologna, Bolzano, Milano, and Verona in Italy, and Birmingham 
city in the United Kingdom. For the present study only data from Denmark, the 
Netherlands, Italy, and Sweden was used because of absence of data on community 
controls in the other countries. The total study period ran from October 1st 1994 to 
December 31st 1998, but differed in the participating countries. Local medical ethical 
committees approved the study, and written informed consent was obtained from all 
participants.
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Case identifi cation and validation
In the Netherlands, Sweden, and Denmark potential cases were identifi ed by regular 
screening of serum amylase and lipase values of admitted patients in the participat-
ing hospitals. In Italy, the departments of internal medicine, gastroenterology, and 
surgery were regularly screened for patients admitted with acute abdominal pain. 
Patients were considered potential cases of acute pancreatitis if they had acute abdom-
inal pain combined with elevated serum amylase and lipase values of more than 2 
times the upper limit of normal within the fi rst week of admission, or if they had 
acute abdominal pain with confi rmatory evidence of acute pancreatitis on ultrasonog-
raphy, computerised tomography, laparotomy, or autopsy. Patients with post-ERCP 
pancreatitis, abdominal trauma, a perforated gastrointestinal ulcer, malignancy of the 
gastrointestinal tract, a positive HIV test, or chronic pancreatitis were excluded. Addi-
tionally, patients were excluded if they were resident in a nursing home, did not speak 
the native language, died before the interview was conducted, or if no reliable drug 
history could be obtained. Since Sweden combined the EDIP study with a national 
study their exclusion criteria were slightly different in the cities Stockholm and Umeå. 
In these cities, patients with a history of biliary diseases and patients with a relapse 
of acute pancreatitis were also excluded. Acute pancreatitis was considered of biliary 
origin if gallstones were present at imaging procedures or at laparotomy.
The clinical notes of all eligible cases were reviewed by consultant gastroenterolo-
gists who were blinded to drug exposure. The index date for the cases was defi ned as 
the date of fi rst recorded symptoms. 
Control selection
In Sweden, Denmark, and Italy community controls were randomly selected from 
population registries. Community controls were randomly selected from the general 
practitioner’s practice of the case in the Netherlands. Controls were matched to cases 
on gender and age (± 5 years). The index date of the controls was defi ned as the date 
of interview. Exclusion criteria for controls were equal to exclusion criteria for cases.
Data collection
Each country used similar structured questionnaire and coding manuals (Interna-
tional Classifi cation of Diseases, 9th edition and the Drug Dictionary of the World 
Health Organization). Interviewers were centrally trained and supervised. The ques-
tionnaire included questions on demographics, life-long medical history, smoking 
and drinking habits, plus drug intake in the preceding six months. In order to reduce 
recall bias, participants were asked to retrieve all packages of drugs that they had 
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used before start of the interview. For each drug, the indication, strength, formulation, 
dosing regimen, plus start and end of therapy were recorded. 
Exposure
Use of TCAs, SSRIs, benzodiazepines, or antipsychotic drugs was defi ned as use within 
one week before the index date. To study potential recall bias, we verifi ed use of psy-
chotropic drugs at the community pharmacy of the participants in the Netherlands.
Covariates
As potential confounders we considered smoking, alcohol use, and co-morbidity. 
Smoking was expressed as the number of cigarettes smoked per day: 0, 1-10, 11-20, 
and more than 21. Alcohol use was expressed as the average intake of  per day: 1 unit, 
2-4 units, 5-7 units, and 8 or more units.Weight categories were created on the basis 
of body mass index (BMI): underweight (<18.5), normal (≥18.5 – <25), overweight
(≥25 – <30), and obese (≥ 30).(22) Working status was divided into employed, ill, 
unemployed, student or military service, and other. 
Analyses
Maximum likelihood estimates of odds ratios (ORs) and their 95% confi dence inter-
vals (CIs) were computed using a conditional logistic regression model. In the multi-
variate analysis risk estimates for use of psychotropic drugs were adjusted for alcohol 
use, smoking, history of pancreatic disease, history of biliary disease, and history of 
diabetes mellitus, We performed additional analyses restricted to patients with a fi rst 
attack of acute pancreatitis and patients with non-biliary acute pancreatitis. All analy-
ses were performed in SPSS 8.0 for Windows.
RESULTS
During the study period 823 cases met our inclusion criteria. After the expert review, 
80 eligible cases were excluded as the diagnosis acute pancreatitis could not be sub-
stantiated. Furthermore, 19 cases did not have a matched community control and 
were therefore excluded from the analyses. Among the fi nal 724 cases, 658 (91%) were 
admitted for a fi rst attack of acute pancreatitis. Three hundred patients had evidence 
of gallstones and 88 patients had a history of alcohol abuse or used 5 units or more per 
day. A total of 1791 community controls were matched to the fi nal 724 cases. 
A high number of previous hospitalisations, smoking, high intake of alcohol, a his-
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Table 1
Patient characteristics
Cases (n=724) Community controls (n=1791) OR
unadjusted
Country Denmark 69 155
 Italy 120 151
 Netherlands 112 112
 Sweden 423 1373
Male 422 930
Age (years) 62.7 (SD 11.7) 60.6 (SD 11.9)
BMI 25.7 (SD 4.1) 25.2 (SD 3.7)
 <18.5 10 25 1.2 (0.6-2.7)
 ≥18.5 - <25 328 895 ref.
 ≥25 - <30 288 663 1.1 (0.9-1.4)
 ≥30 90 185 1.3 (0.9-1.7)
 Unknown 8 23
No. Hosp.* 0 78 250 ref.
 1 148 387 1.3 (0.9-1.8)
 2 139 337 1.3 (0.9-1.8)
 3 97 270 1.2 (0.8-1.7)
 4 80 195 1.4 (0.9-2.0)
 ≥5 181 349 1.7 (1.3-2.4)
 Unknown 1 3
Smoking† 0 509 1343 ref.
 1-10 67 197 0.9 (0.7-1.3)
 11-20 116 196 1.7 (1.3-2.2)
 ≥21 29 37 2.0 (1.1-3.4)
 Unknown 3 18
Alcohol use‡ 0 152 276 1.3 (0.97-1.6)
 1-7 321 927 ref.
 8-28 181 526 0.8 (0.7-1.1)
 29-49 24 43 1.2 (0.7-2.1)
 ≥50 40 6 15.3 (5.9-39.9)
 Unknown 6 13
ADR§ 199 539 1.1 (0.9-1.3)
Knowledge on ADR¶ 33 196 0.4 (0.3-0.6)
Gall tract diseases ≤ 1 yr. 34 8 11.7 (5.3-25.8)
 2-5 yr. 18 12 3.5 (1.6-7.8)
 >5 yr. 75 179 1.2 (0.9-1.6)
Hyperlipidemia§ 49 70 1.7 (1.2-2.5)
Ulcus pepticum§ 92 114 2.0 (1.5-2.8)
Renal failure§ 8 9 1.9 (0.7-5.2)
Infl ammatory bowel disease§ 9 14 2.2 (0.9-5.1)
Pancreas diseases§ 52 9 13.8 (6.4-29.2)
Diabetes mellitus§ 70 77 2.1 (1.5-3.0)
Psychosis§ 2 5 1.1 (0.2-5.7)
Depression§ 74 152 1.3 (0.98-1.8)
Vitamin C** 44 130 0.9 (0.6-1.3)
OR=odds ratio, SD=standard deviation, BMI=body mass index, ADR=adverse drug reaction,  * Number of hospi-
talisations in entire life, † number of cigarettes smoker per day, ‡ Units of  alcohol per week, § Ever history of,
¶ Knowledge that drugs may cause acute pancreatitis, ** use in the week before the index date.
IE43.indd   142 04-11-2002, 14:24:36
Psychotropic drugs
143
tory of biliary disease, hyperlipidemia, peptic ulcer disease, diabetes mellitus, and 
pancreatic disease were all positively associated with development of acute pancre-
atitis (table 1). 
Use of TCAs, SSRIs, and benzodiazepines all showed a modest, non-signifi cantly 
increased risk of acute pancreatitis (table 2). Short- and long acting benzodiazepines 
had similar risk estimates for acute pancreatitis. Use of antipsychotic drugs in the 
week prior to the index date showed an increased relative risk of 3.0  (95% CI: 1.5-6.0). 
The risk of acute pancreatitis associated with antipsychotics was largely confi ned to 
elderly patients (table 2). It was not possible to assess the risk of atypical antipsychot-
ics separately as only three cases and no controls used an atypical antipsychotic. Data 
on dispensed prescriptions of antipsychotics showed that reported data on antipsy-
chotics was complete in the Netherlands for both cases and controls. The numbers 
were too low to assess dose- and duration responses. Restriction of the analysis to 
patients with a fi rst attack of acute pancreatitis did not change the results. 
DISCUSSION
In this multinational study on drug-induced acute pancreatitis, we demonstrated that 
use of antipsychotics was associated with an increased risk of acute pancreatitis and 
that this risk was largely confi ned to elderly patients. 
Several case-reports have suggested a causal relationship between use of the 
antidepressants and acute pancreatitis. Both TCAs(6-10) and SSRIs(11) have been 
incriminated. Clomipramine-, imipramine-, amoxapine-, and maprotiline-induced 
acute pancreatitis is briefl y mentioned in two surveys from spontaneous reporting 
centres.(9,10) Two reports mention acute pancreatitis after deliberate overdoses of 
amoxapine and clomipramine.(7,8) However, both patients used other drugs con-
Table 2
Association between use of TCAs, SSRIs, benzodiazepines, antipsychotics and acute pancreatitis.
Drug*
Cases
(n=724)
Community controls
(n=1791)
OR
adjusted
†
TCA  12  18 1.7 (0.8-4.0)
SSRI  19  28 1.7 (0.9-3.3)
Benzodiazepines  68  104 1.3 (0.9-1.9)
Antipsychotics  20  20 3.0 (1.5-6.0)
                 Age 40-59 years  6  10 1.3 (0.4-4.6)
 60-85 years  14  10 4.1 (1.7-9.9)
TCA=tricyclic antidepressant, SSRI=selective serotonine reuptake inhibitor, *use in the week before the index 
date, † adjusted for alcohol use, smoking, history of pancreatic, history of biliary disease, history of diabetes mel-
litus
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comitantly and both had other conditions that might explain elevated enzyme levels. 
None of the patients were rechallenged with the suspected antidepressant. Reports 
on antipsychotic-associated acute pancreatitis concerned the atypical agents clozap-
ine, olanzapine, and risperidone.(12-21). Two patients had a return of abdominal pain 
on restarting clozapine, but serum amylase was not measured in one patient and the 
other had concomitant cholelithiasis.(15,23) As our study ended in 1998, only three 
cases and none of the controls used an atypical antipsychotic, hence it was not pos-
sible to estimate risks for typical and atypical antipsychotics separately.
The mechanism by which antipsychotic drugs may cause acute pancreatitis is 
unknown. Drugs may cause acute pancreatitis by an allergic reaction. However, rash 
was not reported in any of the patients and hypereosinophilia was only reported in 2 
patients.(15,23) Alternatively, drugs may induce other risk factors for acute pancre-
atitis. For instance, vitamin D intoxication predisposes to hypercalcemia,(24) fi brates 
may induce cholelithiasis,(25) and estrogens may lead to hypertriglyceridemia.(26) 
Hypercalcemia, cholelithiasis, and hypertriglyceridemia are known causes of acute 
pancreatitis. Increased triglyceride levels are associated with use of antipsychot-
ics.(27) Dopamine had an anti-infl ammatory effect in an animal model of acute pan-
creatitis. This anti-infl ammatory effect was antagonised by simultaneous haloperidol 
administration.(28) This may provide a rationale for the increased risk of pancreatitis 
associated with use of antipsychotics. 
Most information on drug-associated acute pancreatitis is derived from anecdotal 
reports. Our study is unique in its size and its aim to quantify the risk of acute pancre-
atitis. However, one must consider the results of our study in light of its potential limi-
tations. We limited underascertainment of potential cases by using standardised and 
objective screening criteria.  Although mild cases may have been missed, symptom-
atic cases of acute pancreatitis are mostly recognised and admitted irrespective of the 
suspected aetiology, hence selection bias is unlikely. Diagnostic bias due to diagnos-
ing acute pancreatitis more easily in patients who use psychotropic drugs is not likely 
due to the acute nature of the disease, the screening procedures that we used, and due 
to the widespread belief that drugs have a low attributable risk for acute pancreatitis. 
In addition, all cases were validated by experts who were blinded to exposure. 
Information bias regarding exposure is a particular problem in case-control studies 
as cases might recall drug use more accurately than controls due to their recent ill-
ness. However, verifi cation at community pharmacies in the Netherland showed that 
data on use of antipsychotic drugs was complete for both cases and controls. We stud-
ied the infl uence of recall bias by including a question on use of vitamin C (not known 
to be associated with acute pancreatitis) and by asking whether participants knew that 
drugs may cause acute pancreatitis. Vitamin C was not associated with development 
of acute pancreatitis and slightly more controls than cases knew that drugs may be a 
possible cause of acute pancreatitis. These fi ndings suggest that recall bias did not a 
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play a major role in our study. 
In our analyses we adjusted for smoking, alcohol abuse, a history of biliary diseases, 
a history of diabetes, and a history of pancreatic diseases. We had no information on 
the presence of gallstones in controls at the time of interview. Therefore we adjusted 
for a history of biliary diseases which was strongly associated with an increased risk 
of acute pancreatitis. Alcohol use may be an important confouder in the relationship 
between psychotropic drugs and acute pancreatitis. We adjusted for alcohol use in our 
analysis, but residual confounding due to underascertainment of alcohol exposure can 
not be excluded with certainty. However, misclassifi cation of alcohol exposure is only 
of importance in distinguishing alcohol abuse from modest alcohol consumption as 
our analyses showed an increased risk for high alcohol consumption only.
In conclusion, antipsychotic drugs were associated with an increased risk of acute 
pancreatitis and should be considered as a potential cause in patients with acute pan-
creatitis.
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Acute pancreatitis associated with the use of fi brates:
The European case-control study on drug-induced acute pancreatitis (EDIP)
Introduction: Fibrates and hydroxymethylglutaryl-co-enzym-A (HMG-Co-A) reductase 
inhibitors have both been associated with acute pancreatitis. We quantifi ed the risk of acute 
pancreatitis associated with use of lipid lowering drugs in the European study on drug-
induced acute pancreatitis (EDIP).
Methods: The EDIP study is a multi-centre population-based European case-control study 
on the association between drug use and acute pancreatitis. Patients between 40 and 85 
years of age with acute pancreatitis were included between October 1st 1994 and Decem-
ber 31st 1998. Age- and gender-matched community controls were recruited for each case. 
Detailed information on drug use and potential confounders (e.g. co-morbidity, alcohol use) 
was obtained through a structured interview. 
Results: During the study period, we identifi ed and interviewed 724 patients with acute pan-
creatitis and 1791 community controls. A high number of previous hospitalisations, smok-
ing, high intake of alcohol, a history of biliary disease, hyperlipidemia, peptic ulcer disease, 
and pancreatic disease were positively associated with development of acute pancreatitis. 
Use of fi brates in the week before the index date was associated with a 3.5 fold increase in 
the risk of acute pancreatitis (95% CI: 1.4-9.2). Use of HMG-CoA-reductase inhibitors was 
not associated with an increased risk of acute pancreatitis.
Conclusion: Use of fi brates is associated with an increased risk of acute pancreatitis.
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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas which may lead to 
considerable morbidity and mortality. The incidence of acute pancreatitis shows an 
increasing trend in European countries.(1,2) The most important risk factors for acute 
pancreatitis are gallstones and alcohol abuse. Other risk factors include hyperlipid-
emia, hypercalcemia, and endoscopic retrograde cholangiopancreaticography (ERCP). 
The etiology remains unknown in 10 to 25% of patients with acute pancreatitis.(3)
Drugs have since long been implicated as a potential cause of acute pancreatitis.(4) 
However, most information on drug-induced acute pancreatitis is derived from anec-
dotal case-reports and little is known about the incidence and mechanisms of drug-
induced acute pancreatitis.(5)
Acute pancreatitis has been associated with fi brates,(6-10) hydroxymethylglu-
tarylco-enzym-A (HMG-Co-A) reductase inhibitors, (11-18) and combined use of these 
two drug classes.(11,19) In addition cholestyramine-associated acute pancreatitis has 
been described.(12,20) 
We assessed the risk of acute pancreatitis associated with use of lipid lowering 
drugs in the European study on drug-induced acute pancreatitis (EDIP).
METHODS 
Setting 
This study is part of the European case-control study on drug-induced acute pancreati-
tis (EDIP), which was initiated by the European Pharmacovigilance Research Group. 
Participating countries include Denmark, Italy, the Netherlands, Portugal, Sweden, 
and the United Kingdom. The source population comprised all persons between 40 to 
85 years of age in the county of Funen in Denmark, the Rijnmond area in the Neth-
erlands, the Coimbra area in Portugal, the cities Malmö, Stockholm, Uppsala, and 
Umeå in Sweden, the cities Bologna, Bolzano, Milano, and Verona in Italy, and Bir-
mingham city in the United Kingdom. For the present study only data from Denmark, 
the Netherlands, Italy, and Sweden was used because of absence of data on commu-
nity controls in the other countries. The study period ran from October 1st 1994 to 
December 31st 1998, but differed in the participating countries. Local medical ethical 
committees approved the study, and written informed consent was obtained from all 
participants.
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Case identifi cation and validation
In the Netherlands, Sweden, and Denmark potential cases were identifi ed by regular 
screening of serum amylase and lipase values of admitted patients in the participat-
ing hospitals. In Italy, the departments of internal medicine, gastroenterology, and 
surgery were regularly screened for patients admitted with acute abdominal pain. 
Patients were considered potential cases of acute pancreatitis if they had acute abdom-
inal pain combined with elevated serum amylase and lipase values of more than 2 
times the upper limit of normal within the fi rst week of admission, or if they had 
acute abdominal pain with confi rmatory evidence of acute pancreatitis on ultrasonog-
raphy, computerized tomography, laparotomy, or autopsy. Patients with post-ERCP 
pancreatitis, abdominal trauma, a perforated gastrointestinal ulcer, malignancy of the 
gastrointestinal tract, a positive HIV test, or chronic pancreatitis were excluded. Addi-
tionally, patients were excluded if they were resident in a nursing home, did not speak 
the native language, died before study assessments were completed, or if no reliable 
interview data could be obtained (e.g. due to dementia). Since Sweden combined the 
EDIP study with a national study, their exclusion criteria were slightly different in the 
cities Stockholm and Umeå. In these cities, patients with a history of biliary diseases 
and patients with a relapse of acute pancreatitis were also excluded. Acute pancreati-
tis was considered of biliary origin if gallstones were present at imaging procedures 
or at laparotomy.
The clinical notes of all eligible cases were reviewed by consultant gastroenterolo-
gists who were blinded to drug exposure.  The index date for the cases was defi ned as 
the date of fi rst recorded symptoms. 
Control selection
In Sweden, Denmark, and Italy community controls were randomly selected from 
population registries. Community controls were randomly selected from the general 
practitioner’s practice of the case in the Netherlands. Controls were matched to cases 
on gender and age (± 5 years). The index date of the controls was defi ned as the date 
of interview. Exclusion criteria for controls were equal to exclusion criteria for cases.
Data collection
Each country used similar structured questionnaires and coding manuals (Interna-
tional Classifi cation of Diseases, 9th edition and the Drug Dictionary of the World 
Health Organization). Interviewers were centrally trained and supervised. The ques-
tionnaire included questions on demographics, life-long medical history, smoking 
and drinking habits, plus drug intake in the preceding six months. In order to reduce 
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recall bias, participants were asked to retrieve all packages of drugs that they had 
used before start of the interview. For each drug, the indication, strength, formulation, 
dosing regimen, start and stop dates were recorded. 
Exposure
Use of fi brates was defi ned as use of fenofi brate, bezafi brate, ciprofi brate, and gem-
fi brozil in the week before the index date. Use of HMG-CoA-reductase inhibitors was 
defi ned similarly as use of simvastatin, lovastatin, fl uvastatin, pravastatin, and ator-
vastatin. To study potential recall bias, we verifi ed use of lipid lowering drugs at the 
community pharmacy of the study participants in the Netherlands.
Covariates
As potential confounders we considered smoking, alcohol use, and co-morbidity. Smok-
ing was expressed as the number of cigarettes smoked per day: 0, 1-10, 11-20, and more 
than 21. Alcohol use was expressed as the average intake of units of alcohol per day: 
1 unit, 2-4 units, 5-7 units, and 8 or more units. Weight categories were created on the 
basis of body mass index (BMI): underweight (<18.5), normal (≥18.5 – <25), overweight
(≥25 – <30), and obese (≥ 30).(21) Working status was divided into employed, ill, unem-
ployed, student or military service, and other.
Analyses
Maximum likelihood estimates of odds ratios (ORs) and their 95% confi dence inter-
vals (CIs) were computed using a conditional logistic regression model. In the multi-
variate analyses risk estimates for use of fi brates and HMG-CoA-reductase inhibitors 
were adjusted for alcohol use, smoking, BMI, index year (1994-1996 and 1997-1998), 
history of pancreatic disease, history of biliary disease, and history of diabetes mel-
litus. We performed additional analyses restricted to patients with a fi rst attack of 
acute pancreatitis and patients with non-biliary acute pancreatitis. All analyses were 
performed in SPSS 8.0 for Windows. 
RESULTS
During the study period 823 cases met our inclusion criteria. Eighty  cases were 
excluded after expert review, as the diagnosis acute pancreatitis could not be substan-
tiated. Furthermore, 19 cases did not have a matched community control and were 
therefore excluded from the analyses. Among the fi nal 724 cases, 658 (91%) were 
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Table 1
Patient characteristics
Cases (n=724) Community controls (n=1791) OR
unadjusted
Country Denmark 69 155
 Italy 120 151
 Netherlands 112 112
 Sweden 423 1373
Male 422 930
Age (years) 62.7 (SD 11.7) 60.6 (SD 11.9)
BMI 25.7 (SD 4.1) 25.2 (SD 3.7)
 <18.5 10 25 1.2 (0.6-2.7)
 ≥18.5 - <25 328 895 ref.
 ≥25 - <30 288 663 1.1 (0.9-1.4)
 ≥30 90 185 1.3 (0.9-1.7)
 Unknown 8 23
No. Hosp.* 0 78 250 ref.
 1 148 387 1.3 (0.9-1.8)
 2 139 337 1.3 (0.9-1.8)
 3 97 270 1.2 (0.8-1.7)
 4 80 195 1.4 (0.9-2.0)
 ≥5 181 349 1.7 (1.3-2.4)
 Unknown 1 3
Smoking† 0 509 1343 ref.
 1-10 67 197 0.9 (0.7-1.3)
 11-20 116 196 1.7 (1.3-2.2)
 ≥21 29 37 2.0 (1.1-3.4)
 Unknown 3 18
Alcohol use‡ 0 152 276 1.3 (0.97-1.6)
 1-7 321 927 ref.
 8-28 181 526 0.8 (0.7-1.1)
 29-49 24 43 1.2 (0.7-2.1)
 ≥50 40 6 15.3 (5.9-39.9)
 Unknown 6 13
ADR§ 199 539 1.1 (0.9-1.3)
Knowledge on ADR¶ 33 196 0.4 (0.3-0.6)
Gall tract diseases ≤ 1 yr. 34 8 11.7 (5.3-25.8)
 2-5 yr. 18 12 3.5 (1.6-7.8)
 >5 yr. 75 179 1.2 (0.9-1.6)
Hyperlipidemia§ 49 70 1.7 (1.2-2.5)
Ulcus pepticum§ 92 114 2.0 (1.5-2.8)
Renal failure§ 8 9 1.9 (0.7-5.2)
Infl ammatory bowel disease§ 9 14 2.2 (0.9-5.1)
Pancreas diseases§ 52 9 13.8 (6.4-29.2)
Diabetes mellitus§ 70 77 2.1 (1.5-3.0)
Vitamin C** 44 130 0.9 (0.6-1.3)
OR=odds ratio, SD=standard deviation, BMI=body mass index, ADR=adverse drug reaction,  * Number of hospi-
talisations in entire life, † number of cigarettes smoker per day, ‡ Units of  alcohol per week, § Ever history of,
¶ Knowledge that drugs may cause acute pancreatitis, ** use in the week before the index date.
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admitted for a fi rst attack of acute pancreatitis. Three hundred (41%) patients had 
evidence of gallstones and 88 (12%) patients had a history of alcohol abuse or used 5 
units or more per day. A total of 1791 community controls were matched to the fi nal 
724 cases. 
A high number of previous hospitalisations, smoking, high intake of alcohol, and a 
history of biliary disease, hyperlipidemia, peptic ulcer disease, diabetes mellitus and 
pancreatic disease were all positively associated with development of acute pancre-
atitis (table 1). 
Use of fi brates in the week prior to the index date was associated with an increased 
risk of acute pancreatitis with an adjusted OR of 3.5 (95% CI: 1.4-9.2). Restriction to 
patients with a fi rst attack of acute pancreatitis did not change the results. The risk of 
acute pancreatits during use of fi brates seemed higher in patients aged 60 years and 
over with an OR of 5.4 (95% CI: 1.4-20.1), in patients without biliary disease with an 
OR of 19.7 (2.0-192.9), and in users of bezafi brate with OR of 15.2 (95% CI: 1.4-159.7), 
but numbers were low. Use of HMG-CoA-reductase inhibitors did not  increase the risk 
of acute pancreatitis and did not modify the risk of fi brates since only 4 patients used 
fi brates and HMG-CoA-reductase inhibitors together. Since most of the fi brates were 
prescribed for a similar dose and all patient currently using fi brates used fi brates for 
a longer  period of time we could not assess dose and duration response relationships. 
The risk of acute pancreatitis associated with bile acid binders and nicotinic acid 
derivates could not be estimated due to low exposure prevalence. Data on dispensed 
prescriptions of fi brate at community pharmacies in the Netherlands showed that 
reported data on fi brate use was complete for controls. One case had fi lled a prescrip-
tion for fi brate, while fi brate use was not reported in the interview.
Table 2
Association between use of fi brates and acute pancreatitis.
Cases
(n=724)
Community controls
(n=1791)
OR
adjusted
†
Fibrates*  14  10 3.5 (1.4-9.2)
 Bezafi brate  5  1 15.2 (1.4-159.7)
 Gemfi brozil  8  9 1.9 (0.6-5.8)
HMG CoA red.  27  48 1.1 (0.7-2.0)
Inhibitors*   
 Simvastatin  21  35 1.1 (0.6-2.1)
 Pravastatin  4  3 3.7 (0.4-32.7)
 Fluvastatin  2  6 1.5 (0.3-8.2)
OR=odds ratio, HMG CoA red = hydroxymethylglutaryl-co-enzym-A reductase, *use in the week before the index 
date, † adjusted for alcohol use, smoking, bmi, index year, history of pancreatic disease, history of biliary disease, 
history of diabetes mellitus.
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DISCUSSION
In this multinational study we found an increased risk of acute pancreatitis in users of 
fi brates. The risk of acute pancreatitis associated with fi brate seemed higher in elderly 
patients. Use of HMG-CoA-reductase inhibitors was not associated with an elevated 
risk of acute pancreatitis.
Acute pancreatitis has been attributed to fi brates in the literature, but to our knowl-
edge epidemiological studies on this subject have not been performed.(6-10) Prompt 
recurrence of pancreatitis occurred twice after restart of bezafi brate in one reported 
patient, suggesting a potential allergic reaction.(9) Secondary biliary pancreatitis 
may be an alternative mechanism for fi brate-associated acute pancreatitis, as fi brates 
are capable of inducing cholelithiasis.(22) However, our study does not confi rm this 
mechanism as the risk was higher after exclusion of patients with biliary pancreati-
tis.
Acute pancreatitis has been attributed to HMG-CoA-reductase inhibitors, but 
detailed rechallenge studies have not been described. (11-13, 15-18) Rhabdomyolysis 
attributed to HMG-CoA-reductase inhibitors therapy, and in particular to combined 
use of HMG-CoA-reductase inhibitors  and fi brates is well documented (23) and acute 
pancreatitis secondary to rhabdomyolysis after use of HMG-CoA-reductase inhibitors 
has been reported.(14,19)
The results of our study should be interpreted in light of potential limitations 
which can be classifi ed as selection, information and confounding bias. Selection bias 
is limited since both diagnostic bias and underascertainment bias are low. We limited 
underascertainment of potential cases by using standardised and objective screening 
criteria. Although mild cases may have been missed, symptomatic cases of acute pan-
creatitis are mostly recognised and admitted irrespective of the suspected aetiology. 
Diagnostic bias due to diagnosing acute pancreatitis more easily in patients who use 
fi brates is not likely due to the acute nature of the disease, the screening procedures 
that we used, and due to the widespread belief that drugs have a low attributable 
risk for acute pancreatitis. In addition, all cases were validated by experts who were 
blinded to exposure. 
Information bias regarding exposure is a particular problem in case-control studies 
as cases might recall drug use more accurately than controls due to their recent ill-
ness. However, data on dispensed prescriptions of fi brates at community pharmacies 
in the Netherlands showed that data on fi brate use was complete for controls. In addi-
tion, we studied the infl uence of recall bias by including a question on use of vitamin 
C (not known to be associated with acute pancreatitis) and by asking whether partici-
pants knew that drugs may cause acute pancreatitis. Vitamin C was not associated 
with development of acute pancreatitis and slightly more controls than cases knew 
that drugs may be a possible cause of acute pancreatitis. These fi ndings suggest that 
IE44.indd   156 04-11-2002, 14:25:06
Lipid lowering drugs
157
recall bias did not a play a major role in our study. 
Confounding by indication is a particular problem when assessing the relation 
between fi brates and acute pancreatitis. Hyperlipidemia may induce acute pancre-
atitis, but only at grossly elevated levels.(24) In our study confounding by indication 
cannot be excluded as a possible explanation for the observed relationship.
In our analyses we adjusted for smoking, alcohol abuse, a history of biliary diseases, 
a history of diabetes, and a history of pancreatic diseases. We had no information on 
the presence of gallstones in controls at the time of interview. Therefore we adjusted 
for a history of biliary diseases which was strongly associated with an increased risk of 
acute pancreatitist. Alcohol use may induce hyperlipidemia with subsequent prescrip-
tion of lipid lowering drugs. We adjusted for alcohol use in our analysis, but residual 
confounding due to underascertainment of alcohol exposure can not be excluded. 
However, misclassifi cation of alcohol exposure is only of importance in distinguishing 
alcohol abuse from modest alcohol consumption as our analyses showed an increased 
risk for high alcohol consumption only. 
In conclusion, fi brates were associated with an increased risk of acute pancreatitis 
and should be considered as a potential cause in patients with acute pancreatitis.
ACKNOWLEDGEMENTS
This study was fi nancially supported by grants from the European Commission 
(Biomed II program, contract number BMH4-CT95-0467), the Netherlands Organi-
zation for Scientifi c Research (NWO) ZonMW, the “Vereniging Trustfonds Erasmus 
Universiteit Rotterdam”, and the Medical Products Agency. Their support and the 
cooperation of the participants is gratefully acknowledged.
EDIP study group of the European Pharmacovigilance Research Group*.
Denmark
Researchers: M. Andersen, L. Gram.
Monitors: L. Ledderer, A. Lee
Italy
Researcher: G. Velo. Monitor: U. Moretti
The Netherlands
Researchers: I.A. Eland, M.C.J.M. Sturkenboom, B.H.Ch. Stricker.
Monitors: I.J. Posthumus, J. van Reeuwijk
Portugal
Researcher: F. Teixeira.
Monitor: F. Reis
IE44.indd   157 04-11-2002, 14:25:07
DRUG-INDUCED ACUTE PANCREATITIS: ANALYTICAL STUDIES
158
Sweden
Researchers: B-E. Wiholm (coordinator), A.S. Sundström.
Monitors: L. Arnesson, E. Ekman, E. Stjernberg
United Kingdom
Researcher: M.J.S. Langman.
Monitor: T. Murphy
* European Pharmacovigilance Research Group coordinator: Professor Sir M.D. Rawlins.
LITERATURE
1. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW. High early mortality rate from acute 
pancreatitis in Scotland, 1984-1995. Br J Surg 1999;86:1302-5.
2. Eland IA, Sturkenboom MJCM, Wilson JHP, Stricker BHCh. Incidence and mortality of 
acute pancreatitis between 1985 and 1995. Scan J Gastroenterol 2000;35:1110-6.
3. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med 1994;330:1198-210.
4. Johnston DH, Cornish AL. Acute pancreatitis in patients receiving chlorothiazide. JAMA 
1959;170:2054-6.
5. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf 1996;14:406-23.
6. Smith RB, Prior IA, Cooke NJ. The effect of clofi brate on raised serum lipid levels. N Z Med 
J 1968;68:231-4.
7. De Gennes JL, Dairou F, Surbled-Delas B. Demonstration du role de la lithiase biliaire dans 
le declenchement des pancreatites aigues survenant au cours de traitement par le clofi -
brate (ou analogues) des hyperlipidemies atherogenes. Ann Med Interne (Paris) 1978;129:
435-9.
8. A co-operative trial in the primary prevention of ischaemic heart disease using clofi brate. 
Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-118.
9. Gang N, Langevitz P, Livneh A. Relapsing acute pancreatitis induced by re-exposure to the 
cholesterol lowering agent bezafi brate. Am J Gastroenterol 1999;94:3626-8.
10. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JHP, Stricker BH. Drug-associated 
acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands . Am J 
Gastroenterol 1999;94:2417-22.
11. McDonald KB, Garber BG, Perreault MM. Pancreatitis associated with simvastatin plus 
fenofi brate. Ann Pharmacother 2002;36:275-9.
12. Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in 
Denmark from 1968 to 1999. Eur J Clin Pharmacol 2001;57:517-21.
13. Belaiche G, Ley G, Slama JL. Pancreatite aigue associee a la prise d’atorvastatine. Gastroen-
terol Clin Biol 2000;24:471.
14. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with 
simvastatin use . Nephron 1991;57:365-6.
15. Couderc M, Blanc P, Rouillon JM, Bauret P, Larrey D, Michel H. Un nouveau cas de pancre-
atite aigue apres la prise de simvastatine. Gastroenterol Clin Biol 1991;15:986-7.
16. Lons T, Chousterman M. La simvastatine: une nouvelle molecule responsable de pancre-
atite aigue? Gastroenterol Clin Biol 1991;15:93-4.
IE44.indd   158 04-11-2002, 14:25:07
Lipid lowering drugs
159
17. Pluhar W. Ein Fall moglicher Lovastatin-induzierter Pankreatitis bei gleichzeitigem Gilbert-
Syndrom. Wien Klin Wochenschr 1989;101:551-4.
18. Ramdani M, Schmitt AM, Liautard J, Duhamel O, Legroux P, Gislon J, et al. Pancreatite 
aigue a la simvastatine: deux cas. Gastroenterol Clin Biol 1991;15:986.
19. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovas-
tatin-gemfi brozil therapy. J Clin Gastroenterol 1995;21:340-1.
20. Casdorph HR. The effi cacy and safety of cholestyramine therapy in hyperlipidemic 
patients. Ann Intern Med 1971;74:818.
21. National Institutes of Health NHL, and Blood Institute. Clinical guidelines on the indentifi -
cation, evaluation, and treatment of overweight and obesity in adults: the evidence report. 
Bethesda (MD): National Institutes of Health; 1998.
22. Palmer RH. Effects of fi bric acid derivatives on biliary lipid composition. Am J Med 1987;83:
37-43.
23. Shek A, Ferrill MJ. Statin-fi brate combination therapy. Ann Pharmacother 2001;35:908-17.
24. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990;19:783-91.
IE44.indd   159 04-11-2002, 14:25:08
IE44.indd   160 04-11-2002, 14:25:08
4.5The risk of acute pancreatitisassociated with the use of vitamin D
IE45.indd   161 04-11-2002, 14:25:34
DRUG-INDUCED ACUTE PANCREATITIS: ANALYTICAL STUDIES
162
Acute pancreatitis associated with the use of vitamin D:
The European case-control study on drug-induced acute pancreatitis (EDIP)
Introduction: Use of vitamin D may induce hypercalcemia, which is a risk factor for acute 
pancreatitis. We investigated the association between vitamin D use and acute pancreatitis 
in the European study on drug-induced acute pancreatitis (EDIP)
Methods: The EDIP study is a multi-centre population-based European case-control study 
on the association between drug use and acute pancreatitis. Patients between 40 and 85 
years of age with acute pancreatitis were included between October 1st 1994 and Decem-
ber 31st 1998. Age- and gender-matched community controls were recruited for each case. 
Detailed information on drug use and potential confounders (e.g. co-morbidity, alcohol use) 
was obtained through a structured interview. 
Results: During the study period, we identifi ed and interviewed 724 patients with acute 
pancreatitis and 1791 community controls. A high number of previous hospitalisations, 
smoking, high intake of alcohol, a history of biliary disease, hyperlipidemia, peptic ulcer 
disease, and pancreatic disease were positively associated with development of acute pan-
creatitis. Use of vitamin D in the week before the index date was associated with a 3.5 fold 
increase in the risk of acute pancreatitis (95% CI: 1.01-12.2). 
Conclusion: Vitamin D use is associated with an increased risk of acute pancreatitis, pos-
sibly  might be explained by vitamin D induced hypercalcemia.
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INTRODUCTION
Acute pancreatitis is an infl ammatory disease of the pancreas which may lead to 
considerable morbidity and mortality. The incidence of acute pancreatitis shows an 
increasing trend in European countries.(1,2) The most important risk factors for acute 
pancreatitis are gallstones and alcohol abuse.  Hypercalcemia is another risk factor 
for acute pancreatitis.(3) Acute pancreatitis due to hypercalcemia has been described 
in patients with hyperparathyroidism, sarcoidosis, malignancy, myeloma, and in a 
patient with vitamin D intoxication.(4-8) We assessed the risk of acute pancreatitis 
associated with use of vitamin D in the European study on drug-induced acute pan-
creatitis (EDIP).
METHODS 
Setting 
This study is part of the European case-control study on drug-induced acute pancreati-
tis (EDIP), which was initiated by the European Pharmacovigilance Research Group. 
Participating countries include Denmark, Italy, the Netherlands, Portugal, Sweden, 
and the United Kingdom. The source population comprised all persons between 40 to 
85 years of age in the county of Funen in Denmark, the Rijnmond area in the Neth-
erlands, the Coimbra area in Portugal, the cities Malmö, Stockholm, Uppsala, and 
Umeå in Sweden, the cities Bologna, Bolzano, Milano, and Verona in Italy, and Bir-
mingham city in the United Kingdom. For the present study only data from Denmark, 
the Netherlands, Italy, and Sweden was used because of absence of data on commu-
nity controls in the other countries. The study period ran from October 1st 1994 to 
December 31st 1998, but differed in the participating countries. Local medical ethical 
committees approved the study, and written informed consent was obtained from all 
participants.
Case identifi cation and validation
In the Netherlands, Sweden, and Denmark potential cases were identifi ed by regular 
screening of serum amylase and lipase values of admitted patients in the participat-
ing hospitals. In Italy, the departments of internal medicine, gastroenterology, and 
surgery were regularly screened for patients admitted with acute abdominal pain. 
Patients were considered potential cases of acute pancreatitis if they had acute abdom-
inal pain combined with elevated serum amylase and lipase values of more than 2 
times the upper limit of normal within the fi rst week of admission, or if they had 
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acute abdominal pain with confi rmatory evidence of acute pancreatitis on ultrasonog-
raphy, computerised tomography, laparotomy, or autopsy. Patients with post-ERCP 
pancreatitis, abdominal trauma, a perforated gastrointestinal ulcer, malignancy of the 
gastrointestinal tract, a positive HIV test, or chronic pancreatitis were excluded. Addi-
tionally, patients were excluded if they were resident in a nursing home, did not speak 
the native language, died before study assessments were completed, or if no reliable 
interview data could be obtained (e.g. due to dementia). Since Sweden combined the 
EDIP study with a national study, their exclusion criteria were slightly different in the 
cities Stockholm and Umeå. In these cities, patients with a history of biliary diseases 
and patients with a relapse of acute pancreatitis were also excluded. Acute pancreati-
tis was considered of biliary origin if gallstones were present at imaging procedures 
or at laparotomy.
The clinical notes of all eligible cases were reviewed by consultant gastroenterolo-
gists who were blinded to drug exposure.  The index date for the cases was defi ned as 
the date of fi rst recorded symptoms. 
Control selection
In Sweden, Denmark, and Italy community controls were randomly selected from 
population registries. Community controls were randomly selected from the general 
practitioner’s practice of the case in the Netherlands c. Controls were matched to 
cases on gender and age (± 5 years). The index date of the controls was defi ned as 
the date of interview. Exclusion criteria for controls were equal to exclusion criteria 
for cases.
Data collection
Each country used similar structured questionnaires and coding manuals (Interna-
tional Classifi cation of Diseases, 9th edition and the Drug Dictionary of the World 
Health Organisation). Interviewers were centrally trained and supervised. The ques-
tionnaire included questions on demographics, life-long medical history, smoking 
and drinking habits, plus drug intake in the preceding six months. In order to reduce 
recall bias, participants were asked to retrieve all packages of drugs that they had 
used before start of the interview. For each drug, the indication, strength, formulation, 
dosing regimen, start and stop dates were recorded. 
Exposure
Use of vitamin D analogues was defi ned as use of these compounds in the week before 
the index date. Use of multivitamin preparations was not considered in this analysis. 
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To study potential recall bias, we verifi ed use of vitamin D preparations at the com-
munity pharmacy of the participants in the Netherlands.
Covariates
As potential confounders we considered smoking, alcohol use, and co-morbidity. 
Smoking was expressed as the number of cigarettes smoked per day: 0, 1-10, 11-20, 
and more than 21. Alcohol use was expressed as the average intake of per day: 1 unit, 
2-4 units, 5-7 units, and 8 or more units. Weight categories were created on the basis 
of body mass index (BMI): underweight (<18.5), normal (≥18.5 – <25), overweight
(≥25 – <30), and obese (≥ 30).(9) Working status was divided into employed, ill, unem-
ployed, student or military service, and other.
Analyses
Maximum likelihood estimates of odds ratios (ORs) and their 95% confi dence intervals 
(CIs) were computed using a conditional logistic regression model. In the multivariate 
analysis risk estimates for use of vitamin D preparations were adjusted for alcohol use, 
smoking, BMI, index year (1994-1996 and 1997-1998), history of pancreatic disease, 
history of biliary disease, and history of diabetes mellitus. We performed additional 
analyses restricted to patients with a fi rst attack of acute pancreatitis and patients with 
non-biliary acute pancreatitis. All analyses were performed in SPSS 8.0 for Windows. 
RESULTS
During the study period 823 cases met our inclusion criteria. In the expert review, 80 
cases were excluded as the diagnosis acute pancreatitis could not be substantiated. 
Furthermore, 19 cases did not have a matched community control and were therefore 
excluded from the analyses. Among the fi nal 724 cases, 658 (91%) were admitted for a 
fi rst attack of acute pancreatitis. Three hundred  (41%) patients had evidence of gall-
stones and 88 (12%) patients had a history of alcohol abuse or used 5 units or more per 
day. A total of 1791 community controls were matched to the fi nal 724 cases. 
A high number of previous hospitalisations, smoking, high intake of alcohol, and a 
history of biliary disease, hyperlipidemia, peptic ulcer disease, diabetes mellitus, and 
pancreatic disease were all positively associated with development of acute pancre-
atitis (table 1). 
Use of vitamin D in the week prior to the index date was associated with an 
increased risk of acute pancreatitis: adjusted OR 3.5 (95% CI: 1.01-12.2). The risk of 
vitamin D associated acute pancreatitis seemed higher in patients without biliairy 
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Table 1
Patient characteristics
Cases (n=724) Community controls (n=1791) OR
unadjusted
Country Denmark 69 155
 Italy 120 151
 Netherlands 112 112
 Sweden 423 1373
Male 422 930
Age (years) 62.7 (SD 11.7) 60.6 (SD 11.9)
BMI 25.7 (SD 4.1) 25.2 (SD 3.7)
 <18.5 10 25 1.2 (0.6-2.7)
 ≥18.5 - <25 328 895 ref.
 ≥25 - <30 288 663 1.1 (0.9-1.4)
 ≥30 90 185 1.3 (0.9-1.7)
 Unknown 8 23
No. Hosp.* 0 78 250 ref.
 1 148 387 1.3 (0.9-1.8)
 2 139 337 1.3 (0.9-1.8)
 3 97 270 1.2 (0.8-1.7)
 4 80 195 1.4 (0.9-2.0)
 ≥5 181 349 1.7 (1.3-2.4)
 Unknown 1 3
Smoking† 0 509 1343 ref.
 1-10 67 197 0.9 (0.7-1.3)
 11-20 116 196 1.7 (1.3-2.2)
 ≥21 29 37 2.0 (1.1-3.4)
 Unknown 3 18
Alcohol use‡ 0 152 276 1.3 (0.97-1.6)
 1-7 321 927 ref.
 8-28 181 526 0.8 (0.7-1.1)
 29-49 24 43 1.2 (0.7-2.1)
 ≥50 40 6 15.3 (5.9-39.9)
 Unknown 6 13
ADR§ 199 539 1.1 (0.9-1.3)
Knowledge on ADR¶ 33 196 0.4 (0.3-0.6)
Gall tract diseases ≤ 1 yr. 34 8 11.7 (5.3-25.8)
 2-5 yr. 18 12 3.5 (1.6-7.8)
 >5 yr. 75 179 1.2 (0.9-1.6)
Hyperlipidemia§ 49 70 1.7 (1.2-2.5)
Ulcus pepticum§ 92 114 2.0 (1.5-2.8)
Renal failure§ 8 9 1.9 (0.7-5.2)
Infl ammatory bowel disease§ 9 14 2.2 (0.9-5.1)
Pancreas diseases§ 52 9 13.8 (6.4-29.2)
Diabetes mellitus§ 70 77 2.1 (1.5-3.0)
Vitamin C** 44 130 0.9 (0.6-1.3)
OR=odds ratio, SD=standard deviation, BMI=body mass index, ADR=adverse drug reaction,  * Number of hospi-
talisations in entire life, † number of cigarettes smoker per day, ‡ Units of  alcohol per week, § Ever history of,
¶ Knowledge that drugs may cause acute pancreatitis, ** use in the week before the index date.
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pancreatitis: OR (24.7 (95% CI: 1.4-424.0), in patients aged 40-60 years:  OR 10.3 (95% 
CI: 1.4-75.1), and in users of hydroxylated vitamin D: OR 13.5 (95% CI: 1.3-143.7), but 
numbers were low. Adjustment for renal failure did not change the results. None of 
the users of vitamin D used pancreatic enzymes concomitantly. The exposure preva-
lence was too low to estimate duration-, and dose response relationships. Data on 
dispensed prescriptions of vitamin D preparations at community pharmacies in the 
Netherlands showed that data on vitamin D use was complete.
DISCUSSION
In this multinational study we found an increased risk of acute pancreatitis in users 
of vitamin D preparations. The risk of acute pancreatitis associated with vitamin D 
preparations may be higher in patients using hydroxylated vitamin D.  
In the skin, 7-dehydrocholesterol is changed into vitamin D3 under the infl uence 
of sunlight. People with low exposure to sunlight and people with low vitamin D 
production capacity (blacks, elderly) need dietary vitamin D to maintain adequate 
vitamin D levels. Vitamin D3 is hydroxylated to 25-hydroxy-vitamin D3 in the liver, 
which is subsequently hydroxylated to 1,25-hydroxy-vitamin D3 in the kidney. This 
most active form of vitamin D promotes active absorption of phosphate and calcium 
in the small intestine. Intoxication with vitamin D leads to hypercalcemia, which is 
a well-known risk factor for acute pancreatitis. This is especially true for 1-hydroxyl-
ated vitamin D3 since hydroxylation by 1-α-hydroxylase is the rate-limiting step in the 
production of 1,25-hydroxy-vitamin D3. 
Acute pancreatitis attributed to vitamin D intoxication has been described in one 
ase-report. This patient had recurrent pancreatitis associated with hypercalcemia, 
which was precipitated by excessive self-medication with vitamin D preparations. This 
patient had elevated 25-hydroxy-vitamin D3 (4.5 x N), refl ecting increased body stores 
of vitamin D. However, he had subnormal levels of 1,25-hydroxy-vitamin D probably 
due to suppressed 1-α-hydroxylase activity by low PTH levels and high serum phos-
phate levels. 
The results of our study should be interpreted in light of its potential limitations. 
We limited underascertainment of potential cases by using standardised and objective 
screening criteria. Although mild cases may have been missed, symptomatic cases of 
acute pancreatitis are mostly recognised and admitted irrespective of the suspected 
aetiology. Hence selection bias is unlikely. Diagnostic bias due to diagnosing acute 
pancreatitis more easily in patients who use vitamin D is not likely due to the acute 
nature of the disease, the screening procedures that we used, and due to the wide-
spread belief that drugs have a low attributable risk for acute pancreatitis. In addition, 
all cases were validated by experts who were blinded to exposure. 
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Information bias regarding exposure is a particular problem in case-control stud-
ies as cases might recall drug use more accurately than controls due to their recent 
illness. However, data on dispensed prescriptions of vitamin D at community pharma-
cies in the Netherlands showed that data on vitamin D use was complete. In addition, 
we studied the infl uence of recall bias by including a question on use of vitamin C (not 
known to be associated with acute pancreatitis) and by asking whether participants 
knew that drugs may cause acute pancreatitis. Vitamin C was not associated with 
development of acute pancreatitis and slightly more controls than cases knew that 
drugs may be a cause of acute pancreatitis. These fi ndings suggest that recall bias did 
not a play a major role in our study. 
Confounding by indication is a particular problem when assessing the relation 
between vitamin D use and acute pancreatitis. Vitamin D may be prescribed in 
patients with pancreatic insuffi ciency due to previous or chronic pancreatitis. In our 
study, patients with signs of chronic pancreatitis were excluded and we adjusted for 
history of pancreatitis in our analyses. None of the users of vitamin D used pancreatic 
enzymes, indicating that none had manifest pancreatic insuffi ciency. Vitamin D is 
also prescribed in patients with renal insuffi ciency to correct secondary hyperpara-
thyroidism. Renal insuffi ciency has been proposed as a risk factor for acute pancreati-
tis, but adjusting for renal insuffi ciency did not change the risk estimates of vitamin 
D in our analyses. 
In conclusion, use of vitamin D was associated with an increased risk of acute 
pancreatitis and should be considered as a potential cause in patients with acute pan-
creatitis.
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In this thesis, the objective was to study drugs as a potential cause of acute pancre-atitis. Drugs received relatively little attention as a risk factor for acute pancreatitis 
in the medical literature.(1) In the fi rst part of this thesis, we estimated the incidence 
and mortality of acute pancreatitis to assess the potential public health impact of our 
topic. In the second part, we applied several methods and used different sources to 
study the association between drugs and acute pancreatitis. In the following para-
graphs, we will consecutively discuss the incidence and mortality of acute pancreati-
tis, the different  tools  for drug safety assessment, and our studies on drug-induced 
acute pancreatitis.  
INCIDENCE AND MORTALITY OF ACUTE PANCREATITIS
The incidence of acute pancreatitis  has increased in several developed countries 
between 1960 and 1985.(2-7) Apart from a real increase in incidence, an alterna-
tive explanation for this observation might be the improvement of diagnostic tests 
for acute pancreatitis. Our nationwide incidence study showed that this increase 
continued during the period between 1985-1995, despite the unchanged character of 
diagnostic procedures such as ultrasonography and assessement of serum amylase. 
Hence, it is likely that the increased incidence of acute pancreatitis is genuine and 
not explained by better diagnostic procedures.  Our study showed that the incidence 
of acute pancreatitis increased strongly with age, which could not be explained by 
ageing of the Dutch population since age-standardised incidence rates increased as 
well. Despite an increasing incidence of acute pancreatitis, overall mortality rates due 
to acute pancreatitis were stable in the period 1985-1995. The lower case-fatality may 
be the result of more effective intensive care treatment or to more frequently diagnos-
ing of milder forms of acute pancreatitis (e.g. after ERCP).
Since we intended to study trends over a broad time interval, we used hospital 
discharge data to study the incidence of acute pancreatitis. Incidence studies based on 
hospital data, however, may underestimate the true incidence rate if not all patients 
with acute pancreatitis are referred to hospital. Therefore, we also performed a study 
on the incidence of acute pancreatitis in a large database with information from gen-
eral practices. This study showed that 98% of all patients diagnosed with acute pan-
creatitis by general practitioners were referred to hospital. Consequently, incidence 
estimates in both studies were of similar magnitude. 
The incidence of acute pancreatitis may also be underestimated if autopsy data are 
ignored.(8, 9) We did not include data from pathology databases in our two incidence 
studies. However, autopsy data were included indirectly as they are reported to the 
general practitioner and used for the coding of discharge diagnoses. Hence, it is not 
likely that we missed more than an incidental case.
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In conclusion, the incidence of acute pancreatitis rose in the period 1985-1995. 
This rise can not be explained by an ageing population, nor by improvement of diag-
nostic tests. In the study period, the incidence of both biliary diseases and endoscopic 
procedures increased, both of which may be a potential explanation for the rise in the 
incidence of acute pancreatitis.  
TOOLS FOR DRUG SAFETY
Since pre-marketing studies are primarily designed to investigate effi cacy of drugs, 
they are not able to detect rare adverse events such as acute pancreatitis. Besides the 
lack of power to detect rare adverse drug reactions, the duration of follow-up is usu-
ally too short to detect adverse drug reactions with delayed onset. In addition, most 
pre-marketing studies are conducted in selected patient groups. Children, elderly, 
and patients with extensive co-morbidity are usually excluded, whereas these patient 
groups may have an increased risk of adverse drug reactions. 
The limitations of pre-marketing studies emphasize the need for other methods to 
study adverse drug reactions. Spontaneous reporting of adverse drug reactions to drug 
monitoring centres has been the mainstay of pharmacovigilance for many years but 
this system has some limitations. Only a small proportion of adverse drug reactions 
are notifi ed to monitoring centres, (10) which is true even for severe reactions such as 
anaphylaxis.(11) Moreover, reports to such centres often lack suffi cient data to assess 
the causal relationship between the suspected drug and the adverse event. Despite 
these limitations, the important advantage of these systems is their potential to gener-
ate signals of new and severe adverse drug reactions. 
Often, observed adverse reactions are not reported to monitoring centres but pub-
lished in the medical literature. Such case-reports may provide even more important 
signals on adverse drug reactions thanks to their detailed descriptions of individual 
case histories. However, in the absence of rechallenge it may be diffi cult to draw con-
clusions on the causal relationship. 
The signals provided by spontaneous reporting systems and by reports in the lit-
erature may be the start of subsequent analytical pharmacoepidemiological studies. 
On fi rst thought, a post-marketing clinical trial may seem the ideal method for quan-
tifi cation of a potential adverse drug reaction. However, if one requires 90% power 
(α<0.05; β=0.1) to detect a relative risk as high as 3.0 for the association between 
a certain drug and acute pancreatitis (assuming a background incidence of 0.015%), 
one would need to randomise over 100,000 patients. A post-marketing trial of that size 
is clearly too expensive to perform. Observational (=non-experimental) pharmaco-
epidemiological studies are, therefore, essential in assessing the risks of rare adverse 
reactions such as acute pancreatitis. The validity of observational studies is frequently 
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questioned because of potential bias and confounding but a careful design may deal 
with most of these problems. The two main observational approaches in pharmacoepi-
demiology follow cohort and case-control designs. In the cohort design, the frequency 
of the adverse reaction is compared between patients with and without the exposure 
of interest. The advantages of this study design are the direct measurement of the inci-
dence of the adverse event, prospective assessment of exposure, which avoids recall 
bias, and its suitability to study adverse reactions to infrequently used drugs. However, 
the studied adverse event needs to be rather frequent. Since acute pancreatitis is a 
rare event, cohort studies are usually not an effi cient approach to study associations 
between drugs and acute pancreatitis.
In pharmaco-epidemiological case-control studies, drug exposure is compared 
between patients with and without the adverse event. The case-control design is an 
effi cient design to study rare adverse reactions, as drug exposure is only measured 
in patients with the adverse event and in a sample of the source population. Another 
advantage of the case-control design in studying drug-associated acute pancreatitis 
is its suitability to study multiple drug exposures. However, case-control studies are 
less suitable to study rare drug exposures, as drug exposure in controls may be too 
low to validly estimate risks. An important limitation of case-control studies is their 
vulnerability to bias. Inclusion of cases and controls may depend on exposure status 
(selection bias) and patients with the disease may recollect former drug exposure 
more accurately than controls due to their recent disease (recall bias). This form  of 
information bias is absent if prospectively recorded data on exposure are used.
Many of the advantages and disadvantages of the different study designs depend 
on the system of data collection. In pharmaco-epidemiological research, two types 
of data sources can be distinguished. One source concerns the use of computerised 
databases which consist of billing data or electronic patient records. An example of the 
latter is the General Practice Research Database (GPRD) which contains medical data 
on more than four million residents in the United Kingdom. The GPRD has proven 
to be useful for pharmaco-epidemiological research since it allows for the study of 
rare adverse drug reactions. Since the data are collected prospectively during general 
practitioner visits and recorded in a database, studies can be performed in a relatively 
short time. This is of special value in pharmaco-epidemiology, as drug safety ques-
tions often need quick answers. Second, data on drug use is prospectively collected, 
irrespective of and before the adverse event occurred and therefore selection bias and 
information bias are limited.
A potential problem with database studies concerns adjustment for other risk fac-
tors. Automated databases usually have no information on alcohol use and smoking 
and these factors may be important confounders in the association between drugs 
and acute pancreatitis. De novo data collection in an epidemiological fi eld study may 
overcome this lack of information on important risk factors. A fi eld study has the 
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advantage that one can assess potential confounders, but has the disadvantage that it 
is timely and costly. Since adverse drug reactions usually have a low frequency, the 
case-control design is mostly followed. Another advantage of the case-control design 
in pharmaco-epidemiological fi eld studies is that ad hoc case-control studies take less 
time to perform than ad hoc cohort studies.
DRUG-INDUCED ACUTE PANCREATITIS
Drugs as a potential risk factor for acute pancreatitis have received relatively few 
attention, and little is known about which drugs are associated with acute pancreatitis. 
We started our exploration of drug-induced acute pancreatitis with the evaluation of 
spontaneous reports of drug-induced acute pancreatitis and a review of the literature. 
On the basis of these studies, we quantifi ed the association between fi ve different drug 
classes and acute pancreatitis.  
Descriptive studies
Over 7000 reports of drug-associated acute pancreatitis have been sent to the World 
Health Organisation. To assess the usefulness of spontaneous reports on drug-induced 
acute pancreatitis we obtained additional clinical information on all reports notifi ed 
to the Netherlands Center for Monitoring of Adverse Reactions to Drugs of the Inspec-
torate for Health Care and to the Netherlands Pharmacovigilance Foundation LAREB. 
In 11 of the 55 reports, there was insuffi cient evidence for the diagnosis acute pancre-
atitis and in another 10 the causal relationship between the suspected drug and acute 
pancreatitis was unlikely. This shows that thorough evaluation of spontaneous reports 
and evaluation of additional clinical information is essential before inferences on any 
kind of frequency or association can be made. One of the evaluated reports concerned 
acute pancreatitis attributed to interferon-α. This patient and another patient both 
experienced a relapse of acute pancreatitis after rechallenge. The case-histories of 
these two patients were prescribed in more detail in a gastroenterological journal to 
alert medical doctors to interferon-α as a potential cause of acute pancreatitis.
Many reports in the medical literature have suggested an association between indi-
vidual drugs and acute pancreatitis.(12) We performed an extensive literature search 
to summarise the current knowledge on drug-induced acute pancreatitis. Over 150 
individual drugs and drug classes have been suggested as a potential cause of acute 
pancreatitis. For several reasons, assessment of the causal relationship between sus-
pected drugs and acute pancreatitis in these reports is complicated. Many reports 
have insuffi cient data and in reports with complete information a ‘chance’ association 
is diffi cult to exclude if rechallenge was not performed. Information on rechallenge is 
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sparse since it is only ethical when it concerns a drug which is essential for the treat-
ment of the patient. In some conditions, drug effects may be diffi cult to separate from 
the underlying condition for which they were prescribed (confounding by indication). 
For instance, mesalazine and azathioprine are used in the treatment of infl ammatory 
bowel disease, a disease which increases the risk of acute pancreatitis itself. Prescrip-
tion of drugs for unrecognised prodromal signs of acute pancreatitis (protopathic 
bias) may further complicate assessment of the causal relationship between drugs 
and acute pancreatitis. This bias may, for instance, explain the suggested association 
between H2-blocker-and acute pancreatitis. Despite these problems, some reports 
strongly suggest a causal relationship for a number of drugs. Didanosine-induced 
acute pancreatitis, for instance, was reported as soon as the fi rst dose escalating stud-
ies were performed and it has consistently been reported since then. For some drugs, 
a causal relationship with acute pancreatitis is certain despite a low incidence. The 
causal relationship between ACE-inhibitors, azathioprine, and metronidazole has been 
confi rmed by several well-documented rechallenges. However, as mentioned above 
case-reports do not permit quantifi cation of the risk of acute pancreatitis.
Analytical studies
Based on the descriptive studies, we quantifi ed the association between fi ve different 
drug classes and acute pancreatitis. Our fi rst study, which was conducted in the GPRD, 
concerned anti-ulcer drugs as a potential cause of acute pancreatitis. In assessing the 
association between anti-ulcer drugs and acute pancreatitis, some methodological 
issues require special attention. Indications (e.g. ulcers) for which anti-ulcer drugs are 
prescribed may be associated with an increased risk of acute pancreatitis. We limited 
confounding by indication by selecting a cohort of patients who ever used an anti-
ulcer drug and thus ever had an indication for use of these drugs. Anti-ulcer drugs 
can also be prescribed for unrecognised prodromal signs of acute pancreatitis, which 
could explain an association between these drugs and acute pancreatitis. We tried 
to reduce this form of bias by taking the day of onset of symptoms as index date for 
patients with acute pancreatitis. This is, however, diffi cult in the GPRD, as prodromal 
symptoms may not always have been registered in the database. To limit confound-
ing, we restricted our study to people without major risk factors for acute pancreatitis. 
We should, however, acknowledge that the success of this approach depends on the 
completeness of pre-recorded information on these confounders. Recording of biliary 
diseases may be near complete, but alcohol abuse may be recorded less accurately. 
To avoid the problems related to control of confounding in database studies, a 
multinational case-control fi eld study on drug-induced acute pancreatitis was initi-
ated in 1996. This European case-control study on drug-induced acute pancreatitis 
was performed simultaneously in Denmark, Italy, the Netherlands, Portugal, Sweden, 
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and the United Kingdom. In the studies prescribed in this thesis, drug use in patients 
with acute pancreatitis was compared to controls who were randomly selected from 
the community. In these studies, data from Portugal and the United Kingdom was not 
used since they ascertained hospital controls.
Adverse reactions may be more easily diagnosed if patients use drugs that are widely 
known as a potential cause (diagnostic bias). This type of bias is, however, unlikely 
for acute pancreatitis since the symptoms merit prompt medical care independent of 
aetiology. In addition, drugs are generally believed to have a low attributable risk for 
acute pancreatitis and are thus not among the fi rst etiological factors sought. Recall 
bias is the most important form of information bias in case-control studies that rely on 
interview as source of information. Compared to community controls, patients with 
acute pancreatitis may remember former drug use more accurately due to their recent 
illness. Use of pharmacy dispensing data or GP prescription data prevents recall bias, 
but has the disadvantage that ‘over the counter’ drugs are missed and that non-compli-
ance is not taken into account. Since pharmacy dispensing data were not available in 
all participating countries, we relied on interview to assess drug exposure. We studied 
the infl uence of recall bias by including a question on use of vitamin C (not known to 
be associated with acute pancreatitis) and by asking whether participants knew that 
drugs may cause acute pancreatitis. Vitamin C was not associated with development 
of acute pancreatitis and slightly more controls than cases knew that drugs may be 
a potential cause of acute pancreatitis. In the fi eld study data from the Netherlands, 
pharmacy dispensing data were compared to drug exposure data derived from inter-
view. Interview data were virtually complete for the drugs we studied: ACE-inhibitors, 
psychotropic drugs, lipid lowering drugs, and vitamin D. These fi ndings suggest that 
recall bias did not play a major role in our studies. Confounding is the third aspect that 
deserves attention in pharmacoepidemiological studies. Alcohol abuse is an important 
risk factor for acute pancreatitis and may be associated with use of certain drug classes. 
One of the main advantages of the EDIP fi eld study above the GPRD study is the avail-
ability of more accurate data on alcohol use. Apart from the fact that this allows for the 
study of a dose-relationship between alcohol use and acute pancreatitis, we were able 
to control for the potentially confounding effect of alcohol. However, one has to bear 
in mind that residual confounding due to misclassifi cation of alcohol use can never 
be excluded. Gallstones are an important risk factor for acute pancreatitis as well and 
may be a confounder if associated with drug use. Since we used community controls 
tp provide us information about the exposure prevalence in the source population, we 
had no imaging information on the presence of gallstones in controls at the time of 
interview. Therefore, we were only able to adjust for a history of biliary diseases.
Confounding by indication is a particular problem in pharmacoepidemiological 
studies. The indication for which a drug is prescribed may be an independent risk 
factor for acute pancreatitis, thereby explaining an association between the prescribed 
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drug and development of acute pancreatitis. Confounding by indication probably did 
not play a major role in our studies on ACE-inhibitor-associated pancreatitis and anti-
psychotic drug-associated pancreatitis since hypertension, congestive heart failure, 
and psychotic disorders are not established risk factors for acute pancreatitis. Hyper-
lipidemia is a risk factor for acute pancreatitis and confounding by indication could 
therefore play a role in our study on fi brate-associated acute pancreatitis.  Among 
other indications, vitamin D is prescribed to patients with pancreatic insuffi ciency 
and to  patients with renal failure. Pancreatic insuffi ciency may be due to previous 
pancreatitis, which could predispose to subsequent relapses. However, none of the 
patients using vitamin D preparations used pancreatic enzymes concomitantly, indi-
cating that none of them had overt pancreatic insuffi ciency. Moreover, we adjusted for 
a history of pancreatic diseases in the analyses. Renal failure has been suggested as a 
potential cause of acute pancreatitis, but adjustment for history of renal failure had no 
effect on the risk estimate and is therefore unlikely to explain the association between 
vitamin D and acute pancreatitis.
The lack of quantitative studies on drug-associated acute pancreatitis and the large 
number of drugs that have been suggested as a potential cause of acute pancreatitis 
prompted us to use the case-control design in the EDIP study. The case-control design 
allowed us to study multiple drug exposures for a relatively rare disease such as 
acute pancreatitis. However, the case-control design is not very effi cient for studying 
adverse reactions to drugs that are infrequently used. Many case-reports confi rmed 
a causal association between azathioprine and acute pancreatitis by prompt relapse 
after controlled rechallenge.(12) Since exposure to azathioprine is low in the general 
population, we were unable to quantify the risk of acute pancreatitis associated with 
use of azathioprine in our international case-control study.
Pathogenesis and incidence of drug-induced acute pancreatitis
The pathogenesis of drug-induced acute pancreatitis is incompletely understood. 
Drugs or drug metabolites may theoretically have a direct toxic effect on the pancreas. 
Among the NSAIDs, sulindac seems to stand out in its ability to induce pancreatitis. 
The delay between start of sulindac and development of symptoms is several weeks 
to months, and after rechallenge symptoms re-appear within weeks. This is compat-
ible with a toxic effect on the pancreas. Didanosine-associated acute pancreatitis 
usually develops 10-18 weeks after start of therapy, which is well compatible with 
didanosine-induced mitochondrial toxicity.(13) ACE-inhibitors may predispose to pan-
creatitis by diminished degradation of bradykinin and substance P. For other drugs, an 
immunoallergic idiosyncratic reaction is more likely. Time between start of treatment 
and development of acute pancreatitis is usually within a few weeks for mesalazine, 
azathioprine, methyldopa and sulphonamides. Rechallenge with these drugs usually 
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leads to prompt recurrence of symptoms in a dose-independent manner. Other drugs 
may indirectly lead to acute pancreatitis by inducing known risk factors. For instance, 
estrogens, ritonavir, β-blockers, and other drugs are known to induce hyperlipidemia 
in susceptible patients. Hypercalcemia may develop secondary to excessive vitamin D 
intake. Erythromycin, somatostatine, and codeine increase the pressure of the sphinc-
ter of Oddi and may thereby induce pancreatitis. Fibrate-induced cholelithiasis may 
be responsible for subsequent acute pancreatitis. 
The incidence of drug-induced pancreatitis is unknown. Reports to adverse reac-
tion monitoring centers seem to indicate a low incidence of drug-induced pancreatitis, 
but as already mentioned, due to underreporting incidence rates cannot be validly 
estimated from spontaneous reporting schemes.(14-16) In clinical studies, 1-2% of 
acute pancreatitis is attributed to drugs.(9,17,18) This may be an underestimation, as 
drugs are often not recognized as a potential cause of acute pancreatitis.
DRUG-INDUCED ACUTE PANCREATITIS IN PERSPECTIVE
In this thesis, we studied drug-induced acute pancreatitis with different pharmaco-epi-
demiological methods. Spontaneous reporting systems are an excellent tool to gener-
ate signals and hypotheses on new associations between drugs and acute pancreatitis. 
We showed, however, that these systems cannot be used to draw inferences on indi-
vidual causal relationships between drugs and acute pancreatitis. The common view 
is that this also applies to case-reports described in the medical literature. However, in 
particular circumstances it is possible to assess the causal relationship between acute 
pancreatitis and an individual drug, based on information provided in case-reports. 
The detailed description of multiple patients who experienced a relapse of acute 
pancreatitis after controlled re-exposure to for instance mesalazine, azathioprine, or 
ACE-inhibitors proves that a defi nite causal relationship exists between these drugs 
and acute pancreatitis.
Guided by our studies on spontaneous reports and our review of the literature, we 
were able to quantify the association between fi ve commonly used drug classes and 
acute pancreatitis. For many other drugs, exposure was too low to estimate the risk 
of acute pancreatitis. This means that future research on drug-induced acute pancre-
atitis should decide between an even larger fi eld case-control study to increase the 
chance of detecting rare drug exposures as a cause, and initiating such studies in large 
databases such as the GPRD knowing that control of confounding will be diffi cult to 
achieve. Possibly, there is no real gain in performing such large studies if the expected 
incidence of a certain drug-pancreatitis association is low. Then, it may be better to 
rely on well-described individual case-histories.
This thesis shows that although some drugs are associated with acute pancreati-
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tis, the clinical impact of drug-induced acute pancreatitis in the general population 
is modest. Of course, this tells little about the personal suffering of individuals who 
develop this potentially life-threatening adverse reaction. Because of the low inci-
dence, we should rely on spontaneous reporting systems and case-reports in the 
medical literature to provide signals on new associations between drugs and acute 
pancreatitis. For associations that seem to be relatively frequent, a study in special 
patient groups might be initiated. For instance, a case-control study on azathioprine-
associated pancreatitis could be nested in a cohort of patients with infl ammatory 
bowel disease.
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The objective of this thesis was to estimate the incidence and mortality of acute pancreatitis and to study drugs as potential risk factors for acute pancreatitis. We 
started our exploration of drug-induced acute pancreatitis by studying reports of drug-
induced acute pancreatitis notifi ed to spontaneous reporting centres. After a literature 
review, we quantifi ed the risk of acute pancreatitis associated with fi ve different drug 
classes.
Chapter 1 provides a brief overview of acute pancreatitis and its aetiology, diagnosis, 
treatment and pathogenesis.
The incidence and mortality of acute pancreatitis between 1985 and 1995 was 
described in chapter 2.1. In this period, there were over 22,000 admissions for acute 
pancreatitis in the Netherlands. Of the nearly 10,000 patients with a fi rst attack of 
acute pancreatitis between 1985 and 1990, 11% experienced a relapse within 5 years 
and 6% developed chronic pancreatitis. The overall incidence of acute pancreatitis 
rose from 12.4 per 100,000 person-years in 1985 to 15.9/100,000 person-years in 1995. 
The incidence of acute pancreatitis rose in men as well as in women and increased 
markedly with age. The incidence of acute pancreatitis was low in children but 
increased with age to approximately 20 per 100,000 person-years at the age of 50 and 
to approximately 50 per 100,000 person-years in patients aged 80 years and over. The 
observed increase in the incidence of acute pancreatitis could not be explained by an 
increasing proportion of elderly in the population since the incidence standardised 
for age and gender increased from 12.4 per 100,000 person-years in 1985 to 14.8 per 
100,000 in 1995. The overall annual mortality rates for acute pancreatitis remained 
fairly stable at 1.5/100,000 person-years between 1985 and 1995. The mortality was 
very low in children and young adults, but increased rapidly after 30 years of age 
to 14.4/100,000 person-years in patients aged 85 years and over. The case-fatality of 
fi rst admissions declined from 14.3% in 1985 to 10.7% in 1995, but  remained stable 
at approximately 3.2% for relapses of acute pancreatitis. The case-fatality  increased 
rapidly with age up to approximately 35% in patients aged 85 years and over.
In studies based on hospital data, the incidence of acute pancreatitis may be under-
estimated if not all patients with acute pancreatitis are admitted to hospital. Chapter 
2.2 describes a study on the incidence of acute pancreatitis in the general population. 
This study was performed in the Integrated Primary Care Information project, a gen-
eral practitioner’s database in the Netherlands. The total study population comprised 
242,451 individuals who contributed a total of 599,368 person-years of experience 
to the study. There were 84 patients with a fi rst attack of acute pancreatitis. Biliary 
pancreatitis was more frequent in women than in men (46% vs. 35%) while alcohol-
related pancreatitis was more frequent in men than in women (29% vs. 3%). Five 
patients died during their fi rst attack of acute pancreatitis. Two patients with defi nite 
pancreatitis were not referred to hospital. The incidence rate - standardised for age 
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and gender structure of the Dutch population in 1995 - was 14.2/100,000 person-years, 
which was close to the incidence of a fi rst attack of acute pancreatitis in the study 
described in chapter 2.1 (13.7 per 100,000 person-years).
Chapter 3 consists of the description and evaluation of reports of drug-induced acute 
pancreatitis notifi ed to drug monitoring centres and of reports of drug-induced acute 
pancreatitis described in the medical literature.
In chapter 3.1 we studied all reports of drug-induced acute pancreatitis notifi ed to 
the Netherlands Center for Monitoring of Adverse Reactions to Drugs and the Neth-
erlands Pharmacovigilance Foundation LAREB between January 1st 1977 and Janu-
ary 1st 1998. In total, 55 reports were notifi ed to these drug monitoring centres. We 
obtained additional clinical information from the original reporters for all reports. The 
reports were reviewed, as to the probability of the diagnosis of acute pancreatitis, and 
the likelihood of a causal relationship with the suspected drug. Eleven reports were 
excluded, as we could not confi rm the diagnosis of acute pancreatitis. In another ten 
reports, the causal relationship between the suspected drug and acute pancreatitis was 
considered unlikely. In the remaining 34 case-histories, the causal relationship with 
the suspected drug was considered defi nite in nine, probable in ten, and possible in 
15 cases. Based on our algorithm, azathioprine, cimetidine, interferon-α, methyldopa, 
metronidazole, olsalazine, and oxyphenbutazon had a defi nite causal relationship 
with acute pancreatitis. The association between interferon-α and acute pancreatitis 
was described in more detail in chapter 3.2. To summarize current knowledge, we 
performed an extensive literature search on drug-induced acute pancreatitis and its 
associated terms (Chapter 3.3). All English, German, French, and Dutch papers on 
drug-induced acute pancreatitis were retrieved. The causal relationship between 
drugs and acute pancreatitis was assessed according to a pre-specifi ed algorithm that 
took into account the time relationship between drug exposure and development of 
acute pancreatitis, the absence or presence of other risk factors for acute pancreatitis, 
whether or not a rechallenge was performed, and the number of patients described. 
In total, over 150 drugs and drug classes have been associated with acute pancreatitis. 
According to our algorithm, 14 drugs or drug classes had a defi nite causal relation 
with acute pancreatitis: ACE-inhibitors, 5-ASA, asparaginase, azathioprine, codeine, 
didanosine, isoniazid, metronidazole, estrogens, pentavalent antimonials, beta-block-
ers, sulindac, tetracycline, and valproic acid.
Chapter 4 deals with the quantifi cation of the association between acute pancreatitis 
and fi ve different drug classes. We estimated the risk of acute pancreatitis associated 
with use of anti-ulcer drugs in the General Practice Research Database (GPRD) in 
chapter 4.1. The GPRD is a general practitioners database with medical data on more 
than four million inhabitants of the United Kingdom. To diminish potential confound-
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ing by indication and protopathic bias, we selected all patients who received at least 
one prescription for an anti-ulcer drug in the period 1992-1997. The total study cohort 
consisted of 180,178 patients who received a total of 1,545,921 prescriptions for anti-
ulcer drugs. In this cohort, there were only 36 patients with an idiopathic fi rst episode 
of acute pancreatitis. The overall incidence rate of idiopathic acute pancreatitis during 
current use of acid-suppressing drugs was 9.9 per 100,000 person years (PY), 7.6 per 
100,000 PY for past users, and 4.4 per 100,000 PY for non-users. After adjustment for 
age, gender and calendar year the RR was 1.6 for current use and 1.6 for past use of an 
acid-suppressing drug. A nested case-control analysis did not show an apparent dura-
tion or dose response relationship.
To further explore the association between drugs and acute pancreatitis, a multi-
centre case-control study was initiated: the European study on drug-induced acute 
pancreatitis (EDIP). This study was performed simultaneously in Denmark, Italy, the 
Netherlands, Portugal, Sweden, and the United Kingdom. In the studies described 
in this thesis, drug use in patients with acute pancreatitis aged 50 to 85 years was 
compared to community controls. In these studies, data from Portugal and the United 
Kingdom was not used since in these countries no community controls were enrolled. 
Among the fi nal 724 cases, 658 were admitted for a fi rst attack of acute pancreatitis. 
Three hundred patients had evidence of gallstones and 88 patients had a history of 
alcohol abuse or used 5 units or more per day. A total of 1791 community controls 
were matched to the 724 cases. A high number of hospitalisations, smoking, high 
intake of alcohol, and a history of biliary disease, hyperlipidemia, peptic ulcer disease, 
pancreatic disease, and diabetes mellitus were all positively associated with develop-
ment of acute pancreatitis.
Both spontaneous reports and case-reports suggest an association between ACE-
inhibitors and acute pancreatitis, some with documented relapse after rechallenge to 
these agents. We assessed the risk of acute pancreatitis associated with these agents 
in Chapter 4.2. A higher proportion of patients with acute pancreatitis had used ACE-
inhibitors than controls. Use of an ACE-inhibitor increased the risk of acute pancreati-
tis with 60%. Although the relative risk estimates varied slightly between individual 
ACE inhibitors, the confi dence intervals overlapped. The risk of acute pancreatitis was 
higher during the fi rst 6 months of therapy (OR 3.3) than in subsequent years (OR 1.4). 
There was a positive dose-effect relationship between the daily dose of ACE inhibitors 
and acute pancreatitis: OR 1.2  for < 1 DDD, 1.8 for 1-2 DDD, and 3.5 for > 2 DDD. 
The risk of acute pancreatitis associated with the use of ACE-inhibitors was higher in 
patients without biliary diseases: 2.7. Use of angiotensin receptor blockers was not 
associated with an elevated risk of acute pancreatitis (OR 0.9). Use of calcium chan-
nel blockers was also signifi cantly associated with acute pancreatitis (OR 1.5). Two 
small case-control studies suggested a causal relationship between diuretics and acute 
pancreatitis. Our study could not substantiate this: neither loop diuretics, nor thiazide 
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diuretics were associated with an increased risk of acute pancreatitis.
Chapter 4.3 deals with the risk of acute pancreatitis associated with use of differ-
ent psychotropic drugs. Use of tricyclic antidepressants, serotonin reuptake inhibitors, 
and benzodiazepines all showed a modest, non-signifi cantly increased risk of acute 
pancreatitis. Short- and long acting benzodiazepines had similar risk estimates for 
acute pancreatitis. Use of antipsychotic drugs showed an adjusted odds ratio of 3.0. 
The risk of acute pancreatitis associated with antipsychotics was higher in patients 
aged 60-85 years (OR 4.1), than in younger patients (OR 1.3). 
The risk of acute pancreatitis associated with use of lipid lowering drugs is described 
in chapter 4.4. Use of fi brates was associated with an increased risk of acute pancre-
atitis with an OR of 3.5. The risk of acute pancreatits during use of fi brates seemed 
higher in patients aged 60 years and over with an OR of 5.4, and in users of bezafi brate 
with an OR of 15.2. Use of HMG-CoA-reductase inhibitors was not associated with an 
increased risk of acute pancreatitis. In a subsequent study, the association between 
intake of vitamin D and acute pancreatitis was investigated. Use of vitamin D in the 
week prior to the index date was associated with an increased risk of acute pancre-
atitis with an : adjusted OR of 3.5. The risk of vitamin D associated acute pancreatitis 
seemed higher in patients without biliairy pancreatitis: OR (24.7), in patients aged 40-
60 years: OR 10.3, and in users of hydroxylated vitamin D: OR 13.9.
In the general discussion (chapter 5), the fi ndings of the studies in this thesis are dis-
cussed against the background of drug safety aspects, strengths and limitations of our 
studies, and future perspectives of studies on drug-induced acute pancreatitis.
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Dit proefschrift handelt over de associatie tussen het gebruik van geneesmiddelen en het ontstaan van acute pancreatitis. De in dit proefschrift beschreven onder-
zoeken werden uitgevoerd naar aanleiding van meldingen van aan geneesmiddelen 
toegeschreven acute pancreatitis, die werden ontvangen door de Sectie Geneesmidde-
lenbewaking van de Inspectie voor de Gezondheidszorg. Na een beschrijving van deze 
meldingen en een uitgebreid literatuuronderzoek werd het risico bestudeerd op het 
onstaan van acute pancreatitis na het gebruik van geneesmiddelen uit vijf verschil-
lende groepen.
Hoofdstuk 1 geeft een overzicht van de oorzaken, diagnose, behandeling en pathoge-
nese van acute pancreatitis.
De incidentie en mortaliteit van acute pancreatitis tussen 1985 en 1995 werd 
beschreven in hoofdstuk 2.1. Gedurende deze 10-jaars periode werden er circa 22.000 
opnames in Nederland toegeschreven aan acute pancreatitis. Van de bijna 10.000 
patiënten met een eerste aanval van acute pancreatitis kreeg 11% een recidief in de 
eerste vijf jaar en 6% ontwikkelde chronische pancreatitis. De incidentie van acute 
pancreatitis steeg van 12,4 naar 15,9 gevallen per 100.000 persoonsjaren. Deze stijging 
was zichtbaar bij zowel mannen als vrouwen. De incidentie van acute pancreatitis 
nam sterk toe met opklimmende leeftijd. Op de kinderleeftijd was de incidentie zeer 
laag maar de incidentie steeg tot 50 per 100.000 persoonsjaren op tachtigjarige leef-
tijd. De stijgende incidentie van acute pancreatitis kon niet worden verklaard door 
een vergrijzende populatie daar de voor leeftijd en geslacht gecorrigeerde incidentie 
eveneens steeg tussen 1985 en 1995 (van 12,4 naar 14,8 per 100.000 persoonsjaren). 
De mortaliteit van acute pancreatitis bleef stabiel op 1,5 per 100.000 persoonsjaren. 
De mortaliteit was laag bij kinderen, maar steeg snel na het 30e levensjaar tot 14,4 
per 100.000 persoonsjaren op 85-jarige leeftijd. Ook de letaliteit steeg snel met toe-
nemende leeftijd tot 35% op 85 jarige leeftijd. De letaliteit van patiënten met een 
eerste aanval van acute pancreatitis daalde van 14,3% in 1985 naar 10,7% in 1995. De 
letaliteit van patiënten met een recidief van acute pancreatitis bleef gelijk op 3,2%. 
De hierboven beschreven studie was gebaseerd op ontslaggegevens van ziekenhui-
zen. Incidentiestudies die gebaseerd zijn op ontslaggegevens kunnen de werkelijke 
incidentie onderschatten wanneer niet alle patiënten naar het ziekenhuis worden 
verwezen. In hoofdstuk 2.2 wordt een studie beschreven naar de incidentie van acute 
pancreatitis welke werd uitgevoerd in een huisartsendatabestand: de ‘Integrated 
Primary Care Information project’ (IPCI). Dit betreft geautomatiseerde huisartsen-
gegevens van een populatie van ongeveer 300.000 personen. Middels dit databestand 
konden we bepalen  welk percentage van de patiënten met acute pancreatitis werd 
verwezen naar het ziekenhuis. De totale studiepopulatie betrof 242.451 personen met 
een totale ‘follow-up’ tijd van 599.368 persoonsjaren. Er waren 84 patiënten met een 
eerste aanval van acute pancreatitis. Acute pancreatitis door galstenen was frequenter 
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bij vrouwen dan bij mannen (46 vs. 35%). Acute pancreatitis bij gebruik van alcohol 
was daarentegen frequenter bij mannen (29 vs. 3%). Vijf patiënten overleden aan de 
aanval van acute pancreatitis. Slechts twee patiënten werden niet naar het zieken-
huis verwezen. De voor leeftijd en geslacht gecorrigeerde incidentie bedroeg 14,2 per 
100.000 persoonsjaren, hetgeen overeen kwam met de incidentie die werd beschreven 
in hoofdstuk 2.1.
Hoofdstuk 3.1 beschrijft alle meldingen in de periode 1977-1998 van aan geneesmid-
delen toegeschreven acute pancreatitis van de Sectie Geneesmiddelenbewaking van 
de Inspectie voor de Gezondheidszorg en de stichting LAREB. Gedurende deze jaren 
waren er in totaal 55 meldingen van acute pancreatitis. Om de diagnose acute pancre-
atitis en de causale relatie tussen gebruik van het geneesmiddel en het onstaan van 
acute pancreatitis te valideren werd aanvullende klinische informatie opgevraagd bij 
de oorspronkelijke melders. In 11 meldingen kon de diagnose acute pancreatitis niet 
worden bevestigd. In 10 andere meldingen was de causale relatie tussen het gebruik 
van het verdachte geneesmiddel en het ontstaan van acute pancreatitis onwaarschijn-
lijk. In negen meldingen was de causale relatie zeker. Het betrof de geneesmiddelen 
azathioprine, cimetidine, interferon-α, methyldopa, metronidazole, olsalazine en 
oxyphenbutazon. De causale relatie was waarschijnlijk in 10 andere meldingen en 
mogelijk in de 15 overgebleven meldingen. De associatie tussen het gebruik van 
interferon-α en het onstaan van acute pancreatitis werd in meer detail in hoofdstuk 
3.2 beschreven. Hoofdstuk 3.3  geeft een literatuuroverzicht over acute pancreatitis 
door geneesmiddelen. Alle Engels-, Duits-, Frans- en Nederlandstalige artikelen over 
aan geneesmiddelen toegeschreven acute pancreatitis werden beoordeeld op hun cau-
saliteit volgens een vooraf gedefi nieerd beslismodel. Meer dan 150 geneesmiddelen 
en geneesmiddelgroepen werden met het ontstaan van acute pancreatitis in verband 
gebracht. Op basis van het beslismodel hadden 14 geneesmiddelen een zekere causale 
relatie met het ontstaan van acute pancreatitis. Het betrof ACE-remmers, 5-ASA, aspa-
raginase, azathioprine, codeine, didanosine, isoniazide, metronidazole, oestrogenen, 
pentavalente antimonials, beta-blokkers, sulindac, tetracycline en valproinezuur.
In hoofdstuk 4 wordt de associatie tussen vijf verschillende geneesmiddelengroepen 
en acute pancreatitis gekwantifi ceerd. De associatie tussen het gebruik van maagzuur-
remmende middelen en acute pancreatitis werd onderzocht in de General Practice 
Research Database (GPRD). De GPRD is een geautomatiseerd huisartsenbestand met 
de medische gegevens van vier miljoen inwoners van het Verenigd Koninkrijk. Om de 
invloed van ‘confounding by indication’ en ‘protopathic bias’ te verminderen, selec-
teerden we alle patiënten die tussen 1992-1997 tenminste één prescriptie van een 
maagzuurremmer kregen. Het studiecohort bestond uit 180.178 patiënten, die in totaal 
1.545.921 prescripties ontvingen voor maagzuurremmer. In dit cohort ontwikkelden 
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36 personen een eerste idiopathische aanval van acute pancreatitis. De incidentie 
bedroeg 9,9 per 100.000 persoonsjaren gedurende het gebruik van zuurremmers en 
4,4 per 100.000 persoonsjaren voor personen die nooit zuurremmers hadden gebruikt. 
Hoewel de incidentie hoger leek was dit niet statistisch signifi cant: RR 1.6 (95% BI: 0.6-
4.2). Een genest patiënt-controle onderzoek liet geen duur- of dosisrelatie zien.
Om de relatie tussen geneesmiddelen en acute pancreatitis verder te onderzoeken 
werd een internationaal patiënt-controle onderzoek verricht: de ‘European study on 
drug-induced acute pancreatitis (EDIP)’. Deze studie werd verricht in Denemarken, 
Italië, Nederland, Portugal, Zweden en het Verenigd Koninkrijk. Het gebruik van 
geneesmiddelen door patiënten met acute pancreatitis werd vergeleken met het 
geneesmiddelengebruik van aselect getrokken controlepersonen uit de algemene 
populatie. De in dit proefschrift beschreven studies maken alleen gebruik van de 
verzamelde gegevens uit Denemarken, Italië, Nederland, Portugal, en Zweden, daar 
in de overige landen uitsluitend ziekenhuiscontroles werden verzameld. Van de uit-
eindelijke 724 patiënten met acute pancreatitis hadden 658 een eerste aanval. Bij 
driehonderd patiënten werden galstenen vastgesteld, bij 88 patiënten was sprake 
van een te hoog  alcoholgebruik. In totaal werden 1791 controlepersonen vergeleken 
met  de 724 patiënten met acute pancreatitis. Een hoog aantal ziekenhuisopnames, 
roken, alcoholmisbruik, en aanwezigheid van galwegziekten, hyperlipidemie, ulcus 
pepticum, pancreasziekten en diabetes mellitus in de voorgeschiedenis waren allen 
positief geassocieerd met acute pancreatitis.
In de literatuur is meermalen een associatie gesuggereerd tussen tussen het 
gebruik van ACE-remmers en het ontstaan van acute pancreatitis. In hoofdstuk 4.2 
onderzochten we deze relatie in de EDIP studie. Het gebruik van ACE-remmers in de 
week voorafgaand aan opname was geassocieerd met een verhoogd risico op het ver-
krijgen van acute pancreatitis: OR 1.6 (95% BI:1.1-2.3). Het risico op acute pancreatitis 
was het hoogst gedurende de eerste zes maanden van ACE-remmer therapie en nam 
toe bij het gebruik van een hogere dosis. Het met ACE-remmers geassocieerde risico 
op acute pancreatitis was iets hoger bij patiënten die geen galstenen hadden: OR 2.7 
(95% BI: 1.3-5.8). Het gebruik van ATII receptor blokkers verhoogde het  risico op 
acute pancreatitis niet. Twee kleine patiënt-controle onderzoeken die werden uitge-
voerd in de jaren zeventig suggereerden een verband tussen het gebruik van diuretica 
en acute pancreatits. In deze studie kon geen verband worden aangetoond tussen 
acute pancreatitis en het gebruik van thiazide- of lisdiuretica. Wel leek er een verband 
te zijn tussen het gebruik van kaliumsparende diuretica en acute pancreatitis.
Hoofdstuk 4.3 beschrijft een studie waarbij de relatie tussen het gebruik van psy-
chotrope middelen en het ontstaan van acute pancreatitis werd onderzocht. Gebruik 
van tricyclische antidepressiva, serotonine re-uptake inhibitors en benzodiazepines 
hadden allen een klein en niet-signifi cant verhoogd risico op acute pancreatitis. 
Gebruik van antipsychotica daarentegen verhoogde het risico op acute pancreatitis 
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met een factor 3. Dit verhoogde risico leek meer uitgesproken bij oudere patiënten 
(OR 4.1).
Het verband tussen het gebruik van lipideverlagende geneesmiddelen en het 
optreden van acute pancreatitis wordt beschreven in hoofdstuk 4.4. Fibraten waren 
geassocieerd met een verhoogd risico op acute pancreatitis met een OR van 3.5. Het 
risico op acute pancreatitis tijdens het gebruik van fi braten leek hoger bij ouderen (OR 
5.4), en bij gebruikers van bezafi brate (OR 15.2). Gebruik van HMG-CoA-reductase 
remmers was niet geassocieerd met een verhoogd risico op acute pancreatitis.
In hoofdstuk 4.5 onderzochten we de relatie tussen het gebruik van vitamine D 
en het ontstaan van acute pancreatitis. Gebruik van vitamine D was geassocieerd 
met een verhoogd risico op acute pancreatitis met een OR van 3.5. Het risico van aan 
vitamine D toegeschreven acute pancreatitis leek relatief hoog bij oudere patiënten 
met een  OR van 10.3, en bij gebruikers van gehydroxyleerd vitamine D met een  OR 
van 13.9.
In hoofdstuk 5 worden de studies samengevat en worden de verschillende metho-
dologische aspecten besproken. Voorts wordt in dit hoofdstuk het onderwerp acute 
pancreatitis door geneesmiddelen in perpectief geplaatst.
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Velen ben ik dank verschuldigd voor hun hulp bij het tot stand komen van dit proef-schrift. In onderstaande niet random getrokken steekproef wil ik enkele van hen 
speciaal bedanken.
Beste Bruno, onze jaren van samenwerking waren een belevenis. Niet snel zal 
ik jouw eerste woorden vergeten: “Ik ben Bruno Stricker en jij komt bij mij werken”. 
En zo geschiedde het, hoewel de fi nanciering van het onderzoek verre van rond was. 
Samen hebben we de fi nanciering rond gekregen en het proefschrift vorm gegeven, 
waarbij jouw optimistische instelling mijn soms wat pessimistische inslag ruimschoots 
compenseerde. Ik vind het dan ook prachtig dat jij mijn promotor kan zijn.
Beste professor Wilson, ons overleg was niet frequent, wel zeer effi ciënt. Op de 
achtergrond hield u de lijn van het proefschrift in de gaten en gaf u de klinische ‘touch’ 
aan de manuscripten. Ook wil u danken voor uw hulp bij mijn eerste schreden op het 
interne pad.
Lieve Miriam, jouw komst was een impuls voor de hele farmaco-epi groep. Helaas 
is van onze plannen een grote internationale farmaco-epidemiologische database op 
te bouwen weinig terecht gekomen. Plotse invoering van een rigide privacy wetgeving 
en niet nagekomen toezeggingen stonden onze ambities in de weg. Ik hoop dat we ook 
in de toekomst onze discussies met een lach, voortkomende uit jouw pure epidemio-
logische houding en mijn ietwat gemende epidemiologische/klinische houding, voort 
kunnen zetten. Ik wens jou en Gino veel geluk met Tom.
I would like to thank all members of the EDIP study group (M. Andersen, Prof. L. 
Gram, Prof. M.J.S. Langman, Prof. sir. M.D. Rawlins, Prof. B.H.Ch. Stricker, Prof. T. 
Teixeira, Prof. G. Velo, B.-E Wiholm). Dear Beje, as study co-ordinator your role in the 
EDIP study was essential. I thank you for giving me the opportunity to analyse the 
EDIP data and prepare the EDIP manuscripts. I much enjoyed our discussions regar-
ding EDIP and non-EDIP subjects. I hope your scientifi c work will be as creative at 
Merck as it was at the Karolinska Institute and the Medical Products Agency.
Dear Anders, I would like to thank you for your splendid ‘IT’ assistence during the 
whole EDIP period. If it wasn’t for your CCNET software, EDIP data accumulation 
would have been a mess. Even the distance Uppsala-Rotterdam did not hamper your 
ability to solve computer problems on the spot. Much more I would like to thank you 
for our co-operation in the analysis of the EDIP data and your hospitality during my 
visits to Sweden. May many papers from our hand reach the medical literature.
Dear professor Langman, I thank you for your extensive work on the validation of 
the EDIP cases.
Loni Ledderer, Anne Lee, Ugo Moretti, Ingrid Posthumus, Jaap van Reeuwijk, 
Flavio Reis, Lotta Arnesson, Elisabet Ekman, Elisabet Stjernberg, Kerstin Blömgren, 
and Teresa Murphy, many thanks for the enormous work load that you performed in 
collecting the data.
Het Nederlandse deel van de EDIP studie had niet verricht kunnen worden zonder 
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de uitstekende samenwerking met de ziekenhuizen in de regio Rijnmond. Met 
name wil ik onze contactpersonen binnen de afdelingen Inwendige Geneeskunde, 
Heelkunde en Klinische Chemie bedanken: dr. B.G. Blijenberg, dr. A.G.C. Bauer, dr. 
C.K. Jongsma, W.C.H. van Helden, dr. C.J. van Steensel, dr. R.J.Th. Ouwendijk, dr. 
R. Oosterom, dr. J.F. Lange, dr. A.F. Grootendorst, M.G.M. van Wilgenburg, dr. J.W. 
Janssen, dr. H.S.L.M. Tjen, dr. J.C.J. Wereldsma, dr. P.L. Batenburg, M.J. Mantel, dr. 
R.W. Wulkan, dr. M.K.M. Salu, S.W. van Leeuwen, dr. S.G.T. Hulst, A.A. Schaftenaar, 
N.M. Kramer, L. Rijk, C.M.A. Geers, A.J. van Beek, C.P. Modder, E.Th. Hermans, dr. H. 
Geldof, dr. F.E.A.M. Verheul, dr. R.N. Idema.
Bovenal gaat mijn dank uit naar de vele patiënten en controlepersonen die geheel 
vrijblijvend en kosteloos hebben meegewerkt aan de EDIP studie.
Dear dr. García Rodríguez, many thanks for giving me the opportunity to analyse 
and prepare the manuscript for our anti-ulcer drug study. I much appreciated our 
co-operation. I  have never met anyone who can match your speed. The time bet-
ween any question from my side and your response has never been more than a few 
hours.
De afdeling Medische Informatica van het Erasmus MC wil ik hartelijk bedanken 
voor de mogelijkheid om gebruik te kunnen maken van de IPCI database. Met name 
wil ik Mees, Albert en Johan bedanken voor hun hulp bij het wegwijs worden in de 
IPCI database. 
Ria en Jannie wil ik hartelijk bedanken voor ondersteuning bij verschillende van 
mijn studies. Met name jullie hulp bij het achterhalen van artikelen die niet in onze 
Medische Bibliotheek beschikbaar waren was onmisbaar. Ook jullie niet afl atende 
ijver in het achterhalen van Bruno’s verblijfplaats is onovertroffen.
I thank Marijke Rasch, Frank Bekkering, Hans Brouwer, Jean Delwaide, Jacques 
Belaiche, and Ghislain Houbiers for their co-operation in the article on interferon-
associated acute pancreatitis. I thank Michel Biour for his help in completing the 
search for references on drug-induced acute pancreatitis. Eugène van Puijenbroek, 
samenwerking tussen de Stichting Lareb en de Sectie Geneesmiddelenbewaking van 
de Inspectie voor de Gezondheidszorg zorgde voor een groter aantal meldingen van 
acute pancreatitis door geneesmiddelen in onze studie. Mijn dank voor de prettige 
samenwerking.
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